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General introduction, 





 Vaccination is the one of the greatest achievements in medicine. 
It prevents approximately 6 million deaths per year according to 
the World Health Organization, and has resulted in high-income 
countries that infectious diseases are not the most common cause 
of death anymore [1, 2]. Important pioneers who greatly contributed 
to the concept of vaccination and its introduction to protect humans 
against infectious diseases were Edward Jenner (1749-1823) and Louis 
Pasteur (1822-1895). In 1796 Jenner extracted the content of pustules 
from a cowpox infected milk maid and injected it in an 8 year old boy. 
Subsequently, he inoculated this boy with the smallpox virus and the 
boy did not show any symptoms of the disease. Pasteur introduced the 
use of live attenuated microorganisms for vaccination. He discovered 
that pathogenic bacteria became less pathogenic when they were 
cultured for a few months, while retaining their immunogenicity and 
thereby their ability to induce protective immunity upon vaccination. 
Since then vaccination has been highly improved and became available 
against multiple infectious diseases, such as hepatitis B, diphtheria, 
pertussis, and poliomyelitis. Moreover, therapeutic vaccines, such 
as vaccines against cancer and cardiovascular diseases, are under 
development [3-5].
 Despite the efforts and success of vaccination campaigns, in 
low-income countries infectious diseases still are the main cause of 
death [6]. Besides, vaccination is very expensive, which is not only 
because of the production costs. Factors such as transport, cold-
chain requirements and the need for trained medical personnel to 
administer the vaccine contribute to the vaccination costs [7, 8]. 
Furthermore, vaccination does not always induce sufficient immune 
responses. For example, despite enormous efforts made during 
several decades, there are still no effective vaccines available against 
infectious diseases such as HIV, malaria and tuberculosis. Finally, since 
most vaccines are administered subcutaneously or intramuscularly by 
using hypodermic needles, vaccination causes pain, fear and stress in 
children and their parents, resulting in a reduction of the vaccination 
coverage [8-10]. To overcome these hurdles alternative minimally-
invasive vaccination strategies have been considered and studied. 
One of the alternative administration routes is the dermal route.
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Dermal vaccination
 As the skin is constantly challenged by foreign substances such as pathogens trying to 
enter the body, the skin has evolved into an outstanding protective barrier. The first barrier 
is the stratum corneum, which is a physical barrier that is impermeable for most compounds. 
Besides, the skin is immunologically very active and contains specialized cells that prevent 
incoming pathogens from causing systemic infections. Reversely, the stratum corneum 
complicates the dermal route for minimally-invasive vaccine delivery [8, 9]. Therefore, it 
was until the mid 90’s that non- and minimally-invasive vaccination via the skin, also called 
dermal vaccination, was first successfully applied. In this study Paul et al. obtained high 
antigen-specific antibody titers against gap junction protein and bovine serum albumin upon 
topical application of transfersomes in mice [11]. Later, Glen et al. confirmed the applicability 
of the dermal route for non- and minimally-invasive vaccination in mice [12] and in humans 
[13] by applying cholera toxin-containing formulations onto intact skin. Another method for 
minimally-invasive dermal vaccination is by using microneedles that were firstly described in 
1998 by Henry et al. [14].
Microneedles
 Microneedles are micron-sized structures with a length of less than 1 mm that are used to 
deliver a drug, including vaccines, into the skin in a minimally-invasive and potentially pain free 
manner [9, 15, 16]. Therefore, microneedles could lead to an increased vaccination coverage. 
Moreover, since microneedles allow self administration of vaccines [8, 9] and can circumvent 
the cold-chain [17], their use could contribute to a significant reduction of vaccination costs. 
Finally, dermal vaccination has a dose-sparing potential, as the skin is a potent immune organ. 
In general, microneedles can be used by four different approaches to deliver a drug into the 
skin: 
1. ‘Poke and flow’. Hollow microneedles are pierced into the skin after which a drug 
formulation is delivered through the bore of the microneedle. 
2. ‘Poke and patch’. Solid microneedles are used to pierce the skin, creating 
microchannels in the skin. Subsequently, a patch containing a drug formulation is 
applied onto the microchannels through which a drug can diffuse into the skin.
3. ‘Poke and release’. A drug is encapsulated into dissolving or porous solid microneedles 
and is released upon piercing them into the skin. 
4. ‘Coat and poke’. The microneedle surface is coated with a drug that is released upon 
piercing of the microneedles into the skin.
 Although microneedles have great potential for application in dermal vaccine delivery, 
microneedles do not always successfully and/or reproducibly pierce the skin and therefore 
often insertion devices (microneedle applicators) are required. These devices reduce the 
required insertion forces of skin penetration by microneedles.
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The main goals of this research were to:
1. Investigate skin-penetrating ability of microneedles with and without using an 
applicator;
2. Prepare and characterize nanolayered pH-sensitive surfaces to improve the coating 
and delivery efficiency of microneedles with vaccines without impairing microneedle 
sharpness and penetration ability; 
3. Fabricate and characterize hollow microneedles for depth controlled microinjections 
into skin;
4. Evaluate the application of the ‘poke and patch’, the ‘coat and poke’, and the ‘poke 
and flow’ approach for vaccination in animal studies.
 In Chapter 2 an overview of microneedle technologies for (trans)dermal drug delivery 
is provided whereby the four ways of drug delivery via microneedles with their advantages 
and disadvantages are described. Furthermore, this chapter describes production methods 
of microneedles as well as conditions that influence skin penetration. Finally, the use of 
microneedles for the delivery of vaccines and therapeutic proteins is discussed.
 The research described in Chapter 3 focuses on solid microneedles that are applied by the 
‘poke and patch’ method. In Chapter 3.1 the necessity of an impact-insertion applicator was 
tested for reproducible microneedle insertion of high-density microneedle arrays into the 
skin. Chapter 3.2 describes different types of solid microneedles that were evaluated for their 
ability to pierce the stratum corneum and to deliver a model vaccine, ovalbumin, into the skin. 
Subsequently, mice were vaccinated with ovalbumin to investigate the induction of antigen-
specific IgG responses upon the application of the different microneedle arrays. Moreover, 
the effect of several parameters, such as the effect of an impact-insertion applicator, the 
microneedle application area, site of microneedle application, and the delivered antigen dose, 
on the antibody responses was investigated to optimize microneedle-based immunization.
 Chapter 4 describes a novel method to coat solid microneedle arrays that are modified 
with pH-sensitive groups. To this end, first a novel surface characterization tool was 
developed for determining the pKa of modified silicon surfaces by using fluorescently labeled 
nanoparticles, as described in Chapter 4.1. Subsequently, in the research described in Chapter 
4.2 this technology was used to prepare and analyze surfaces that were modified with pH-
sensitive surface groups, a weak base, to coat surfaces with a model vaccine and to trigger 
the release upon contact with physiological pH. Next, microneedle surfaces were modified 
with pH-sensitive surface groups and were tested for pH-dependent ovalbumin binding and 
subsequent ovalbumin release into ex vivo human skin. To evaluate the in vivo applicability 
of these antigen-coated pH-sensitive microneedles, in Chapter 4.3 the ovalbumin-coated 
microneedles were used to immunize mice for the induction of antigen-specific antibody 
and T-cell responses. To further extend the applicability of pH-sensitive coatings, surfaces 
with a surface isoelectric point (sIEP) were developed in Chapter 4.4. These surfaces aid 
Aim and outline of this thesis
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electrostatic adsorption of positively charged (bio)polymers at a pH value above the sIEP 
and their repulsion from the surface at a pH value below the sIEP. It is demonstrated that 
negatively charged (bio)polymers can be reversely coated and released. Finally, Chapter 
4.5 describes the preparation of microneedles with a pH-sensitive surface onto which 
polyelectrolyte multilayers consisting of negatively charged inactivated polio vaccine and 
positively charged trimethyl chitosan were coated. The release of inactivated polio vaccine 
and trimethyl chitosan from the microneedles was evaluated in ex vivo human skin and the 
immunogenicity was assessed after topical application of the coated microneedles in rats.
 In Chapter 5 the preparation and usage of hollow microneedles for dermal drug delivery 
by the ‘poke and flow’ approach is described. These hollow microneedles were prepared 
by etching fused silica capillaries by hydrofluoric acid. Furthermore, this chapter describes 
a novel applicator for depth controlled microinjections into skin. Finally, the potential of the 
newly developed applicator and hollow microneedles for dermal vaccination was studied in 
an immunization study in rats with inactivated poliovirus vaccine.
 Chapter 6 summarizes the results and conclusions of this thesis. Besides, the prospects of 
microneedle-based immunization and drug delivery are discussed. 
References
[1] F. Andre, R. Booy, H. Bock, J. Clemens, S. Datta, 
T. John, B. Lee, S. Lolekha, H. Peltola, T. Ruff, M. 
Santosham, H. Schmitt, Vaccination greatly reduces 
disease, disability, death and inequity worldwide. 
Bulletin of the World Health Organization 86 (2008) 
140-146.
[2] CDC, Vaccines & Immunizations, available from: 
http://www.cdc.gov/vaccines/.
[3] M.G. Carstens, Opportunities and challenges in 
vaccine delivery. European Journal of Pharmaceutical 
Sciences 36 (2009) 605-608.
[4] Janeway, Immunobiology, 2005.
[5] J. Chen, G. Ni, X.S. Liu, Papillomavirus virus 
like particle-based therapeutic vaccine against 
human papillomavirus infection related diseases: 
Immunological problems and future directions. 
Cellular Immunology 269 (2011) 5-9.
[6] WHO, The top 10 causes of death, available from: 
http://www.who.int/mediacentre/factsheets/fs310/
en/index2.html.
[7] WHO, Controlled Temperature Chain (CTC); 
available from: http://www.who.int/biologicals/areas/
vaccines/controlledtemperaturechain/en/.
[8] S.M. Bal, Z. Ding, E. van Riet, W. Jiskoot, J. 
Bouwstra, Advances in transcutaneous vaccine 
delivery: do all ways lead to Rome? Journal of 
Controlled Release 148 (2010) 266-282.
[9] Y.-C. Kim, J.-H. Park, M.R. Prausnitz, Microneedles 
for drug and vaccine delivery. Advanced Drug Delivery 
Reviews 64 (2012) 1547-1568.
[10] T. Warger, H. Schild, G. Rechtsteiner, Initiation 
of adaptive immune responses by transcutaneous 
immunization. Immunology Letters 109 (2007) 13-20.
[11] A. Paul, G. Cevc, B.K. Bachhawat, Transdermal 
immunization with large proteins by means of 
ultradeformable drug carriers. European Journal of 
Immunology 25 (1995) 3521-3524.
[12] G.M. Glenn, M. Rao, G.R. Matyas, C.R. Alving, Skin 
immunization made possible by cholera toxin. Nature 
391 (1998) 851.
[13] G.M. Glenn, D.N. Taylor, X. Li, S. Frankel, 
A. Montemarano, C.R. Alving, Transcutaneous 
immunization: A human vaccine delivery strategy using 
a patch. Nature Medicine 6 (2000) 1403-1406.
[14] S. Henry, D.V. McAllister, M.G. Allen, M.R. 
Prausnitz, Microfabricated microneedles: A novel 
approach to transdermal drug delivery. Journal of 
Pharmaceutical Sciences 87 (1998) 922-925.
[15] M.I. Haq, E. Smith, D.N. John, M. Kalavala, C. 
Edwards, A. Anstey, A. Morrissey, J.C. Birchall, Clinical 
administration of microneedles: skin puncture, pain 
and sensation. Biomed Microdevices 11 (2009) 35-47.
[16] S.M. Bal, J. Caussin, S. Pavel, J.A. Bouwstra, In vivo 
assessment of safety of microneedle arrays in human 
skin. Journal of Controlled Release 35 (2008) 193-202.
[17] H.S. Gill, M.R. Prausnitz, Coated microneedles for 








 Microneedles have been used for the dermal and transdermal 
delivery of a broad range of drugs, such as small molecular weight 
drugs, oligonucleotides, DNA, peptides, proteins and inactivated 
viruses. However, until now there are no microneedle-based (trans)
dermal drug delivery systems on the market. In the past decade 
various types of microneedles have been developed by a number of 
production processes. Numerous geometries of microneedles have 
been designed from various materials. These microneedles have 
been used for different approaches of microneedle-based (trans)
dermal drug delivery. Following a brief introduction about dermal and 
transdermal drug delivery, this review describes different production 
methods for solid and hollow microneedles as well as conditions 
that influence skin penetration. Besides, the four microneedle-based 
(trans)dermal drug delivery approaches are discussed: ‘poke and flow’, 
‘poke and patch’, ‘poke and release’, and ‘coat and poke’. A separate 
section of this review is devoted to the use of microneedles for the 
delivery of therapeutic proteins and vaccines. Finally, we give our view 
on research and development that is needed to render microneedle-
based (trans)dermal drug delivery technologies clinically useful in the 
near future.
Microneedle technologies for 
(trans)dermal drug and vaccine 
delivery
Chapter 2
Koen van der Maaden
Wim Jiskoot
Joke Bouwstra
Journal of Controlled Release, 
161 (2012) 645-655
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1. Introduction
 The field of microelectronics and micromachinery is becoming more and more applicable 
for medical purposes, because nowadays it is possible to accurately make nano-scaled 
geometries by techniques developed for the computer industry. One application of these 
techniques is the production of microneedles for dermal and transdermal drug delivery, i.e., 
the delivery of drugs into and through the skin, respectively (see table 1 for terminology). 
Microneedles are needle-like structures with diameters in the size order of microns and 
lengths up to one millimeter. These structures are used to pierce the upper layer of the skin 
to enable (trans)dermal drug delivery. Scientists are now able to produce microneedles 
made of different materials with different geometries and sizes, and with or without a bore. 
Microneedles have been used for (trans)dermal drug delivery and for taking biological 
samples via the skin. The major advantage of microneedles is their ability to pierce the skin 
in a minimally-invasive and potentially painless way. Furthermore, microneedles can be 
integrated into “lab-on-a-chip” systems, whereby hollow microneedles are combined with 
either microsensors, micropumps, or both. Such systems can be used as health monitoring 
systems for diseases, such as diabetes. The ultimate goal of “lab-on-a-chip” approaches is to 
create minimally-invasive, fully automated modules for constantly extracting and analyzing 
biological fluid and directly responding on the analytical results by the delivery of drugs [1-5]. 
However, until now there are no microneedle-based drug delivery systems on the market for 
(trans)dermal delivery. 
 After a short introduction about (trans)dermal drug delivery, this review describes 
different production methods for microneedles as well as factors that influence skin 
penetration, such as microneedle geometry and the use of an applicator. Then different 
(trans)dermal drug delivery approaches by microneedles are described for solid and hollow 
microneedles. Subsequently, the (trans)dermal delivery of specific drug categories, namely 
vaccines and therapeutic proteins, by microneedles is discussed. Finally, perspectives are 
given for the clinical application of microneedle-based (trans)dermal drug delivery.
2. The skin and its implications for drug delivery
 The skin is the largest organ in the human body and is of great importance for the 
protection of the body against excessive water loss and to offer a protective barrier against 
unwanted influences, such as pathogens. The skin owes its protective function to its efficient 
physical barrier, the stratum corneum, which is 15-20 μm thick and is indispensible for a proper 
barrier function as it complicates foreign compounds, including drugs, to penetrate the skin 
[6, 7]. The viable epidermis is located below the stratum corneum and has a thickness of 
130-180 µm. Below the epidermis lies the dermis, which is about 2000 μm thick and contains 
nerves, blood vessels, nociceptors, lymph vessels, hair follicles and sweat glands [8-10], as 
depicted in figure 1. 
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 Many drugs are delivered into the body by using conventional hypodermic needles and 
metal lancets for, e.g., subcutaneous and intramuscular injections, whereby the needles are 
used to pierce through the skin in order to reach the target site of injection. However, these 
procedures cause pain and carry the risk of transmitting various biohazardous pathogens [10-
12]. The skin, however, has a great potential for non- or minimally-invasive drug delivery. First of 
all, the skin has a large surface area for drug application and the (trans)dermal route bypasses 
the fi rst-pass eff ect of the liver. Besides, steady blood concentrations of a pharmacon can be 
reached by the transdermal route, thereby avoiding fl uctuations of the drug concentration 
in the blood, associated toxicity and ineffi  cacy. Furthermore, swallowing problems and drug 
absorption and stability problems in the gastrointestinal tract can be circumvented [9, 13-
17]. Also, because of the large number of immune cells, the skin off ers a great potential for 
vaccination [10-12]. Altogether, drug delivery via the skin has multiple benefi ts over both 
the oral route and conventional injections. However, the dense structure of the stratum 
Figure 1: Representati on of the skin microanatomy.
1 Longer needles have been used (up to 3 mm), which are however not microneedles in the strictest sense
Table 1: Terminology
Term Defi nition
Microneedle Micron-scaled needle-like structure with a maximum length of 1 mm1
Dermal drug 
delivery
Delivery of drugs into the skin with the skin as the target (local delivery)
Transdermal 
drug delivery
Delivery of drugs through the skin, thus where the skin is not the target 
(systemic delivery)
CHAPTER 2: Microneedle technologies 
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corneum and the limited number of hair follicles and sebaceous glands complicates the 
delivery of therapeutic doses via the skin. Therefore, several methods have been developed 
for (trans)dermal drug delivery, such as chemical and lipid enhancers, and electric fields for 
iontophoresis [6, 14-17]. About 40 (trans)dermal products (20 drug molecules) are on the 
market, however, they are all low-molecular-weight drugs with a high potency [16, 18, 19]. 
This illustrates that it is difficult to overcome the skin barrier. As it is even more difficult to 
deliver high-molecular-weight drugs, such as proteins, polypeptides, oligonucleotides, and 
DNA, and even larger entities such as vaccines, novel methods have been developed to 
deliver such drugs via the skin. Among these methods are various microneedle approaches, 
which are the focus of our review. Microneedles are very promising for the (trans)dermal 
delivery of high-molecular-weight drugs because they enabling large molecules to pass the 
stratum corneum via micropores.
3. Microneedle production, geometry, and application technology
3.1 Production of microneedles
 Numerous types of microneedles composed of various materials have been used for the 
(trans)dermal delivery of a broad range of compounds in a potentially painless manner, a 
selection of which is shown in figure 2. The first produced microneedles for drug delivery were 
made from silicon wafers by photolithography and deep reactive ion etching [13, 20, 21]. The 
used microfabrication technologies were initially developed for the production of integrated 
circuits and turned out to be very suitable for the highly-reproducible mass production of 
microneedles. Furthermore, these technologies enable the integration of, e.g., microsensors, 
micropumps, electrical circuits, and microneedles into one device [1, 13, 21-26]. Another 
benefit of silicon microneedles is that they are usually much sharper than polymeric and 
metal microneedles [27]. However, the production process for silicon microneedles requires 
expensive micro-fabrication processes and clean room processing. Another drawback of 
silicon needles is that they may break and stay behind in the skin due to the fragile nature of 
silicon [28-35].
 Microneedles produced from silicon wafers have been developed with multiple geometries 
and can be divided into two major groups: in-plane and out-of-plane microneedles, as shown in 
figure 3. In-plane microneedles are formed in parallel with the machined surface of the silicon 
wafer, enabling the production of needles with various lengths over a large range. In-plane 
production techniques are state-of-the-art techniques, including surface micromachining and 
a variety of etching methods. Furthermore, they offer flexibility regarding needle design and 
shape, and are beneficial for the integration of microneedles with biosensors and micropumps 
[1, 22, 40-43]. Out-of-plane microneedles are formed perpendicular to the silicon wafer and 
are more easily produced in arrays than in-plane microneedles. Furthermore, out-of-plane 
microneedles have the major advantage of arranging the single microneedles of an array in 
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such a way that the drug can be delivered over a larger surface area of the skin. However, out-
of-plane hollow microneedles are more difficult to integrate with lab-on-a-chip technologies 
than in-plane hollow microneedles [1, 20, 22, 24, 25, 42, 43]. 
 More recently, other microneedle production processes have been introduced for the 
generation of cheaper and biocompatible microneedles, including metal, polymer and sugar-
based microneedles. Solid metal microneedles can be produced by laser cutting them out 
of sheet metal and subsequently bending them out-of-plane [37, 44, 45]. Furthermore, solid 
microneedle arrays with a length of 300 µm have been made from the tip of 30 G needles, 
molded in a plastic backplate [46, 47], and stainless steel 34 G hollow microneedles have been 
developed for insulin delivery [48]. Hollow metal microneedles are often made from metal 
tubing by laser machining, electrochemical etching or by electrode discharge machining [22]. 
Another technology to produce metal microneedles is laser patterning. This is a technique 
whereby liquid particles, containing the microneedle material of interest, are deposited on a 
substrate in order to produce an out-of-plane 3-dimensional structure [49]. Laser patterning 
may be a versatile method to create microneedles from a broad range of materials.
 Polymeric microneedles could have important benefits over microneedles made of other 
materials, because polymers are inexpensive, can be biocompatible, and they are amenable 
to mass production. Furthermore, because of their viscoelastic properties polymeric 
microneedles may be less sensitive to shear-induced breakage, and drugs may be incorporated 
Figure 2: Microneedles made of different materials. (A) 770 µm long stainless steel microneedles from 
Dermaroller® [36], 330 µm long Macroflux® microneedles made of titanium [37], (C) silicon microneedles with 
a length of 150 µm [38], (D) microneedles of pulled glass capillary [39], (E) 500 µm long microneedles made of 
maltose [30], and (F) PLGA microneedles of 600 µm [32].
Figure 3: Schematic 
representation of the 
manufacturing of in-plane 
(right) and out-of-plain 
(below) microneedles from 
silicon wafers (upper left).
CHAPTER 2: Microneedle technologies 
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into biodegradable polymeric microneedles for controlled drug delivery [22, 25, 28, 32, 34, 
35]. Furthermore, polymeric microneedles are extremely suited for the development of an 
all-in-one drug delivery system, whereby the microneedle is the drug delivery device as well 
as the drug formulation [50-55]. 
3.2 Microneedle geometry
 Several factors may prevent microneedles from penetrating the skin. In particular, the 
elastic nature of skin can prevent microneedles from penetration by folding around the 
needles during microneedle application, especially in case of blunt and short microneedles. 
Due to the robustness of the skin, microneedle insertion forces may exceed the ultimate 
tensile forces of the microneedle and thereby damage the microneedles, especially for 
longer microneedles and microneedles made of relatively weak materials [34, 43, 46, 47, 54, 
56-58]. Therefore, microneedle geometry is crucial for efficient microneedle-based (trans)
dermal drug delivery, because it influences the strength of the microneedles, their ability 
to pierce the skin, the drug flow (through hollow microneedles), and therefore the rate of 
drug delivery. Various different microneedle shapes have been developed, ranging from 
cylindrical, rectangular, pyramidal, conical, octagonal, to quadrangular, with different needle 
lengths and widths. The sharpness of the microneedle tip is a very important factor for skin 
penetration, as sharper microneedles have higher potential for sufficiently penetrating the 
skin at a certain insertion force [13, 28, 29, 32, 34, 59, 60], i.e., larger tip diameters need higher 
insertion forces [61]. 
 For hollow microneedles it is important that a sufficient and constant flow rate is 
generated for delivering drugs into the skin, without affecting the microneedle strength. 
The main factor affecting the flow rate is the compression of the dense dermal tissue at the 
needle tip during insertion [39]. Therefore, the shape of the tip is of great importance for 
the flow rate, e.g., the flow from a blunt-tip microneedle supports less flow than a bevel-
tip microneedle, because a blunt-tip microneedle compresses the skin more extensively 
and thereby has an increased risk of clogging [25, 59]. Hence, it could be beneficial to have 
very sharp microneedles with the bore of the microneedle off-centered or on the side of the 
microneedle [25, 39, 42, 59]. Increasing the microneedle bore may increase the flow rate, 
however, this results in a decreased microneedle strength and a reduction in sharpness [42]. A 
way to increase the microneedle strength is by applying a metal coating on the microneedles 
[62, 63], which however, may decrease their sharpness. 
 For both hollow and solid microneedles, a low density of microneedle arrays may be 
beneficial for piercing the skin because they can pull the skin tied between the needles. 
Conversely, very dense microneedle arrays may be less efficient in piercing the skin because 
they can cause a ‘bed of nails’ effect [10, 28, 43]. Therefore, designing microneedles involves 
making compromises and using microneedle insertion devices [25, 47, 56, 59, 60], as described 
below.
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3.3 Microneedle application devices
 For medical application reproducible piercing is crucial, which demands the use of an 
applicator, even in the case of sharp microneedle arrays. However, the importance of using 
microneedle applicators has been underestimated for a long time.
 Applicators for microneedles should meet certain requirements to be suitable for clinical 
use. Since microneedles are developed for decreasing patient discomfort and eliminating 
pain sensation, the applicator itself should not induce any pain. Furthermore, the use of an 
applicator should lead to a more effective, reproducible and depth-controlled penetration 
of microneedles into the skin, without increasing the risk of microneedle fracture [10, 28, 
44, 47, 56-58]. Several microneedle application devices have been developed, for example 
an applicator based upon the reduction of insertion forces by a hand-operated rotary 
application for single hollow microneedles, which drills individual microneedles into the 
skin to a predetermined depth [57]. Furthermore, a hand-held microneedle applicator was 
developed to apply microneedles in a single rolling motion from an angle of 45° to 135° with 
the skin [56] and vibration-based microneedle insertion devices have been used to reduce the 
insertion forces [57, 64]. Partial retraction of hollow microneedles is beneficial for the flow 
rate, because this leads to less clogging at the tip opening [57]. However, most application 
devices are based upon impact-insertion, which mainly reduce the insertion forces by 
circumventing the skin’s elasticity. These impact-insertion devices range from simple hand-
held applicators, by which microneedles are either manually punched into the skin [56] or 
via a mechanically-driven applicator [37, 46, 65, 66], to more sophisticated electrically-driven 
microneedle applicators [47, 67]. The latter are preferable for multiple use (e.g. repeated 
dose, multiple patients) because the easily adjustable forces are more stable over time than 
manually or spring-induced forces. However, for a single administration a mechanically-
driven applicator may be beneficial from an economic point of view. In conclusion, there is 
no universal applicator for microneedles and therefore the requirement of the applicator 
is dependent on the geometry, sharpness and density of the relevant microneedle and the 
intended use.
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4. Drug delivery methods via the skin by microneedles
 There are four general approaches of (trans)dermal drug delivery by microneedles, as 
schematically depicted in fi gure 4. The limitations, advantages and disadvantages of each of 
these approaches are summarized in table 2.
Figure 4: Diff erent approaches of drug delivery by hollow and solid microneedles. Hollow microneedles are 
used with the ‘poke and fl ow’ approach, whereby a drug in soluti on is acti vely or passively delivered through 
the bore of the microneedle. Solid microneedles are used in three diff erent manners. By the ‘poke and patch’ 
approach micropores are generated in the skin by microneedles, and aft er removal of the microneedles a 
patch is applied on top of these micropores, allowing the drug in the patch to diff use through the skin. The 
‘poke and release’ approach uses either dissolving microneedles or porous microneedles, which respecti vely 
release the drug by dissoluti on of the microneedles in the skin, or by diff usion of the drug in soluti on from the 
pores into the skin. Finally, with the ‘coat and poke’ method microneedles are pierced through the skin, and 
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4.1 Hollow microneedles
 Hollow microneedles deliver drugs via the ‘poke and flow’ approach. An important 
benefit of hollow microneedles over solid microneedles is the possibility to facilitate force-
driven fluid flow, thereby allowing faster rates of drug delivery [10, 14, 27, 28]. Furthermore, 
the dose of the desired drug in solution can be more easily controlled according to the need 
of the patient. This method of drug delivery can be achieved via passive diffusion through 
the bore of the microneedle [31, 68]. Other methods are also possible whereby the drug 
in solution is actively delivered through the bore of the microneedle. The latter requires a 
driving force through pressure, e.g., by combining a microneedle injection applicator with a 
syringe, a pump, or pressurized gas [10, 39, 41, 57, 69]. Furthermore, a microneedle array may 
Table 2: Main features of the different approaches of drug delivery by microneedles.
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include the incorporation of a microfluidic chip [40] or a micropump to direct the content 
of the drug reservoir into the skin in a controlled way [70]. Another possibility is combining 
a drug reservoir with a heater, whereby the drug solution is pressed into the skin through 
fluid expansion or bubble formation [22]. Also, drug delivery can be accomplished by hand-
pressing a flexible drug reservoir and thereby releasing the drug solution into the skin [42]. 
This is the most promising system for the market because it is fairly easy and relatively cheap 
to produce.
 A disadvantage the ‘poke and flow’ approach is that the infusion rates are normally quite 
low (50-300 nL/min) [39, 57, 68]. However, this can be overcome by partial retraction or 
adding hyaluronidase to the infusion solution, which breaks down hyaluronic acid within skin 
collagen fibers, allowing infusion rates up to 18.8 µL/min [39]. The inclusion of hyaluronidase 
in microneedle-based (trans)dermal drug delivery systems holds promise, because it has 
been approved by the FDA and has been co-administered with insulin in a clinical trial [71]. 
Finally, hollow microneedles can be combined with iontophoresis which allows the active 
displacement of charged particles and drugs through the bore of the hollow microneedles in 
a controlled way, whereby the drug delivery efficiency can be increased [28]. However, this 
leads to skin irritation due to a high current density at the site of the lowest resistance (i.e., at 
the micropores) when a constant current is used [72].
4.2 Solid microneedles
 There are three main mechanisms by which solid microneedles can be used to deliver 
drugs into the skin, which include the ‘poke and patch’ approach, the ‘poke and release’ 
approach, and the ‘coat and poke’ approach, as schematically shown in figure 4.
4.2.1 Poke and patch
 Solid microneedles for (trans)dermal drug delivery were first used in the ‘poke and 
patch’ approach [20]. In this method microneedles are applied onto the skin. Subsequently, 
the microneedles are removed and a patch containing the drug formulation is applied 
onto the site of microneedle application so that the drug can diffuse through the formed 
microchannels into the skin [14, 27, 28, 43]. Microneedle-based skin penetration studies have 
shown that the permeability for different compounds in in vitro skin was increased by solid 
microneedles up to four orders in magnitude [20, 38, 41, 46]. However, passive transport 
of drugs through microchannels does not always lead to a high bioavailability of drugs. The 
‘poke and patch’ approach has been studied in vitro and in vivo for the (trans)dermal delivery 
of multiple types of compounds and for the sustained delivery of drugs [28, 36, 73-75]. For the 
‘poke and patch’ approach it is very important that the micropores stay open during the drug 
application period [36, 67]. It has been reported that micropores in in vivo rat skin generated 
by microneedles were opened until at least 72 h after microneedle treatment when they are 
held under occlusive conditions [73], e.g., using occlusive tape or by exposure to a buffered 
solution [28, 36]. However, micropores close shortly after microneedle application when 
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micropores are not occluded or after patch removal [28, 74]. Furthermore, it has been shown 
that micropore opening can be extended up to seven days when diclofenac is added to the 
patch formulation [75]. However, this approach may not be viable/generally applicable, 
because longer opening times increase the risk of infection. The ‘poke and patch’ approach 
has been combined with iontophoresis, which leads to an increase in uptake of charged drugs 
by several orders in magnitude compared to iontophoresis or microneedles alone [76-80]. A 
disadvantage of this approach is that iontophoresis may cause skin irritation (also described 
in section 4.1). Also dissolving microneedles have been used in the ‘poke and patch’ approach 
[73].
 A variation on the ‘poke and patch’ approach is the ‘scrape and patch’ approach, whereby 
microneedles, microprojections, or microblades are first scraped over the skin to generate 
micro-abrasions, whereon subsequently a patch with a drug solution is applied [81-84]. 
Mikszta et al. (2002) used blunt ended microneedles, named microenhancer arrays (MEAs), 
with the ‘scrape and patch’ approach for the delivery of Coomassie blue in the epidermis [81]. 
This “scrape and patch” approach with MEAs was later used for the dermal delivery of an 
attenuated chimeric flavivirus vaccine in primates [82] and for dermal delivery of an anthrax 
vaccine in mice and rabbits [85]. Finally, the ‘scrape and patch’ approach was used with 
Onvax™ (BD) microneedles for the delivery of a rabies vaccine into the epidermis in healthy 
volunteers, however, no protective immune responses were observed [86]. Therefore, for 
vaccination purposes more efficient approaches are needed.
4.2.2 Poke and release
 The second mechanism for (trans)dermal drug delivery by solid microneedles is via the 
‘poke and release’ approach. This approach features a controlled release of the drug from 
the microneedles by using materials which serve as a drug depot. This implies that, unlike the 
‘poke and patch’ approach the microneedles must remain on the skin after their application 
until the drug is released. This method makes use of either porous, biodegradable, or 
dissolving microneedles from which a drug is slowly released into the skin. However, also 
hybrid microneedles have been made, e.g. solid non-dissolvable silicon microneedles with a 
biodegradable tip [87] or a stainless steel electrode pillar with a dissolvable tip [88].
4.2.2.1 Porous microneedles
 Porous microneedles absorb a drug solution into their pores which is released after 
the microneedles are applied onto the skin. Porous microneedles can be made of non-
biodegradable materials such as porous silicon [89, 90]. Furthermore, porous microneedles 
have been made of silicon from which only the tips of the microneedles were made porous 
by electrochemically etching in acetonitrile/HF [91]. However, because porous structures 
are generally more fragile than solid structures [92], porous silicon microneedles can break 
more easily in the skin and remain in the skin after removing the microneedle patch. This 
may give problems because silicon is not a biodegradable material. Therefore, porous 
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microneedles made of biodegradable materials are preferred, such as stainless steel solid 
microneedles electrochemically coated with micro-porous calcium phosphate, which serve 
as a biodegradable drug reservoir [93]. Furthermore, porous microneedles have been made 
of polylactic acid microparticles, but these microneedles were not able to penetrate human 
cadaver skin after manual application because of insufficient microneedle strength [92]. 
Finally, stainless steel microneedles have been made with pockets through the needle shaft, 
whereby these pockets were coated with one or more drugs. Such microneedles enable 
sustained release of different drugs from microneedles [94-96]. 
4.2.2.2 Dissolving microneedles
 Another way of delivering drugs by the ‘poke and release’ approach is by using 
dissolving/degrading microneedles. These microneedles have a drug encapsulated in their 
matrix and are made of polymers or sugars. Biodegradable microneedles degrade in the 
skin after application, whereby the release of incorporated drugs can be sustained up to 
months by choosing the proper polymer [92]. Furthermore, these microneedles have the 
advantage that they eventually disappear and thereby leave no biohazardous sharps waste, 
enabling a safe disposal of the remaining device [27, 50, 51]. However, for the fabrication 
of the first drug-encapsulated dissolving microneedles UV photo-curing, organic solvents 
or elevated temperatures were often needed, which could impair drug stability in case of 
biomacromolecular drugs such as proteins and DNA [34, 50-52]. Besides, residual organic 
solvents and biodegradable materials itself may lead to skin irritation [67]. Biodegradable 
trimethylene glycol microneedles fabricated by UV stereo lithography can be used as a slow 
release (trans)dermal delivery system [97]. Microneedles made of maltose dissolve in less 
than 10 minutes in human skin after insertion. However, these microneedles need fabrication 
temperatures above 100°C to transit the maltose into the glassy phase [30, 55]. Another 
disadvantage of dissolving is the limited drug loading, e.g., bovine serum albumin (BSA) and 
calcein encapsulated polymeric microneedles have been made, however, a drug loading of 
more than 10% led to insufficient mechanical strength of the microneedles [34].
 In the development of dissolving microneedles much research has been focused on 
improving drug stability. Methods to achieve this include the use of mild temperatures and 
circumventing the use of organic solvents during the microneedle manufacturing process [33, 
50, 51, 53, 54, 98]. Protein-encapsulated dissolving microneedles from carboxymethylcellulose 
(CMC) and amylopectin have been produced, which were shown to dissolute completely in 
porcine cadaver skin within one hour [51]. Furthermore, protein-encapsulated dissolving 
microneedles have been produced from chondroitin sulfate or dextran, which release almost 
all the drug within one hour [33, 54]. Dissolving microneedles made by photopolymerization 
of vinyl pyrrolidone, were able to efficiently deliver insulin within several minutes into porcine 
cadaver skin [50, 53]. Finally, polymeric dissolving microneedles have been produced from 
Gantrez® AN 139, which deliver 83% of the encapsulated theophylline into porcine skin within 
24 h [98].
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4.2.3 Coat and poke
 The fourth current approach of using solid microneedles to enhance the uptake of drugs 
into the viable skin is via the ‘coat and poke’ approach, whereby drug-coated microneedle 
arrays are, just as in the ‘poke and release’ approach, a single-unit drug delivery system 
[99]. Microneedles have been coated with a broad range of drugs, such as hydrophilic 
and hydrophobic low-molecular-weight drugs, DNA, RNA, proteins, peptides, inactivated 
pathogens, and particles [10, 27, 44, 94, 95, 100, 101]. Coating of microneedles can often be 
performed at ambient conditions [44, 45, 66, 94, 95, 102-104] and a dry coating may be more 
stable than a liquid formulation [66, 94, 95]. However, a drawback from this approach is 
that solid microneedles can only be coated with small quantities of drugs as thick coatings 
lead to a very low skin delivery efficiency [37, 44, 45, 102], likely because of a decreased 
sharpness of microneedles [100]. Therefore, coated microneedles for (trans)dermal drug 
delivery are only applicable for very potent drugs, such as vaccines [10, 27, 28]. One of the 
challenges to overcome with this approach is the relatively high loss of drug during coating. 
Over the past decade multiple methods of coating and coating devices have been developed 
for manufacturing drug-coated microneedle arrays. The first coating methods consisted 
of simple coating procedures/solutions, whereas later coating approaches became more 
sophisticated, as exemplified below. 
 Microneedles have been coated by (partial) immersion in aqueous solutions to coat up 
to 238 µg ovalbumin per cm2 (10 µg ovalbumin per cm2 leads to a coating thickness of about 
3 µm). However, coating by immersion leads to a relatively high loss of drug, and variable 
coating thicknesses per microneedle [37, 44]. Therefore, a dip-coating procedure may be 
advantageous, which is a two-step procedure, involving a “dipping and withdrawal” step, 
leading to the formation of a liquid film on the microneedle, and a “drying” step, leading 
to the conversion of the liquid layer into a solid coating. Because the first step is fluid 
mechanically controlled, the microneedle withdrawal speed is important (faster=thicker) and 
has to be above the critical withdrawal speed. The critical withdrawal speed depends on the 
combination of the solid substrate and coating solution, the viscosity (higher=thicker), and 
surface tension (lower=thicker). For a uniform coating the “drying” step is important and 
depends on the rate of solvent evaporation, wettability, viscosity of the coating solution, and 
de-wetting [94, 95]. Therefore, it is important to decrease the surface tension and increase 
the viscosity of the coating solution to develop a microneedle coating [94]. This approach 
was extensively researched by Gill and Prausnitz [94], who as well have developed a coating 
apparatus that requires small volumes of only 100 µL coating solution [95]. The combination 
of the micro-scale dip-coating device whereby the microneedles were dipped 6 times into an 
aqueous surfactant-viscosity enhanced coating solution, composed of 1% CMC and 0.1% Lutrol 
F-68, was used in later studies to coat microneedles with an influenza vaccine [84, 105-113], 
and was further improved by the addition of 15% trehalose to the coating solution to increase 
vaccine stability [108-110, 113].
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Figure 5: Examples of microneedle-based (trans)dermal delivery of model drugs into the skin. (A) Infusion of 
sulforhodamine in human cadaver skin by using hollow microneedles by the ‘poke and flow’ approach. The upper 
picture is the stratum corneum side and the lower picture is the bottom side of the skin [39]. (B) Drug delivery 
by the ‘poke and patch’ approach in ex vivo human skin of FITC labeled 200 nm polystyrene nanoparticles (upper 
and lower right picture, which are respectively an in depth scan and top view of nanoparticle penetrated skin by 
confocal microscopy) and trypan blue (lower left picture) [47]. The delivery of sulforhodamine in ex vivo pig skin 
by the ‘poke and release’ approach. On the left picture sulforhodamine encapsulated dissolving microneedles 
are shown before and after insertion in the skin. The right pictures show ex vivo pig skin after treatment with 
sulforhodamine encapsulated microneedles (the upper shows a top view by light microscopy, the lower shows a 
cross section by fluorescence microscopy) [53]. (D) Drug delivery by the ‘coat and poke’ approach of Cy3 labeled 
DNA (yellow) and Dil labeled PLGA nanoparticles (blue). The upper left picture shows uncoated microneedles and 
the middle picture shows microneedles coated by a nanolayered coating method. The lower pictures show the 
delivery of DNA (left) and PLGA nanoparticles (right) [120].
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 Other microneedle coating technologies have been developed, such as aerosol coating 
of microneedles [114], a roller drum approach whereby coatings of 100 µm thick were 
produced without coating the tip, to circumvent it from becoming blunt [115]. Furthermore, 
a conventional film coating process with hydroxypropyl methylcellulose and CMC for coating 
microneedles has been developed [99]. Also, a gas-jet drying device has been developed 
to coat microneedles with a coating solution, containing a drug, viscosity enhancer and a 
surfactant to generate coatings of 5 µm thick. However, during this procedure the backplate 
of the microneedle array is coated as well, resulting in a drug delivery efficiency of less than 
33% [65, 66, 100].
 Methods to increase the coating efficiency are the pre-coating of the surface of 
microneedles (e.g., with SiO2, PLGA, polyvinylpyrrolidone [94], chitosan [102]) or by 
the generation of polyelectrolyte coatings with microencapsulation properties (e.g., 
poly[di(carboxylatophenoxy)phosphazene] (PCPP) [116, 117], chitosan and CMC [118]). It 
has been shown that some of these pre-coatings lead to improved delivery into the skin, 
adjuvant effect, and improved vaccine stability [116, 117]. Furthermore, a recently developed 
sophisticated method to coat microneedle arrays is a layer-by-layer (LbL) coating approach, 
whereby nanolayers are formed by alternate coating of positively and negatively charged 
polyelectrolytes [119]. LbL coatings for microneedles have been developed by generating 
polyelectrolyte multilayers (PEM) for the (trans)dermal delivery of DNA [120] and proteins 
[104]. LbL PEMs are thin layers which enable nanometer-scale control over film structure 
and composition, provide control over multiple encapsulated agents, and give a robust 
control over the released material. Furthermore, they stabilize the encapsulated materials by 
occlusion and protect them against environmental influences. Finally, because these coatings 
are very thin (~100 nm) the microneedle geometry and sharpness are better preserved [100, 
102, 104, 115, 120].
 A variation on the ‘coat and poke’ method is the ‘dip and scrape’ approach, whereby 
the solid microneedles are first coated and are subsequently scraped over the skin. This 
approach leads to the delivery of drugs and vaccines in the formed micro-abrasions, which 
has the benefit that blunt tip solid microneedles can be used [81]. However, scraping induces 
more disrupture of the epidermis than poking and may therefore induce more skin irritation. 
Moreover, this method most likely suffers from variable, less controlled delivery of the drug 
into the skin.
5. Vaccine and protein delivery by microneedles
 In this review we dedicate a separate section to the delivery of therapeutic proteins and 
antigenic proteins for vaccination by microneedles, because these types of drugs are more 
difficult to deliver (trans)dermally and because of stability challenges. The different methods 
of drug delivery by microneedles, as described above, all have their own advantages and 
disadvantages with respect to (trans)dermal protein delivery. This is dependent on the type 
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of protein that needs to be delivered, e.g., therapeutic proteins have different requirements 
than protein antigens for immunization. For instance, whereas vaccines should be targeted to 
immune cells, for therapeutic proteins the opposite is true. The skin is an excellent organ for 
vaccination because of the large number of immune cells. Not surprisingly, protein delivery 
by microneedles has been studied mainly for the dermal delivery of antigens, as reviewed by 
Bal et al. (2010) [10]. For (trans)dermal vaccine delivery, preservation of protein integrity is 
important because a change in protein structure can lead to impaired vaccination efficacy and 
an altered immune response [109, 111, 112]. 
 There have been several different proteins delivered by microneedles for vaccination 
and therapeutic purposes in both human and animals. Ovalbumin is a frequently used model 
protein antigen for studying the suitability of microneedles for dermal immunization [37, 45, 
121-126]. Bovine serum albumin (BSA) [32, 34, 41, 51, 95, 102] and insulin [31, 41, 48, 50, 57, 94, 
127-130] have been used as model proteins for transdermal delivery of therapeutic proteins 
by microneedles. BSA is a 66 kDa protein, which has been delivered by the ‘poke and flow’ 
approach [41], the ‘poke and patch’ approach [32], the ‘poke and release’ approach [34, 51], 
and the ‘coat and poke’ approach [102]. Though all different approaches of drug delivery 
by microneedles have been used for insulin as well as BSA, the ‘poke and flow’ approach by 
hollow microneedles has been employed most frequently, both in vitro and in animal studies 
[31, 41, 48, 50, 57, 94, 127-130]. Besides, insulin has been delivered by microneedles in human 
studies by the ‘poke and flow’ approach [128, 131-133]. Other model proteins, therapeutic 
proteins, and peptides have been delivered by microneedles, such as erythropoietin [33], 
lysozyme [51], parathyroid hormone (PTH) [115], recombinant human growth hormone (rhGH) 
[48, 54], and etanercept [48]. However, only a few limited studies have been performed on 
the stability of therapeutic proteins (trans)dermally delivered by microneedles (see below). 
Protein stability definitely requires more attention in order to give (trans)dermal protein 
delivery a chance to reach the clinic. 
 Different approaches of drug delivery by microneedles may induce different types of 
protein degradation, as summarized in table 3. Park et al. (2006) produced BSA-containing 
dissolving microneedles by filling a drug containing microneedle mold with a melted polymer 
at 135° C; BSA was kept in the solid state to limit protein degradation. They studied the stability 
of microneedle encapsulated BSA by measuring protein solubility, dynamic light scattering 
(DLS), and circular dichroism (CD). After heating BSA in the solid state for 10 min at 135°C 
no significant difference was found by DLS, whereas heating for 20 and 30 minutes led to 
aggregates in the size order of tens of nanometers. Furthermore, they observed little or no 
changes in the secondary structure after thermal processing of the protein in the solid state. 
However, 10% BSA was irreversibly aggregated after 10 min exposure to the polymer melt, 
and BSA was completely denatured after 1 h exposure to 135°C [34], which shows that this 
approach is not viable for the delivery of BSA and most likely other proteins. Lee et al. (2008) 
generated dissolving microneedles for BSA and lysozyme at ambient temperature conditions. 
They studied the structural and functional integrity of microneedle encapsulated lysozyme by 
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CD and enzymatic activity, respectively, and found that according to these methods lysozyme 
was not substantially degraded after two months of storage at room temperature [51]. 
However, one should keep in mind that lysozyme is a relatively stable model protein that 
may not be representative for relevant therapeutic proteins. Migalska et al. (2011) generated 
insulin encapsulated dissolving microneedles and found no chemical changes of denatured 
insulin by reversed-phase (rp) high-performance liquid chromatography (HPLC) and no 
changes of the secondary structure of insulin by CD [50]. Finally, Fukushima et al. (2011) 
produced rhGH encapsulated in dissolving microneedles and reported that the encapsulated 
rhGH was stable for one month, by an enzyme immunoassay and LC/MS/MS [54]. 
 Ameri et al. (2009) studied the stability of PTH coated on microneedles by rp-HPLC 
and size exclusion-HPLC. They observed that aggregation and oxidation were the primary 
degradation processes of coated PTH, and found that the addition of sucrose to the 
coating decreased the aggregation of PTH from 7% to <0.5%. They reported that solid state 
aggregation (7%) is the main degradation process, and that the oxidation of PTH (1%) may 
be metal catalyzed by metal contamination from excipients or by the titanium microneedles 
themselves [115]. As several studies have demonstrated that protein aggregates induced by 
metal catalyzed oxidation are particularly immunogenic in immune tolerant mouse models 
[134-136], the presence of these degradation products may pose serious immunogenicity 
concerns.
6. Perspectives
 Microneedle technologies offer a way to deliver drugs via the skin in a minimally-invasive 
and potentially painless manner and have been used to deliver drugs (trans)dermally by 
several approaches. However, “the microneedle” does not exist, and the ideal one is yet to 
be determined and may depend on the type of drug and the type of application. 
 Microneedles have been produced by different production methods from a variety of 
materials with a broad range of geometries and have been produced as solid and hollow 
microneedles. Furthermore, microneedles with different lengths have been used with or 
without a microneedle application device. However, all microneedles have restraints based 
on the type of microneedle. An important factor for microneedle-based drug delivery is 
the strength of the microneedles, i.e., they must not break during insertion into the skin. 
Hollow microneedles have a risk of clogging at the tip opening and are usually weaker 
than solid microneedles. This poses constraints on the design and the insertion methods 
of these needles. Furthermore, single hollow microneedles may be preferred over hollow 
microneedle arrays, because with the former there is a lower risk of leakage. However, if 
hollow microneedle arrays are made in such a way that each microneedle has its own drug 
reservoir, they may be preferred over single hollow microneedles because they can deliver a 
larger amount of drug.
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 To ensure that patients obtain the same and required dose during each administration 
microneedles should be able to pierce the skin in a reproducible manner. However, in order 
to obtain a reproducible penetration and a reproducible penetration depth an applicator 
is necessary. It has been shown that successful and reproducible skin penetration by 
microneedles can be reached by different approaches. For example, impact-insertion 
applicators are beneficial for high-density microneedle arrays and blunt microneedles to 
reach sufficient penetration; however, as the microneedle tip becomes sharper, a manual 
hand-held applicator may be sufficient.
 There have been several clinical trials performed for the (trans)dermal delivery of 
various drugs in humans by using microneedles. Zosano Pharma performed a  phase I/II 
study on the delivery of parathyroid hormone by using coated Macroflux® microneedles 
[137] and NanoPass Technologies have used their Micronjet® hollow microneedles for the 
delivery of insulin, influenza vaccine, and lidocaine (for local anesthesia) in clinical studies 
[138]. Also other clinical studies have been performed for the delivery of local anesthetics 
by microneedles. Gupta et al. used pulled hollow microneedles to deliver lidocain to the skin 
[139] and Li et al. used solid microneedles from Nanomed Devices for dermal delivery of 
dyclonine [140]. BD Medical-Pharmaceutical systems tested a rabies vaccine in a clinical trial 
Table 3: Hypotheses of microneedle induced protein degradation mechanisms, which may occur during protein 
delivery by microneedles. 
Stress factor Type of protein 
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by using the BD 34G hollow microneedles [86], and Wermeling et al. used solid microneedles 
for the transdermal delivery of naltrexone [141]. Finally, Gupta et al. used pulled microneedles 
to deliver insulin in a clinical study [128, 131], and Pettis et al. used steel microneedles in a 
clinical trial to administer insulin intradermally [132, 133]. 
 In order to move microneedles to the market for (trans)dermal drug delivery, it is very 
important to properly choose the type of microneedle (e.g., hollow, solid, geometry, material, 
density, length). Furthermore, in order to obtain sufficient and reproducible penetration, 
and the possibility of self-administration, microneedle application devices should be used. 
Therefore, new microneedle-based products for (trans)dermal drug delivery should be one 
complete package for each type of drug; including the drug, a stable drug formulation, 
appropriate microneedles, and a microneedle application device.
 Microneedle-based dermal immunization has been shown to be more dose effective 
than conventional intramuscular and subcutaneous immunization in both human and animal 
studies [66, 142-144]. Therapeutic proteins have been delivered by the different approaches 
of microneedle-based drug delivery, however, in the papers cited above protein structure 
was at best partially studied and still little is known about unwanted immunological effects 
of microneedle-based protein delivery. For therapeutic proteins, preservation of protein 
structure during manufacture, storage and use is considered even more important than for 
vaccines. Importantly, a change in the structure of therapeutic proteins does not only lead to 
a decrease of drug efficacy, it may also affect safety and induce unwanted immunogenicity. 
Furthermore, unwanted immunogenicity can lead to total loss of the therapeutic effect of a 
protein by neutralizing antibodies, and may even lead to depletion of endogenous proteins or 
breaking the immune-tolerance to self-antigens [145-150]. Since the skin is a potent immune 
organ, the latter is perhaps the biggest safety concern. This also underscores the need for 
extensive characterization of protein aggregates and subvisibe particles that may be present 
and released from transdermal microneedle-based formulations, as these are considered 
important risk factors for unwanted protein immunogenicity [145, 151, 152]. However, to 
our knowledge no reports on unwanted immunogenicity of therapeutic protein delivery 
by microneedles have been published and research in this area is urgently needed to move 
this field forward. This implies a rigorous analysis of protein structure to ensure its integrity 
during manufacture and release [153], as well as immunogenicity studies in relevant animal 
models [154]. 
 With the advance of microfluidics and microneedle technologies, microfabrication 
techniques are becoming more sophisticated. These techniques enable, in combination with 
hollow microneedles, the development of delivery and analysis devices on one chip (lab-
on-a-chip). Lab-on-a-chip devices are promising tools for single-cell analysis, diagnostic and 
treatment purposes. Devices can be developed, e.g., for diabetics, whereby microneedles 
may be integrated with a microsensor for glucose detection, a micropump for delivering 
insulin, and a microchip which regulates the blood glucose value by observing it and adjusting 
the delivery of insulin accordingly [1-3, 21, 22, 42, 155].
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 Altogether, microneedle-based (trans)dermal drug delivery may have a great impact in 
future medicine, both for vaccination purposes and for the delivery of therapeutic drugs. 
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 Microneedles are needle-like structures shorter than 1 mm 
that have been advocated as devices for enabling potentially pain 
free intradermal delivery of biomacromolecules [1-5]. To permit a 
reproducible delivery of the drug, microneedles should be inserted 
into the skin in a controlled and reproducible manner [4, 6]. 
Obviously, one of the factors that influence the penetration ability of 
microneedles is the insertion process itself, e.g., microneedles can be 
inserted manually or by using insertion devices [3, 4, 6-9]. Recently, 
the penetration ability of low-density arrays (42 microneedles/cm2) 
with 750 µm long microneedles, applied manually or by using a snap-
based applicator, was investigated [10]. However, no studies have 
been reported on the efficiency and reproducibility of the insertion of 
high-density microneedles into human skin. Therefore, the aim of this 
study was to investigate the effect of the type of application on inter 
and intra individual variability of microneedle insertion into human 
skin by microneedle users.
 We show that participants using an impact-insertion applicator 
inserted high-density microneedles into ex vivo human skin with 
high efficiency and with a low inter and intra individual variation. 
However, when the same microneedle arrays were inserted by using 
a manual insertion device, the penetration efficiency was reduced by 
approximately 40% with a considerably lower reproducibility. Finally, 
the applicability of an impact-insertion applicator/microneedle arrays 
was confirmed in a vaccination study in mice.
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2. Materials and methods
2.1 Microneedle application
 In this study high-density arrays (576 microneedles on a 5x5 mm backplate, gifted by 
Bosch, Germany, Stuttgart) with a microneedle length of 200 µm were used (figure 1). The 
microneedles were applied onto ex vivo human abdominal skin that was obtained from 
hospitals within 24 hours after cosmetic surgery and dermatomed to a thickness of 600 
µm [11]. To investigate factors that influence the penetration efficiency, microneedles were 
applied onto the skin for 10 seconds with different forces (3.43-22.1 N) by applying weight rods 
(350-2250 g) onto the insertion device for manual application. Also, the effect of application 
time (5-60 seconds) with a constant force (7.36 N) was investigated. Next, 15 participants 
(21-57 year; 10 male and 5 female) volunteered to apply a microneedle array three times onto 
ex vivo human skin, in a direction perpendicular to the skin surface, by using either a manual 
application device (figure 1D), or an impact-insertion applicator at a velocity of 3 m/s (figure 
1E) [12]. The type of microneedle application was randomly performed.
2.2 Penetration ability of microneedles
 To determine the penetration ability, 70 µL of an aqueous 0.4% trypan blue (Sigma 
Aldrich) solution was applied and left for one hour at the site of prior microneedle application. 
Subsequently, the skin surface was washed two times with water and once with 70% ethanol. 
Next, the stratum corneum (SC) was removed by tape-stripping (Scotch tape) until no SC 
residue was visually observed on the tape and the skin appeared shiny. Finally, the penetration 
efficiency (PE) was calculated as follows:
PE = (number of blue spots / 576) * 100% 
2.3 Safranin staining
 To visualize the SC removal efficiency, 10 µm thick cryosections of control and tape-
stripped skin were made on a Leica cryostat (CM 3050S) and stained for 1 minute in a 1% (w/v) 
Safranin O solution (Sigma Aldrich). Next, the number of layers was visualized by swelling the 
SC in a 2% (w/v) KOH solution for 20 minutes (n=3). 
Figure 1: Electron micrographs of a high-density array of 200 µm long silicon microneedles with a magnification of 
90x (A), 400x (B), and 3000x (C), mounted on a manual insertion device (D) or an impact-insertion applicator (E).
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2.4 Immunization of mice with ovalbumin
 Eight-week old female BALB/c mice (Charles River) were immunized thrice with intervals 
of three weeks by the ‘poke and patch’ approach (100 µg ovalbumin /70 µL PBS (pH 7.4) for 
two hours, as previously described [13]), by using the impact-insertion applicator to apply 
either the high-density microneedle arrays or our first-generation LU-microneedles. The latter 
are made of 30 G needle tips, 300 µm long, and fixed in a backplate as a 4x4 microneedle 
array. They were previously shown to penetrate the skin when using the impact-insertion 
applicator [12]. A subcutaneous injection of 5 µg ovalbumin in 100 µL PBS was used as positive 
control. Ovalbumin-specific serum IgG responses were determined by a sandwich ELISA, 
as described previously [13]. Antibody titers were expressed as the log value of the serum 
dilution at the mid-point of a complete S-shaped absorbance-dilution curve. The study was 
carried out under the guidelines complied by the animal ethic committee of the Netherlands, 
and was approved by the “Dierexperimentencommisie Universiteit Leiden (UDEC)” under 
number 13065.
3. Results and discussion
3.1 Assessment of piercing efficiency after stratum corneum removal 
 The application of dyes at the site of microneedle application is commonly used to assess 
microneedle penetration in the skin [12, 14-16]. However, when observing the complete skin 
following microneedle application, the resulting spots are not always penetrations, but could 
be indentations of the SC (see supplemental information). Indeed, our study made clear that 
without SC removal the penetration efficiency is overestimated. When microneedle arrays 
were applied with a manual insertion device onto ex vivo human skin, blue spots were visible 
(figure 2A), suggesting successful skin piercing with an efficiency of 81% (figure 2C). However, 
after removal of the SC less blue spots were visible (figure 2B), showing that only 46% of 
the microneedles pierced the skin (figure 2A). The SC consists of 20 layers of corneocytes 
(figure 2D), and after tape-stripping most of the SC was removed (figure 2E), which allowed a 
reliable assessment of the piercing efficiency. Therefore, this approach was used in the study 
described below.
3.2 Penetration ability of high-density microneedle arrays
 First, two factors, application force and time, that potentially influence the penetration 
efficiency of manual microneedle application were investigated (figure 3). Increasing the 
applied force (at a constant application time of 10 seconds) up to 7.36 N greatly improved the 
penetration ability (3A), which is in agreement with the literature [9]. Further increase of the 
force or prolonging the application time of the microneedles at a constant force (7.36 N) only 
minimally increased the penetration efficiency but improved the reproducibility (3B). 
 Next, to investigate whether persons without microneedle experience are able to 
successfully and reproducibly penetrate skin, 15 participants were instructed to apply 
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microneedles onto ex vivo human skin by using a manual insertion device or an impact-
insertion applicator (fi gure 3C and 3D). Using a manual application device resulted in low 
penetration effi  ciencies (56%) and relative high inter and intra individual variation, which 
was probably caused by variations in applied force and that the microneedle application 
conditions were below the optimum insertion conditions. However, when using the impact-
insertion applicator, all participants pierced the skin with signifi cantly lower inter and intra 
individual variation. These results show that using a microneedle applicator is essential for 
effi  cient and reproducible penetration of skin by a high-density microneedle array.
3.3 Vaccination study in mice
 To demonstrate that the use of the impact-insertion applicator can lead to reproducible 
immune responses following microneedle-mediated immunization, we performed a 
vaccination study in mice, using ovalbumin as a model antigen. Figure 4 shows that 
microneedle-based vaccination leads to the induction of reproducible ovalbumin-specifi c IgG 
responses. Interestingly, using high-density microneedles resulted in up to ten-fold higher IgG 
responses as compared to our fi rst-generation LU-microneedles. As both microneedle arrays 
result in reproducible piercing, the diff erence is probably caused by diff erences in microneedle 
density, number (576 versus 16 microneedles/array) and geometry [12]. Furthermore, a 
comparison between microneedle-based and subcutaneous administration revealed that 
vaccination by using high-density microneedles initially led to signifi cantly lower IgG responses 
than subcutaneous vaccination, but the diff erences became negligible after the 2nd boost. 
This shows that microneedle-based vaccination can lead to comparable immune responses as 
Figure 2: Representati ve examples of microneedle-pierced trypan blue stained ex vivo human skin before (A) and 
aft er stratum corneum (SC) removal (B). Calculated penetrati on effi  ciency before and aft er SC removal (mean ± 
SD, n=3) (C). Representati ve examples of Safranin O stained freeze coupes of non-stripped (D) and tape-stripped 

















































































Figure 3: Penetration efficiency after application of a high-density microneedle array onto ex vivo human skin 
with different forces for 10 seconds (A) and at a constant force (7.36 N) with varying application times (B). 
The application of microneedles onto ex vivo human skin by non-experienced microneedle users (C and D). 
15 participants pierced the skin with 200 µm long microneedles by a manual insertion device (open circles) 
or an impact-insertion applicator (closed circles). Each point represents the average penetration efficiency of 
three individual microneedle applications by one individual (C) and the relative standard deviation (RSD) of the 


































s Figure 4: Ovalbumin-specific IgG responses upon microneedle-based (n=8) 
immunization by using an impact-insertion 
applicator with first-generation (LU-MN) 
or high-density (Bosch) microneedles, and 
subcutaneous (s.c.) injection (n=5). Each 
bar represents the mean ± SEM. Non-
responders were given an arbitrary titer of 
1 and significance (*p<0.05, ***p<0.001) 
was determined by a two-way ANOVA with 
a Bonferroni post test.
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compared to conventional immunization. Similar or slightly lower responses of microneedle-
mediated vaccination with ovalbumin, as compared to subcutaneous/intramuscular injection, 
has been observed before [17, 18]. In conclusion, these data show the potential of using high-
density microneedles with an impact-insertion applicator for vaccination.
4. Conclusion
 This study shows that using an impact-insertion applicator improves the efficiency and 
reproducibility of high-density microneedle insertion, enabling reliable self-application of 
microneedle arrays onto the skin. Moreover, it was demonstrated that the impact-insertion 
applicator can be used for microneedle-mediated antigen delivery, yielding robust antigen-
specific IgG responses, which depend on microneedle density and/or geometry.
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Abstract
 Microneedle-based vaccination has several advantages over 
vaccination by using conventional hypodermic needles. Microneedles 
are used to deliver a drug into the skin in a minimally-invasive and 
potentially pain free manner. Besides, the skin is a potent immune 
organ that is highly suitable for vaccination. However, there are 
several factors that influence the penetration ability of the skin by 
microneedles and the immune responses upon microneedle-based 
immunization. In this study we assessed several different microneedle 
arrays for their ability to penetrate ex vivo human skin by using 
trypan blue and (fluorescently or radioactively labeled) ovalbumin. 
Next, these different microneedles and several factors, including the 
dose of ovalbumin, the effect of using an impact-insertion applicator, 
skin location of microneedle application, and the area of microneedle 
application, were tested in vivo in mice. The penetration ability and 
the dose of ovalbumin that is delivered into the skin were shown to 
be dependent on the use of an applicator and on the microneedle 
geometry and size of the array. Besides microneedle penetration, 
the above described factors influenced the immune responses 
upon microneedle-based vaccination in vivo. It was shown that the 
ovalbumin-specific antibody responses upon microneedle-based 
vaccination could be increased up to 12 fold when an impact-insertion 
applicator was used, up to 8 fold when microneedles were applied 
over a larger surface area, and up to 36 fold dependent on the 
location of microneedle application. Therefore, these influencing 
factors should be considered to optimize microneedle-based dermal 
immunization technologies.
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CHAPTER 3.2: Microneedle pretreatment




 Microneedles are needle like structures with a length of less than 1 mm. Microneedles 
are used for the delivery of drugs, including vaccines, into the skin in a minimally-invasive and 
potentially pain free manner [1, 2]. In order to deliver a drug, however, microneedles should 
meet certain criteria. Primarily, microneedles should be long enough to pierce the stratum 
corneum but preferably short enough not to reach blood vessels and nerve endings. Even 
though microneedles have been developed with a sufficient length (300 µm) to penetrate 
human stratum corneum (15-20 µm), they often require an insertion device to overcome the 
skin’s elasticity [3, 4]. 
 Microneedles are used by four different approaches to deliver a drug into the skin, 
as reviewed elsewhere [5, 6]. One of these approaches is the ‘poke and patch’ approach, 
whereby microneedles are first used to pierce conduits into the skin and subsequently a patch 
that contains a drug formulation is applied on the site of microneedle application. The drug 
will diffuse through the conduits into skin [5, 6]. Logically, microneedles should penetrate the 
stratum corneum to enhance drug delivery into the viable skin.  However, there are several 
factors that affect the penetration ability of microneedles, such as the microneedle density, 
the length of microneedles, the sharpness of the microneedle tip, the site of microneedle 
application, and the use of an applicator [4-6]. All of these factors may influence the immune 
responses upon microneedle-based vaccination. For example, it has been reported that the 
microneedle length influences the antigen-specific immune responses, e.g., 200-300 µm long 
microneedles induce lower responses than 800-1000 µm long microneedles [7, 8]. However, 
microneedles longer than 400 µm are more likely to induce pain [5]. A better insight into 
the influence of these factors on the immune responses could help to improve microneedle-
based immunization in general.
 In this study we investigated several of the above-mentioned factors on microneedle-
based vaccine delivery by the poke and patch approach using ovalbumin as a model antigen 
and using microneedles with a length of 300 µm. First, the penetration ability of ex vivo 
human skin by several different microneedles was determined. Subsequently, the depth 
of ovalbumin delivery and the ovalbumin dose into ex vivo human skin was quantified. 
Finally, the effect of multiple parameters on the ovalbumin-specific immune responses was 
investigated. This study shows that antigen-specific IgG responses are dependent on the 
usage of an impact-insertion applicator, the microneedle application area, and the site of 
microneedle application.
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2. Materials and methods
2.1 Chemicals
 Sulfuric acid 96-98% was obtained from BOOM lab equipment, and sterile phosphate 
buffered saline (PBS) (140.3 mM Cl-, 163.9 mM Na+, 8.7 mM HPO4
2-, and H2PO4
-, pH 7.4) 
was obtained from Braun. Chicken egg ovalbumin conjugated with Alexa-Fluor® 555 and 
stabilized Chromogen TMB were purchased from Invitrogen. Chicken egg ovalbumin grade 
VII was purchased from CALBIOCHEM®. Flat bottomed black 96-well plates and MICROLON® 
ELISA-plates were obtained from Greiner Bio-One. Bovine serum albumin fraction V was 
obtained from Roche. Pierce® Iodination Beads and goat anti-mouse IgG-horseradish 
peroxidase (HRP) (γ chain specific) was obtained from SouthernBiotech. Nimatek® (100 mg/
mL ketamine, Eurovet Animal Health B.V., Bladel, the Netherlands), Rompun® (20 mg/mL 
xylazine, Bayer B.V., Mijdrecht, the Netherlands), and Oculentum Simplex were obtained 
from a local pharmacy. Iodine-125 radionuclide, 2 mCi (74 MBq), specific activity: ~17 Ci (629 
GBq)/mg, in 10-5 M NaOH (pH 8-11) (reductant free), concentration: 100 mCi/mL was obtained 
from Perkin-Elmer. Amicon® Ultra centrifugal filter units with a molecular weight cut off of 
30 kDa were obtained from Millipore™. VectaSheld® mounting medium with 4’,6-diamidino-
2-phenylindole (DAPI) was obtained from Vector Lab, Tissue-Tek® O.C.T. compound was 
obtained from Sakura Finetek, and trypan blue was from Sigma Aldrich.
2.2 Mice
 Female BALB/c mice (H2d) were obtained from Charles River (Maastricht, the 
Netherlands) and were maintained under standardized conditions in the animal facility of 
the Leiden Academic Centre for Drug Research, Leiden University. The mice were 8 weeks 
old at the start of the vaccination study and the study was carried out under the guidelines 
complied by the animal ethic committee of the Netherlands, and was approved by the 
“Dierexperimentencommissie Universiteit Leiden (UDEC)” under number 11127 and 13065.
2.3 Preparation of ex vivo human skin
 Abdominal human skin was obtained within 24 h after cosmetic surgery. After the fat 
was removed the skin was dermatomed to a thickness of 600 µm using a Padgett Electro 
Dermatome Model B. Subsequently, the skin was stretched on Styrofoam covered with 
parafilm and was washed once with 70% ethanol and twice with PBS.
2.4 Microneedle application
 In this study six different microneedle arrays were used, as shown in figure 1. All 
microneedles in this study had a length of 300 µm. The U-Needle (UN) microneedle arrays 
contained 17 (8+9), 9 (4+5), 5 (2+3), and 3 (1+2) microneedles per array (figure 1A1-4, 
respectively) and were applied onto the skin with a hand-held applicator. The Tyndall and 
Leiden University (LU) microneedle arrays (fig B and C) contained 16 (4x4) microneedles per 
array and were applied by using an electrically-driven impact-insertion applicator at a velocity 
of 3 m/s, as described previously [9].
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 The different microneedles that were used in this study have been previously described. 
In brief, UN microneedles are in-plane microneedles that are wet-etched (KOH) from 380 µm 
thick <100> silicon wafers at 70° from a <100> wafer, yielding a three faced microneedle tip and 
a three faced shaft with near atomic flat <111> planes. At the intersection of two non-parallel 
<111> planes a near atomic sharp blade is formed, whereas at the intersection of three non-
parallel <111> planes a near atomic sharp tip is formed [10]. Tyndall microneedles are out-of-
plane microneedles that are wet-etched (KOH) from <100> silicon wafers. The microneedles 
have an octagonal shape and a sharp tip that is formed on top of the frustum where the 
eight high index planes <312> come together [11]. Finally, LU microneedles are made from 
commercially available (Becton and Dickinson) stainless steel 30G hypodermic needles that 
are mounted in a polyether ether ketone (PEEK) mold [3].
2.5 Penetration ability of different microneedles into ex vivo human skin by a trypan blue assay
 In order to test the penetration ability of the different microneedle arrays into the skin, 
a trypan blue assay was performed. This was done by first applying the microneedles onto 
ex vivo human skin, and subsequently applying a drop of 70 µL 0.4% trypan blue in PBS onto 
the area of microneedle application at room temperature and at 100% relative humidity to 
prevent evaporation of the drop. After one hour the trypan blue solution was removed and 
the skin was washed once with 70% ethanol and twice with PBS. Subsequently, the stratum 
corneum side of the skin was photographed under a stereo microscope (magnification of 
10x). Next, the epidermis was heat separated from the dermis at 60°C for 2 minutes, and the 
upper dermis side was photographed under a stereo microscope (magnification of 10x).
2.6 Fluorescence microscopy and confocal imaging of ovalbumin delivery into ex vivo human skin
 Fluorescence microcopy was used to evaluate whether ovalbumin is able to diffuse 
into the skin via the formed conduits. Therefore, microneedles were first used to pierce ex 
vivo human skin, and subsequently a drop of 70 µL PBS, containing 100 µg Alexa-Fluor® 555 
labeled ovalbumin, was applied onto the area of microneedle application. The skin was kept 
at 100% relative humidity to prevent evaporation of the drop. After two hours the drop was 
removed and the skin was washed as described above. Subsequently, the skin was analyzed 
by fluorescence microscopy (Nikon Eclipse E600) with a mercury light source, a Cy3 filter set, 
400x magnification, and an exposure time of 18 µs.
 In order to evaluate the depth of ovalbumin delivery and to visualize the microneedle 
conduits generated by the microneedles into ex vivo human skin, confocal laser scanning 
microscopy (CLSM) was used (Bio-Rad Radiance 2100 confocal laser scanning system, 
equipped with a Nikon Eclipse TE2000-U inverted microscope with a helium neon laser at 
543 nm with a 570-nm long-pass emission filter). For controlling the confocal laser scanning 
system and for image acquisition, the Laser Sharp 2000 software (Bio-Rad, Hercules, USA) 
was used. Images of the microneedle conduits in ex vivo human skin were taken with a xy 
scan (2980x2980 µm) from 0-600 µm with depth intervals of 50 µm. Subsequently, these 
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images were used to calculate the depth of ovalbumin delivery with ImageJ (available from 
rsbweb.nih.gov/ij/), by loading the image stack into the program and increasing the depth 
resolution 5x with a bilinear interpolation. Next, the fluorescence intensity as a function of 
depth was calculated. Subsequently, the intensity was plotted as a function of the depth in 
Prism 5 for Windows, and by linear regression (intensity(depth)=10, background fluorescence 
of non-treated skin) the maximum delivery depth was calculated. Furthermore, the confocal 
images were loaded into ImageSurfer version 1.20 (available from http://imagesurfer.cs.unc.
edu/) to reconstruct the conduits generated by the microneedles into human skin in a 3 
dimensional space. 
 To visualize the formed conduits and simultaneously visualize the different layers 
of the skin, fluorescent nanoparticles were visualized in cryo-fixed skin. To this end, 
Figure 1: Images of 300 µm long U-Needle (A, D, G), Tyndall National Institute (B, E, H) and Leiden University 
(C, F, I) microneedle arrays that are mounted on an applicator for manual piercing (A) or on an impact-insertion 
applicator (B and C), and scanning electron microscopy images of these microneedle arrays (D-F) and zoomed in 
on the tip of a single microneedle (G-I). Size bars represents 2 mm (A-C), 500 µm (D-F), and 50 µm (G-I).
CHAPTER 3.2: Microneedle pretreatment
Parameter optimization toward optimal microneedle-based 
dermal vaccination
53
UN 17-microneedle arrays were used to pierce ex vivo human skin onto which 70 µL with 
TMC-Rhodamin B nanoparticles (200-300 nm) were applied as described above. These 
nanoparticles were prepared as previously described [12]. Subsequently, skin was embedded 
in Tissue-Tek® O.C.T. compound in a gelatin capsule and was cryo-fixed in liquid nitrogen. 
Next, cryosections with a thickness of 5 µm were cut on a Leica® CM3050S cryostat, and the 
skin was fixed with acetone for 10 minutes. Then, the nuclei in the fixed skin were labeled 
with VectaSheld® mounting medium with DAPI, and the skin was photographed under a 
fluorescence microscope (magnification of 100x, DAPI and Cy3 filter set with an exposure 
time of 5 s and 1 s, respectively). Finally, the fluorescence images with the two different filter 
sets were overlaid in ImageJ.
2.7 Quantification of ovalbumin delivery into ex vivo human skin
 To quantify the amount of protein that was delivered into ex vivo human skin, 
radioactively labeled (125I) ovalbumin, prepared as previously described [13], was used. Ex vivo 
human skin was pierced with the different microneedle arrays and subsequently a drop of 
70 µL, containing 100 µg of radioactively labeled ovalbumin, was applied onto the skin as 
described above. After 2 hours the drop was removed and the skin was washed and dried 
twice with a cotton swab soaked in PBS. Subsequently, to remove the remaining ovalbumin 
from the skin surface the skin was tape-stripped twice by using Scotch tape. All the cleaning 
and tape samples were kept for γ-measurements, as well as the sheets of skin that were 
treated with microneedles. Next, a calibration curve was prepared (1 ng - 50 µg radioactively 
labeled ovalbumin) to quantify the dose of ovalbumin that was delivered into the skin. Finally, 
the γ-counts of the samples were measured for 1 minute on a Perkin Elmer Wallac Wizard 
1470 automatic gamma counter.
2.8 Immunizations
 In order to test the IgG responses after microneedle-based immunization, mice were 
immunized thrice with intervals of three weeks. The effect of a large number of parameters 
on the serum IgG responses was investigated, as described below: 
1. The effect of the number of microneedles in a microneedle array. For these studies 
UN microneedle arrays were used that contained 3, 5, 9, or 17 microneedles per 
array. 
2. The effect of using differently shaped microneedles with the same length (300 µm). 
Here, the UN 17-, Tyndall 16- and LU 16-microneedles were compared.
3. The adjuvant effect of using an impact-insertion applicator. This was done by first 
manually applying the UN 3- or 17-microneedle arrays onto the skin, followed (after 
removal of the microneedles) by no punch or with a punch of 3 m/s by the impact-
insertion applicator (with an empty backplate). The UN microneedle arrays pierce ex 
vivo human skin when applied with a manual insertion device [13].
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4. The effect of size of microneedle application area. For this study the same number 
of microneedles was applied onto a larger surface area, i.e., a single application by 
a UN 17-microneedle array was compared to six applications by a UN 3-microneedle 
array. 
5. The effect of microneedle application site. For this study mice were immunized by 
using a UN 17-microneedle array on the ventral abdomen or the ear pinna.
 Mice that were immunized to investigate the above described parameters 1-4 were 
treated with microneedles on the ventral abdomen skin. After microneedle application and 
removal, 100 µg of ovalbumin in 70 µL PBS was occlusively applied onto the skin, as previously 
described [14]. After two hours the patch was removed and the skin was washed with hand-
warm tap water. All mice were anesthetized with 150 mg/kg ketamine and 10 mg/kg xylazine 
by intraperitoneal injection, and one day before each immunization the ventral abdomen skin 
of the mice was shaved. Parameters 1 and 2 were investigated with 11 mice per group and 
parameters 3-5 with 8 mice per group.
2.9 Serum IgG detection
 Ovalbumin specific antibodies were determined by a sandwich ELISA as described 
previously [14]. In brief, 96-well plates for ELISA were coated overnight with 1 µg/mL ovalbumin 
in a 0.04 M carbonate buffer at pH 9.6 at 4 °C (100 µL/well). Next, the plates were blocked 
for 1 h at 37°C with 1% BSA in PBS. Thereafter, two-fold dilutions of the sera of individual mice 
were prepared in 96-well plates and were incubated for 1.5 h at 37°C. Then, the wells were 
incubated for 1 h at 37°C with HRP conjugated goat anti-mouse IgG (γ chain specific). Finally, 
100 µL TMB was added per well and after 15 minutes the reaction was stopped by adding 
100 µL/well 2 M H2SO4, after which the optical density was measured at 450 nm. Antibody 
titers were expressed as the log value of the serum dilution at the mid-point of a complete 
S-shaped absorbance-dilution curve.
2.10 Statistical analysis
 Statistical analysis was performed using Prism 5 for Windows. The statistical significance 
of the depth of ovalbumin delivery was calculated by using a one-way ANOVA and the 
statistical significance of ovalbumin-specific IgG titers calculated using a two-way ANOVA 
with a Bonferroni post test.
3. Results and discussion
3.1 Penetration ability of microneedles
 For each microneedle array it is essential that the microneedles penetrate the stratum 
corneum to enable drug delivery into the viable skin [5, 6]. To evaluate skin penetration by 
microneedle arrays several dyes have been used [3, 9, 15-17], including trypan blue [3, 9]. In 
order to examine whether the different microneedle arrays are able to pierce ex vivo human 
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skin a trypan blue assay was performed. As shown in fi gure 2, after microneedle application 
dark blue stains were visible on the stratum corneum. However, this does not prove that 
the microneedles have penetrated the skin. Therefore, the epidermis was separated from 
the dermis, which revealed that trypan blue had penetrated into the top layer of the dermis 
(approximately 150-200 µm deep [6]) after microneedles pretreatment. In contrast, when 
no microneedles were applied, only a weak blue stain was visible on the stratum corneum 
side and no staining in the dermis was observed. Although all the microneedles had a length 
of 300 µm, pretreatment with the UN and Tyndall microneedles, both made of silicon, 
resulted in more intense staining of trypan blue in the dermis compared to pretreatment 
with the LU microneedles. This diff erence in staining can be explained by the geometry of 
the microneedles (fi gure 1): the LU microneedles were thinner and less sharp than the UN 
and Tyndall microneedles. Besides, microneedles etched from silicon are generally sharper 
than microneedles made of stainless steel. Indeed, the LU microneedles had a tip diameter 
Figure 2: Penetrati on ability of microneedles assessed by a trypan blue assay. Diff erent microneedles were 
applied onto dermatomed ex vivo human skin and subsequently a drop of trypan blue was applied for 1 
hour. Then, the skin was photographed from the stratum corneum (upper images) side. Next, the dermis was 
heat separated from the epidermis (lower images). Tyndall and LU microneedles were applied by an impact-
inserti on applicator and UN microneedles by a device for manual inserti on. Photographs were made by a stereo 
microscope with a magnifi cati on of 10x; the size bar represents 1 mm.
Figure 3: Applicati on of fl uorescently 
labeled ovalbumin (Alexafl uor-555) 
onto ex vivo human skin, without 
microneedle pretreatment (A), or 
pretreated with LU 16-microneedles 
(B), Tyndall 16-microneedles (C), and 
UN 17-microneedles. Tyndall and LU 
microneedles were applied by an impact-
inserti on applicator and UN microneedles 
by a device for manual inserti on.
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of 4-5 µm, the Tyndall microneedles 1-1.5 µm, and the UN microneedles had a diameter of less 
than 50 nm. The extreme sharpness of the UN microneedle arrays resulted in an efficient and 
reproducible penetration of the skin by applying the microneedles by only hand-force using 
a device for manual insertion. However, to reproducibly penetrate ex vivo skin with either 
Tyndall or LU microneedle arrays, the use of an impact-insertion applicator was required 
(data not shown) [9]. In conclusion, the trypan blue assay revealed that all the different 
microneedle arrays that were used in this study are able to reproducibly penetrate human 
skin.
3.2 Delivery of fluorescently labeled ovalbumin into ex vivo human skin
 After it was shown that the different microneedle arrays are able to pierce ex vivo human 
skin by using a low-molecular weight model compound (trypan blue), the delivery of a 45-
kDa biomacromolecule, ovalbumin, into the skin was investigated. Therefore, fluorescently 
labeled ovalbumin was applied onto ex vivo human skin that was non-treated or pretreated 
with the LU Tyndall, or UN microneedle arrays (figure 3). Figure 3A shows that hardly any 
fluorescence was visible on non-treated ex vivo human skin, indicating that no ovalbumin 
was delivered into the skin. However, when we pretreated the skin with microneedle arrays, 
fluorescence patterns similar to the trypan blue images (figure 2) were visible (figure 3B-D). 
This already suggests that microneedle pretreatment with all microneedle arrays resulted 
in the delivery of biomacromolecules into the skin. To obtain more evidence on the delivery 
of ovalbumin into ex vivo human skin, studies were also performed by using CLSM. The 
images are shown after application of LU microneedles (figure 4A), Tyndall microneedles 
(figure 4B), and UN microneedles (figure 4C). Subsequently, from the CLSM the penetration 
depth of fluorescently labeled ovalbumin into the skin was calculated (figure 4D). This image 
shows that ovalbumin was delivered to a depth of approximately 75% of the length of the 
microneedles for the LU and Tyndall microneedles. However, upon piercing of the U-Needle 
microneedles, fluorescently labeled ovalbumin was delivered to a depth of approximately 
95% of the microneedle length. Despite this difference, we expect that the LU and Tyndall 
microneedles were fully inserted into the skin, because an impact-insertion applicator was 
used. The difference in depth of ovalbumin delivery might be caused by the shape of the 
microneedles, i.e., U-Needle microneedles are much broader than the ones of the two other 
arrays (figure 1), resulting in the formation of larger conduits upon microneedle pretreatment 
(figure 2), which apparently leads to delivery of ovalbumin deeper into the skin (figure 4).
 Next, to visualize the conduits in the skin as well as the skin structure, TMC-rhodamine 
nanoparticles were used. These large nanoparticles (200-300 nm) are expected to only coat 
the conduits and the slightly negatively charged stratum corneum, i.e., the top layer of the 
skin, but are not expected to rapidly diffuse into the epidermis/dermis. Upon application of 
UN 17-microneedle arrays onto ex vivo human skin, it was shown that the microneedles pierce 
through the stratum corneum, into the skin (figure 4E).
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3.3 Quantifi cation of ovalbumin delivery into ex vivo human skin
 Following common practice [13, 18-20], the amount of ovalbumin delivered into the 
skin via microneedles was quantifi ed by radioactivity. The results are shown in fi gure 5. 
After diff erent microneedle arrays were applied onto ex vivo human skin, a solution with 
radioactively labeled ovalbumin was applied. Subsequently, the solution was removed and 
the skin was washed twice with a cotton swab soaked in PBS, which led to a removal of 
300-700 ng (wash 1, data not shown) and 30-100 ng (wash 2, fi gure 5A) ovalbumin from the 
skin surface. Subsequently, the skin was tape-stripped twice to remove most of the stratum 
corneum adsorbed ovalbumin. The tape-stripping led to the removal of 21-43 (fi rst strip) 
and 4-20 ng (second strip) ovalbumin (fi gure 5A). Finally, the amount of ovalbumin that was 
delivered into the skin, after it was washed and tape-stripped, was quantifi ed (fi gure 5B). 
As expected, hardly any ovalbumin, 0.16±0.04 µg (mean ± SD, n=3), was delivered into the 
skin without microneedle pretreatment. Furthermore, upon LU microneedle pretreatment 
1.04±0.13 µg ovalbumin (mean ± SD, n=3) was delivered into the skin and pretreatment 
with Tyndall microneedles led to an intradermal delivery of 2.55±0.08 µg (mean ± SD, n=3) 
Figure 4: Representati ve confocal laser scanning microscopy (CLSM) imaging (2980x2980x600 µm (x,y,z)) of 
fl uorescently labeled ovalbumin delivery into ex vivo human skin pretreated with LU 16- (A), Tyndall 16- (B), and 
UN 9-microneedle arrays (C). CLSM images were used to determine the depth of ovalbumin delivery into the skin 
(mean ± SD, n=10) (D). Cryosecti on of ex vivo human skin to visualize the conduits formed by UN 17-microneedle 
arrays by using TMC-rhodamine (red) nanoparti cles and DAPI (blue) fl uorescence (E). Stati sti cal signifi cance: 
*p<0.05, **p<0.01.
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ovalbumin. Pretreatment of ex vivo human skin with UN 3-, 5-, 9-, or 17-microneedles led to 
an intradermal delivery of 2.44±0.39, 2.71±0.55, 3.84±0.82, and 6.91±1.52 µg ovalbumin (mean 
± SD, n=3), respectively. In conclusion, the microneedles that were used in this study led 
to an up to 43-fold increased ovalbumin delivery compared to no microneedle treatment. 
Moreover, the delivered dose of ovalbumin into ex vivo human skin was dependent on the 
number of microneedles per microneedle array. The higher levels of radioactively labeled 
ovalbumin after UN microneedle pretreatment compared to the other microneedle arrays 
correspond to the higher fluorescence intensity of fluorescently labeled ovalbumin in figure 
3D.
3.4 Ovalbumin-specific IgG responses after microneedle pretreatment in mice
3.4.1 Effect of dose by different microneedles
 By using the different microneedle arrays a different dose of ovalbumin was delivered 
into the skin. To investigate whether this difference in dose affects the ovalbumin-specific 
IgG responses, mice were immunized by using the UN 3-, 5-, 9-, and 17-microneedle arrays as 
well as the LU 16- and Tyndall 16-microneedles. As shown in figure 6A, the ovalbumin-specific 
IgG responses upon microneedle-based vaccination were similar, no matter which dose was 
delivered by the different microneedles (cf. figure 5B). Similar observations were reported 
by Widera et al., who observed only minimal differences in ovalbumin-specific IgG titers after 
the booster immunization of hairless guinea pigs with 0.4 µg, 5 µg, or 36 µg ovalbumin by 
using 225 µm long microneedles [19]. Therefore, we conclude that the maximum ovalbumin-
specific IgG response in BALB/c mice is already obtained at a dose as low as 1 µg when using 













































































































Figure 5: Delivery of radioactively labeled ovalbumin into ex vivo human skin. Removal of the excess of ovalbumin 
(expressed in ng) by cleaning the skin with a cotton swap soaked with PBS and removal of the stratum corneum 
by tape-stripping (A), and the delivered amount of ovalbumin (expressed in µg) determined after the skin was 
cleaned and the stratum corneum adsorbed ovalbumin was removed  (B). Values are expressed as the mean ± SD 
of three individual measurements.
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3.4.2 Effect of an impact-insertion applicator
 Impact-insertion applicators are often required to pierce microneedles into the skin [4-6, 
9, 20]. Therefore, the effect of applying the impact-insertion applicator itself, other than its 
potentially positive effect on the piercing efficiency, was investigated. To this end, the UN 
3- and 17-microneedle arrays were applied manually with and without subsequent treatment 
with the impact-insertion applicator (with an empty backplate). As shown in figure 6B, the 
ovalbumin-specific IgG responses were on average 5 (prime), 12 (boost) and 2 fold higher (2nd 
boost) when the impact-insertion applicator was applied onto the skin after it was pretreated 
with microneedles. This shows a mechanical adjuvant effect of applying the impact-insertion 
applicator at the microneedle application site. 
3.4.3 Effect of microneedle application area
 The effect on the ovalbumin-specific IgG responses of applying a small (UN 3) microneedle 
array six times on a larger skin surface area was compared to applying one larger microneedle 
array (UN 17) once, so with a similar number of microneedles (18 versus 17). Figure 6C shows 
that applying six times a UN 3-microneedle array led to 2 (prime), 8 (boost), and 4 fold higher 
(2nd boost) IgG responses than applying one UN 17-microneedle array. There might be a 
minimal difference in the delivered dose of ovalbumin by applying these two approaches 
(figure 5). However, we do not expect that this influences the immune response as with a dose 
of 1 µg ovalbumin high IgG levels are already achieved (figure 6A). Rather, this difference in 





















































































































Figure 6: Ovalbumin-specific serum 
IgG responses upon vaccination with 
ovalbumin. Only the LU and Tyndall 
microneedles were applied with an 
applicator (A). After microneedle 
application in the UN + App 
microneedle groups the applicator 
was used with an empty backplate 
(B). Values are shown as mean ± SEM, 
n=11 for panel A, and n=8 for panel 
B-D, and non responding mice were 
given an arbitrary titer of 1. Statistical 
analysis: *p<0.05, **p<0.01, 
***p<0.001.
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a UN 3-microneedle array (0.34 mm2 backplate surface area) is randomly applied on 2 cm2 
skin surface compared to the application of one UN 17-microneedle array (2.2 mm2 backplate 
surface area).
3.4.4 Effect of the vaccination site of microneedles
 In the literature microneedle-based immunization is not uniformly performed via one 
specific skin site, e.g., there are reports about microneedle-based vaccination via the ventral 
abdomen skin [12, 14, 21], the lateral area of the thorax [15, 19] and the ear pinna [18, 20, 22]. In 
our group microneedles have been applied via the ventral abdomen skin. Several studies have 
shown that dermal DNA vaccination via the ear pinna is very potent in mice and dogs [23-25]. 
Forg et al. showed the superiority of the ear pinna over abdominal skin for DNA vaccination 
[23]. This is probably caused by a high number of antigen presenting cells, i.e., the ear pinna 
is very thin resulting in two epidermises close to each other. Furthermore, the ear pinna is 
closely connected to one major draining lymph node (superfiscia cervicalis) [23]. However, 
for microneedle-based vaccination a direct comparison between the ear pinna and the 
abdominal skin has not been reported yet. To study the effect of the location of microneedle 
application, UN 17-microneedles were applied onto the ventral abdomen or onto the left ear 
pinna, upon which subsequently a patch with ovalbumin was applied. Figure 6D shows that 
microneedle-based immunization via the ear pinna leads to 26 (prime), 36 (boost), and 2 fold 
higher (2nd boost) ovalbumin-specific IgG responses than microneedle-based immunization 
via the ventral abdomen. In conclusion, this data shows the importance of the location of 
microneedle application.
3.4.5 Improvement of microneedle-based vaccination
 As discussed above we might have reached the plateau of IgG titers for microneedle-based 
immunization for unadjuvanted ovalbumin in BALB/c mice. Therefore, it might be feasible to 
decrease the delivered amount of ovalbumin by microneedles per immunization, but increase 
the number of immunizations to obtain even higher immune responses. Furthermore, to 
increase antigen-specific IgG responses different complementary approaches should be 
pursued, e.g., applying the microneedles over a larger surface and on a location close to 
lymph nodes, such as the ear pinna, or adjuvanting the vaccine mechanically (e.g., applicator, 
high density microneedles) and/or chemically (e.g., Quil-A, LPS, CpG).
4. Conclusion
 All microneedle arrays that were used in this study successfully penetrated the stratum 
corneum upon application onto the skin, as determined by a trypan blue assay. The amount 
of ovalbumin delivered into ex vivo human skin via the poke and patch approach depended 
on the geometry and size of the microneedle array, but this did not affect the ovalbumin-
specific IgG response. However, antigen-specific IgG responses were found to be dependent 
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on the usage of an impact-insertion applicator, the microneedle application area, and the 
location of microneedle application. Finally, these data can be used to optimize the antigen-
specific IgG responses upon microneedle-based vaccination not only for the poke and patch, 
but also for other microneedle-based immunization approaches that are currently used for 
vaccination.
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 Since the computer industry enables us to generate smaller and 
smaller structures, silicon surface chemistry is becoming increasingly 
important for (bio-) analytical and biological applications. For 
controlling the binding of charged biomacromolecules such as 
DNA and proteins on modified silicon surfaces, the surface pKa is 
an important factor. Here we present a fluorescent nanoparticle 
adhesion assay as a novel method to determine the surface pKa of 
silicon surfaces modified with weak acids or bases. This method is 
based upon electrostatic interactions between the modified silicon 
surface and fluorescent nanoparticles with an opposite charge. 
Silicon slides were modified with 3-aminopropyltriethoxysilane 
(APTES) and were further derivatized with succinic anhydride. 
Layer thickness of these surfaces was determined by ellipsometry. 
After incubating the surfaces with an amine-reactive fluorescent 
dye, fluorescence microscopy revealed that the silicon surfaces 
were successfully modified with amine- and carboxyl-groups. Two 
surface pKa values were found for APTES surfaces by the fluorescent 
nanoparticle adhesion assay. The first surface pKa (6.55±0.73) was 
comparable with the surface pKa obtained by contact angle titration 
(7.3±0.8), and he second surface pKa (9.94±0.19) was only found by 
using the fluorescent nanoparticle adhesion assay. The surface pKa 
of the carboxyl-modified surface by the fluorescent nanoparticle 
adhesion assay (4.37±0.59) did not significantly differ from that found 
by contact angle titration (5.7±1.4). In conclusion, we have developed 
a novel method to determine the surface pKa of modified silicon 
surfaces: the fluorescent nanoparticle adhesion assay. This method 
may provide a useful tool for designing pH-dependent electrostatic 
protein and particle binding/release, and to design surfaces with a pH-
dependent surface charge for (bio-) analytical lab-on-a-chip devices or 
drug delivery purposes.
Chapter 4.1 Fluorescent nanoparticle 
adhesion assay: a novel method 
for surface pKa determination 
of self-assembled monolayers 
on silicon surfaces
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1. Introduction
 Surface modification is used in a broad range of applications. Self-assembling monolayers 
(SAMs) and functionalized surfaces are used for e.g. DNA and protein biosensors [1, 2], 
antibody microarrays [3], protein immobilization [4], long range electron transfer [5], and 
proton transfer reactions [6]. There are multiple strategies for the immobilization of proteins, 
DNA, or colloidal particles on these surfaces, such as immobilization via covalent bonding, 
physical entrapment, van der Waals interactions, hydrophobic interactions, and electrostatic 
interactions [1, 3-5, 7]. Furthermore, the surface properties of SAMs and functionalized 
surfaces are affected by their charged state. Since SAMs and functionalized surfaces are 
often used in an aqueous environment, and much of these surfaces have a pH-dependent 
charge, it is very important to know their surface pKa value [6, 8-10].
 Various methods have been described to determine the surface pKa of SAMs on 
conductive materials, such as gold electrodes, mercury electrodes, silver surfaces, etc. These 
methods include electrochemical titration [11, 12], interfacial capacitance measurements [13], 
surface potential measurements [14, 15], interfacial impedance [16, 17], piezoelectric quartz 
crystal microbalance [18], indirect laser-induced temperature jump method [19], and optical 
absorption [20, 21]. However, most of these methods are complicated or lack accuracy 
because of their invasive character [16, 17]. Moreover, these methods are not suitable for the 
pKa determination of (semi-conductive) silicon surfaces. Silicon is of great interest because 
techniques to generate micro- and nano-structures on silicon are well developed. These 
structures can be used for biological or analytical applications such as lab-on-a-chip devices, 
biosensors, and microneedles [22, 23].
 For the surface pKa determination of modified silicon surfaces contact angle titration [6, 
10, 11, 20, 24], chemical force titration, which is a form of atomic force microscopy (AFM) 
whereby the tip of the AFM is chemically modified [10, 25], and infrared (IR) spectroscopy [26, 
27] have been described. IR spectroscopy has been used for the surface pKa determination of 
carboxyl modified silicon surfaces, whereby the silicon wafer was used as an ATR crystal in a 
pH regulated liquid cell. IR spectroscopy enables the quantification of COOH and COO- groups 
and thereby the determination of the pKa [26, 27]. By chemical force titration the pKa can be 
determined very locally on the modified surface. Consequently, to obtain a representative 
pKa value of the surface, multiple spots on the surface should be measured. Other drawbacks 
of AFM are that the method is expensive, labor intensive, and requires special expertise [28]. 
In addition, a complicated factor is the coating of the tip of the AFM with a molecule which 
has a pKa by itself [9, 10, 25, 28].
 Contact angle titration is a technique to analyze proton transfer reactions at low-energy 
surfaces and surface wettability as a function of pH. By this method the contact angles of 
buffered water drops are measured at various pH values. If the surface has a pKa, the contact 
angle will be a function of the pH. Subsequently, in theory the surface pKa can be extracted 
from the titration curve where the proton transfer reaction takes place, visible as a change 
in the contact angle [6, 8, 24]. The major disadvantage of contact angle titrations is that it is 
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difficult to extract the pKa values from the titration curves, mainly because the contact angle 
rarely forms a unique thermodynamic equilibrium with the SAM as described by Young’s 
equation [29]. 
 Silicon surfaces can be modified with molecules with ionizable groups, such as amine-
terminated and carboxyl-terminated surface groups. The charge of these groups will depend 
on their surface pKa and the surrounding pH value. If the silicon surface is charged, the 
surface should be able to bind particles with an opposite charge. In this paper, we present a 
new method to determine the apparent surface pKa of modified silicon surfaces by an indirect 
method, which is based upon electrostatic interactions between the modified silicon surface 
and fluorescently labeled polystyrene nanoparticles with either a stable positive or negative 




 For the preparation of aqueous solutions and the cleaning of the silicon surfaces 
deionized water with a resistivity of 18 MΩ·cm, produced by a Millipore water purification 
system (MQ water), was used. Hydrogen peroxide (30%), (3-aminopropyl)triethoxysilane 
(APTES), succinic anhydride, (3-carboxypropyl)trimethylammonium chloride (CPTA), 
ethylenediaminetetraacetic acid (EDTA), (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), sulfate-modified (5%) polystyrene fluorescent orange (520 nm excitation/540 nm 
emission) nanoparticles of 100 nm  and, amine-modified (5%) polystyrene fluorescent orange 
nanoparticles of 100 nm were purchased from Sigma Aldrich. Alexa-Fluor® 488 carboxylic 
acid succinimidyl ester was purchased from Invitrogen. N,N’-dicyclohexylcarbodiimide (DCC) 
and N-hydroxysuccinimide  (NHS) were purchased from Fluka, and 1,4-dioxane was from 
J.T. Baker Chemicals B.V. Sulfuric acid 96-98% and acetone were obtained from BOOM lab 
equipment, methanol HPLC grade, tetrahydrofuran (THF) AR, and toluene AR were purchased 
from BIOSOLVE, and acetonitrile HPLC Far UV was from LAB-SCAN Analytical Sciences. Silicon 
wafers <110> dsp of 0.38 mm thickness were a kind gift of U-Needle B.V. The wafers were cut 
in pieces of either 1 by 1 cm or 1 by 2.5 cm. Black 96-well plates were purchased from Greiner 
Bio-One, polystyrene cuvettes (10x4x45 mm) were from Sarstedt, Slide-A-Lyzer® Dialysis 
Cassettes 3,500 MWCO were purchased from Thermo Scientific, and molecular sieves 4Å 8 to 
12 mesh were from Acros Organics.
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2.2 Surface chemistry of amine and carboxyl-modified silicon slides
 The chemical modification of the silicon surfaces, depicted in figure 1, was a multiple step 
procedure involving (1) cleaning of the surface (i.e. fat removal) and generating SiOH groups 
[7, 30], (2) silanization and stabilization of the surface (i.e. curing and removal of residual 
ethoxy groups from APTES as reported by Kim et al. 2009 and Howarter et al. 2006) [7, 31-33], 
and (3) converting the amine surface to a carboxylic surface [4].
 
Each of these steps is described below.
 1. Cleaning of the silicon slides. The silicon slides were treated once with acetone and 
twice with methanol and were subsequently dried in a vacuum oven at 50°C for 30 min. Then, 
the silicon slides were incubated for 60 min at 80°C in a freshly prepared piranha mixture (a 
mixture of 30% H2O2 and 70% H2SO4). Caution: piranha solution reacts violently with organic 
compounds, and it should not be stored in closed containers. Finally, the silicon slides were 
washed twice in MQ water and five times in methanol and then dried in a vacuum oven at 
50°C for 30 min.
 2. Generation of an amine-modified surface. The silicon slides were incubated for 24 h 
at room temperature on a shaking device in 2% (v/v) APTES in toluene. Subsequently, the 
amine-modified silicon slides were washed once with toluene and three times with methanol. 
Then, the amine-modified silicon slides were cured under argon for 30 min at 120°C, and were 
incubated in MQ water for 2 h at 40°C to remove unreacted ethoxy groups. Finally, the slides 
were flushed once with methanol and dried in a vacuum oven at 50°C for 30 min.
 3. Generation of a carboxyl-modified surface. The amine-modified silicon slides were 
incubated in a 20 mg/mL solution of succinic anhydride in 1,4-dioxane for 30 min at 80°C. Then, 
Figure 1: Reaction scheme for the modification of silicon surfaces, showing the generation of SiOH groups, 
modification of these groups with APTES (a), yielding an amine-modified surface and subsequent reaction with 
succinic anhydride (SA) (b), yielding a carboxyl-modified surface.
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the silicon slides were washed three times with methanol and dried in a vacuum oven for 30 
min at 50°C.
 All modified silicon slides were stored under argon until use.
2.3 Preparation and characterization of fluorescent quaternary ammonium-modified 
nanoparticles
 In order to determine the surface pKa of silicon surfaces modified with weak acids and 
weak bases, stable fluorescent nanoparticles are needed with either a positive or negative 
charge over a broad pH range. Since amine-modified polystyrene nanoparticles lack stability 
at pH > 8, these nanoparticles were modified with CPTA into quaternary ammonium-modified 
nanoparticles. This was done in a two-step procedure. First, the carboxylic group of CPTA was 
activated with NHS. Subsequently, CPTA was coupled onto the amine groups of the amine-
modified nanoparticles, shown in figure 2.
 Synthesis of CPTA-NHS: CPTA (100 mg, 0.55 mmol) and NHS (108 mg, 0.94 mmol, 1.7 eq.) 
were dissolved in 12.5 mL acetonitrile with molecular sieves 4A under magnetic stirring for 15 
min at room temperature. Then, the solution was cooled on ice under magnetic stirring for 
15 min. Subsequently, DCC (216 mg, 1.05 mmol, 1.9 eq.) dissolved in 2.15 mL acetonitrile was 
added to the reaction mixture, and the solution was stirred for 16 h at room temperature. 
Subsequently, the stirrer was turned off and the solution was put on ice for 15 min to precipitate 
the dicyclohexylurea, and the resulting suspension was then filtered on a fritted funnel. The 
precipitate was washed with 5 mL acetonitrile, and was then discarded (the reaction product 
is in the acetonitrile). Subsequently, the acetonitrile with the reaction product was vacuum 
evaporated, leaving a brownish residue. Then, 6.25 mL THF was added to this residue to 
dissolve non reacted NHS and DCC, and the mixture was put on ice for 2 h. Then, the product 
was collected on a glass filter and was washed with 5 mL THF [34]. Finally, the product was 
dried in a vacuum oven for 16 h at 30°C, weighed (46 mg, 0.17 mmol, 31% yield), and was 
stored at -80°C until use. For the confirmation of the desired reaction product 1H and 13C NMR 
was used and the following peak shifts were identified: 1H NMR D2O 300 MHz δ 3.45 (2H, 
m, N(CH3)3CH2), 3.15 (9H, s, N(CH3)3), 2.95 (4H, s, CO(CH2)2CO), 2.90 (2H, t, NHS-CO2CH2CH2), 
2.30 (2H, m, CH2CH2CH2). 
13C NMR D2O 75 MHz δ 173.3 (CO of NHS), 169.3 (CO2-NHS), 64.8 
(CH2CH2N(CH3)3), 53.0 (N(CH3)3), 27.3 (CO2CH2), 25.5 (CH2 of NHS), 17.9 (CH2CH2CH2).
 Coupling of CPTA to nanoparticles: For the coupling of CPTA to the amine-modified 
fluorescent polystyrene nanoparticles, 100 μL of these nanoparticles were diluted with 900 
μL solution 1, composed of 1:4 THF: 100 mM HEPES buffer (pH 6.0) under magnetic stirring. 
Then, 10 mg CPTA-NHS dissolved in 100 μL solution 1 was added and the mixture was left to 
react for 1 h at room temperature. To confirm that the CPTA was coupled and thereby stable 
nanoparticles had been formed, the particle size and size distribution was determined by 
dynamic light scattering (DLS) and the zeta potential by laser Doppler electrophoresis on a 
Zetasizer Nano (Malvern Instruments) at pH values between 2-12. Subsequently, the CPTA-
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modified polystyrene nanoparticles were dialyzed on a 5 mM HEPES buffer (pH 6.0) for 6 
h at room temperature, and were stored in a dark vial at 4°C until use. Finally, a calibration 
curve was made with the amine-modified nanoparticles, from which the concentration CPTA-
modified nanoparticles was determined.
2.4 Reactivity of modified surfaces with a fluorescent dye
 To determine whether the silicon surface was successfully modified into an amine-
modified surface and subsequently a carboxyl-modified surface, a fluorescent dye which 
reacts specifically with primary amines was used. Silicon slides of 1 by 2.5 cm were incubated 
for 1 h in 5 mL acetonitrile with 10 μg Alexa Fluor® 488 carboxylic acid succinimidyl ester at 
room temperature. Then, the silicon slides were washed twice with acetonitrile and five times 
with methanol, and were subsequently dried in a vacuum oven at 50°C for 30 min. Finally, 
the silicon surfaces were photographed under a fluorescence microscope, Nikon Eclipse 
E600 with a mercury light source, a GFP filter set, a magnification of 400x and an exposure 
time of 10 seconds. The pictures of the surfaces were analyzed by plotting the pixel intensity 
against the pixel position on the surface by the ‘interactive 3D surface plot’ plugin in ImageJ 
(available from rsbweb.nih.gov/ij/), with the following settings: grid size 128, smoothing 
3.0, max. 40%, and min. 8%. The efficiency (E) of the derivatization of the amine surface with 
succinic anhydride was determined by equation 1, where I0 is the average pixel intensity of 
the non-modified surface, Ia is the average pixel intensity of the amine-modified surface, and 
Ic is the average pixel intensity of the carboxyl-modified surface.
  E = 100 – [{(Ic-I0)/(Ia-I0)}*100]    (Equation 1)
2.5 Ellipsometry
 The layer thickness and the optical properties of the amine coating and the carboxyl 
coating on the silicon slides, compared to the unmodified surface (after piranha treatment), 
was determined by spectroscopic ellipsometry. Spectroscopic ellipsometry measures the 
change in polarization upon reflection, which is represented by Ψ (the amplitude ratio) and 
Figure 2: Synthesis of CPTA-modified nanoparticles. CPTA, (3-carboxypropyl)trimethylammonium chloride; 
NHS, N-hydroxysuccinimide; DCC, dicyclohexylcarbodiimide.
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Δ (the phase difference), and derives the layer thickness from it. Ψ and Δ were measured 
on a Woollam M-2000F rotating compensator spectroscopic ellipsometer at five different 
angles of incidence (55°, 60°, 65°C, 70°, and 75°) and in a range between 246 nm and 1000 
nm, and were analyzed by the WVASE32 software version 3.632. The device was calibrated 
with a standard 25 nm silicon oxide layer on a 0.7 mm silicon wafer. For each type of surface 
three silicon slides were used, where the layer thickness per silicon slide was determined as 
the average of 5 different spots. For the determination of the layer thickness of the organic 
layers the Cauchy fitting model was used with the following settings for the optical constants: 
An=1.45 and Bn=0.01.
2.6 pKa determination by the fluorescent nanoparticle adhesion assay
 For the pKa determination of modified silicon surfaces negatively charged nanoparticles 
were used for the titration of the positive (amine) surface, and positively charged 
nanoparticles were used for the titration of the negative (carboxyl) surface, as depicted in 
figure 3. As a control, non-modified piranha treated surfaces were titrated with positively and 
negatively charged nanoparticles.
 To determine the surface pKa a 1 mM EDTA buffer with 1 μL of 2.5% fluorescent nanoparticles 
per mL was prepared. Then, the pH was adjusted between 2 and 12 with either 0.1 and 0.01 M 
NaOH or 0.1 M and 0.01 M HCl to make 20 nanoparticle suspensions, each with a different pH. 
For each pH value two aliquots of 0.75 mL were transferred into 1.5 mL cuvettes, one with 
and one without the modified silicon slide. The amine-modified silicon slide (weak base) was 
incubated with the negatively charged nanoparticles for 4 h, and the carboxyl-modified silicon 
slide (weak acid) was incubated with the positively charged nanoparticles for 2 h. Incubations 
were done at room temperature and by using a shaking device. Then, two times 200 μL from 
each sample cuvette were transferred to a black 96-well plate and the fluorescence was 
measured at an excitation wavelength of 520 nm and an emission wavelength of 540 nm with 
a Tecan Infinite® M1000 plate reader. Subsequently, the relative fluorescence was calculated 
for the different pH values. Relative fluorescence values (compared to the 100% fluorescence 
value of the nanoparticle sample from the cuvette without silicon slide) were plotted against 
the pH. Finally, according to the Henderson-Hasselbalch equation, the S-shaped curve was 
fitted in Origin version 8.1. From this fitted curve the surface pKa was calculated as the pH 
value at the midpoint of the S-shaped curve.
2.7 pKa determination by contact angle titration
 The surface pKa obtained by contact angle titration was used to compare the obtained 
pKa value with our new method for the surface pKa determination of modified silicon surfaces. 
Therefore, multiple 10 mM HEPES buffers with different pH values in a pH range between 2 
and 13 were prepared. Then, contact angle titrations were performed on non-modified silicon 
surfaces (after piranha treatment), on amine-modified silicon surfaces, and on carboxyl-
modified silicon surfaces. To determine the contact angle, a drop of 5 μL HEPES buffer was 
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put on the silicon surface at room temperature and after 15 seconds a picture was taken (Sony 
Super SteadyShot). Then, the pictures of the contact angles were converted into black-and-
white pictures, and were subsequently analyzed in ImageJ (available from rsbweb.nih.gov/
ij/) by the plugin LB_ADSA (contact angle measurement) as described by Stalder et al. [35]. 
Finally, the surface pKa was determined as the pH value where the contact angle changes.
3. Results and discussion
3.1 Characterization of surface modified fluorescent polystyrene nanoparticles
 To determine in which pH range the surface-modified fluorescent polystyrene 
nanoparticles are usable for determining the pKa of modified silicon surfaces, the pH 
dependence of the physicochemical stability of these nanoparticles was determined. Figure 
4 shows a representative graph of the average size, the PDI, the zeta potential, and the 
fluorescence of the surface-modified nanoparticles as a function of the pH. The sulfate-
modified nanoparticles turned out to be negatively charged and colloidally stable between pH 
2-13, indicating that these nanoparticles can be used as such for the pKa determination over a 
broad pH range of surfaces with basic groups. The amine-modified polystyrene nanoparticles 
started to aggregate at pH ≥ 8, as reflected by an increase in particle size and size distribution 
(PDI), and a drop in zeta potential. This demonstrates that at alkaline conditions these particles 
are colloidally unstable and therefore unsuitable for the surface pKa determination. For this 
reason the particles were modified with CPTA. The CPTA-modified nanoparticles, carrying 
a permanent positive charge (see figure 4c), were shown to be stable until pH > 11 (figure 
Figure 3: Schematic representation of our newly developed fluorescent nanoparticle adhesion assay for 
determination of the surface pKa of modified silicon surfaces.
74
4a, 4b). This indicates that the coupling of CPTA was successful and led to particles that are 
colloidally stable between pH 2-11.  These particles can be used for the titration of surfaces 
with acidic groups within this range. In figure 4d the fluorescence intensity of the three 
different nanoparticles is shown as a function of pH. The fluorescence intensity of the sulfate-
modified fluorescent nanoparticles was shown to be stable from pH 3-12. It was shown that 
the fluorescence intensity of amine-modified fluorescent nanoparticles decreased to 50% at 
pH > 8. However, the fluorescence intensity of the CPTA-modified nanoparticles is stable pH 
2-4 and between pH 6-11. The CPTA-modified nanoparticles show a decrease in fluorescence 
intensity between pH 4-6, which could be due to binding of these particles to the surface 
of the cuvettes. However, this does not influence the pKa determination since the relative 
fluorescence is measured. 
3.2 Confirmation of silicon modification by fluorescence microscopy
 To determine whether the silicon surface was successfully modified using APTES (amine-
modified) and subsequently SA (carboxyl-modified) and to determine the surface coverage, 
a primary amine reactive dye (Alexa-Fluor® 488 carboxylic acid succinimidyl ester) was used 
on non-modified, amine-modified, and carboxyl-modified silicon surfaces. It is expected that 
this dye only binds to the amine-modified surface and not to the non-modified surface and 
the amine-modified surface derivatized with carboxyl-groups. Thus, only the amine-modified 
surface is expected to be fluorescent, which is indicated by an increase of the average pixel 
intensity.
 In figure 5 on the left side fluorescence microscopy pictures are shown of the differently 
modified silicon slides and on the right side their 3D analysis (pixel intensity versus position 
in the picture). The minimum base value for the pixel intensity of the amine-modified surface 
was increased compared to the minimum base value of the pixel intensity of the non-modified 
surface, which indicates that there are amine-groups present on the surface. Besides, in 
figure 5d it appears that there is a complete surface coverage of amine groups. Furthermore, 
the ground value of the pixel intensity of the carboxyl-modified surface was about the same 
as for the non-modified surface, thus the amine-modified surface was successfully converted 
into a carboxyl-modified surface. The efficiency of modifying the amine-modified surface into 
a carboxyl-modified surface was calculated according to equation 1, and was estimated to 
be higher than 95%. This is more than the ca. 40% reported by Kim et al. [4] who used NHS-
carboxyfluorescein for conjugation with surface amine groups on silicon. This discrepancy 
could be explained by the differences between the succinic anhydride coupling procedures: 
5 mg/mL succinic anhydride in THF with 5% triethylamine for 4 h at room temperature by Kim 
et al., versus 20 mg/mL succinic anhydride in 1,4-dioxane for 30 min at 80°C by us.
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3.3 Determination of layer thickness by ellipsometry
 Ellipsometry was used to determine the layer thickness of the non-modified surface, the 
amine-modified surface, and the carboxyl-modified surface. The natural silicon oxide and the 
SiOH groups after piranha treatment accounted for 1.512±0.240 nm (n=3, mean ± SD). The 
thickness of this layer was set as a constant for the fitting of the data of the amine-modified 
surface and the carboxyl-modified surface.
 After the silicon slides were modified with APTES (-SiC3H8N) the layer thickness had 
increased by 0.639±0.159 nm (n=3, mean ± SD) compared to the silicon slides after piranha 
treatment. This value is consistent with data found in the literature for a monolayer of APTES 
[10], however, also values of > 15 nm have been found for the layer thickness of APTES 
coatings [4, 32, 33], whereby the layer thickness was dependent on the used coating method. 
These much larger reported thicknesses correspond to interreacted APTES layers [32].
 After the modification of amine-modified slides with succinic anhydride (-SiC8H14NO3), the 
layer thickness had increased by 1.924±0.462 nm (n=3, mean ± SD) compared to silicon slides 
after piranha treatment. The increase of layer thickness compared to the amine-modified 
silicon slides was 1.285±0.462 nm, which is slightly higher than the value of 0.5±0.1 nm reported 
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Figure 4: Representative graphs showing the physicochemical properties of surface-modified polystyrene 
nanoparticles. Average size (a) and size distribution (PDI) (b) measured by dynamic light scattering, zeta potential 
(c) measured by laser Doppler electrophoresis, and relative fluorescence intensity (d) are shown of CPTA-modified 
nanoparticles (circles), amine-modified nanoparticles (squares) and sulfate modified nanoparticles (triangles). 
Representative standard deviations are indicated for each of the measured parameters at the lowest pH values.
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by Kim et al. [4]. This difference can be explained by the different coating efficiency (40% vs. 
95%). Furthermore, 1.285±0.462 nm corresponds with the theoretical surface thickness (0.9 
nm) of a monolayer of SA. 
3.4 Surface pKa determination by the fluorescent nanoparticle adhesion assay
 The apparent surface pKa of amine-modified surfaces and carboxyl-modified surfaces was 
determined by our new method after the nanoparticle binding conditions were optimized 






Figure 5: Fluorescent surface modification with a primary amine reactive fluorescent dye (Alexa-Fluor® 
488 carboxylic acid succinimidyl ester) for the confirmation of amine-based surface modifications. Left: 
representative pictures by fluorescence microscopy (magnification of 400x, surface of 0.054 mm2, 811x1070 
µm) of non-modified (a), amine-modified (c), and carboxyl-modified (e) silicon surfaces after incubation with the 
fluorescent dye. Right: pixel intensity versus position in the pictures on the left after 3D analysis of non-modified 
(b), amine-modified (d), and carboxyl-modified (f) silicon surfaces. Note the elevated fluorescence background 
level of the amine-modified (d) surface.
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concentration (data not shown). This method is based upon the pH-dependent binding of 
fluorescent nanoparticles with a positive or negative charge to an oppositely charged surface 
with (de)protonatable groups. The surface pKa was defined as the pH value at the midpoint of 
the S-shaped curve of the relative fluorescence intensity versus pH.
 Furthermore, no titratable groups were found for the non-modified surfaces with 
negatively charged nanoparticles (supporting information). However, a gradually decreasing 
relative fluorescence curve between pH 6-9 was found for the non-modified surface with 
positive nanoparticles (supporting information), indicating several degrees of deprotonation 
of the surface silanol groups [36]. However, this did not interfere with the pKa determination 
by the fluorescent nanoparticle adhesion assay, since the CPTA nanoparticle adhesion 
onto piranha treated surfaces started after the point where the carboxylic surface had the 
maximum adsorption of these CPTA nanoparticles. Furthermore, when the surface was 
derivatized with phenolic groups, CPTA nanoparticle adhesion started at pH values above 7 
(supporting information).
 Figure 6a shows a representative surface pKa determination of amine-modified silicon 
slides with sulfate-modified polystyrene fluorescent nanoparticles. Fitting a 2 S-shaped curve 
according to the Henderson-Hasselbalch equation for two pKa values revealed two surface 
pKa values for the amine-modified silicon slides. The midpoint of the first S-shaped curve 
revealed a surface pKa of 6.55±0.73 (n=3, mean ± SD) and a second surface pKa of 9.94±0.19 
(n=3, mean ± SD). The first surface pKa value is in compliance with the literature, where 
comparable surface pKa values (pKa 3.9-7.6) have been reported for APTES films [9, 25, 37]. 
Zhang et al. reported a surface pKa of 7.4 for APTES films on silicon surfaces by chemical force 
titration. However, the same group observed a similarly attractive interaction (similar to the 
pKa of 7.4) in the force curves with chemical force titrations of 3-aminopropyl on the surface 
at pH > 8 when the sample-tip distance was gradually decreased [10]. This may indicate the 
Figure 6: Surface pKa determination of surface-modified silicon by the fluorescent nanoparticle adhesion assay. A 
representative example of 3 independent surface pKa determinations of (a) amine-modified surfaces with sulfate-
modified nanoparticles, and (b) carboxyl-modified surfaces with CPTA-modified nanoparticles is shown.
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presence of a second surface pKa above 8, which would be in compliance with our results 
(second surface pKa of 9.94). Furthermore, our results show that the second surface pKa had 
a much higher influence on the binding of fluorescent nanoparticles to the silicon surface.
  In figure 6b a representative picture is shown of a surface pKa determination of the 
carboxyl-modified silicon surface with CPTA-modified polystyrene fluorescent nanoparticles. 
The surface pKa of the carboxyl-modified silicon surfaces was found to be 4.37±0.59 (n=3, 
mean ± SD). This is in compliance with pKa values found in the literature where pKa values of 
–COOH terminated surfaces between 4.4 and 6.5 have been reported [9, 11, 18, 25]. However, 
also pKa values of up to 10.3 have been reported for aliphatic –COOH terminated surfaces, 
which is dependent on the chain length (-CH2-) between the –COOH group and the surface 
(substrate): longer chain lengths lead to higher surface pKa values [12]. Overall, the surface 
pKa of our carboxyl-modified surface (short chain length) is within the expected and reported 
range.
3.5 pKa determination by contact angle titration
 For comparison, the surface pKa of amine-modified and carboxyl-modified silicon surfaces 
was also determined by contact angle titration, see table 1 and figure 7. The contact angle 
titrations revealed a surface pKa of 7.3±0.8 for the 3-aminopropyl surface (n=3, mean ± SD) 
and a surface pKa of 5.7±1.4 for the carboxyl-modified surface, which is in agreement with 
surface pKa values obtained by the contact angle titration reported in literature [6, 8, 9, 11, 
20]. Furthermore, the surface pKa of the amine-modified surface by contact angle titration 
was comparable to the first surface pKa obtained by the fluorescent nanoparticle adhesion 
assay of the same surface. However, a second surface pKa of an APTES SAM as detected by 
the new method was not observed by contact angle titration. This perhaps could be due to 
lack of sensitivity of the contact angle titration. The surface pKa of the carboxyl-modified 
silicon surface determined by the fluorescent nanoparticle adhesion assay was within the 
standard deviation of the pKa value found by the contact angle titration.
 The standard deviations of the contact angle titrations were very high, and did not lead 
to a precise determination of the surface pKa value. However, the contact angle titrations 
showed a different profile after the silicon surface was modified with APTES or with APTES 
derivatized with succinic anhydride. This offers the possibility to use this method to evaluate 
the surface modification. In conclusion, our new method enabled us to determine the surface 
Table 1: Surface pKa values obtained by the fluorescent nanoparticle adhesion assay and by contact angle  
titration of amine-modified silicon surfaces and carboxyl-modified silicon surfaces.






Contact angle titration pKa: 7.3±0.8 pKa: 5.7±1.4
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pKa value of modified silicon surfaces with smaller standard deviations and could reveal 
surface pKa values which cannot be determined by contact angle titration.
 In summary, we have developed a new method to determine the apparent pKa of 
(modified silicon) surfaces, which is based upon electrostatic interactions between charged 
surface groups and fluorescent polystyrene nanoparticles with a permanent opposite charge. 
The fluorescence intensity of suspensions of fluorescent nanoparticles is determined after the 
nanoparticles are incubated in buffer with and without modified silicon slides at various pH 
values. Subsequently, the binding of nanoparticles to the surface, is calculated by dividing the 
fluorescence intensity of the nanoparticle suspension with a silicon slide by the fluorescence 
intensity of the suspension without silicon slides. Then the relative fluorescence values are 
plotted against the pH, and the surface pKa is obtained from the S-shaped curve according 
to the Henderson-Hasselbalch equation, which leads to a reproducible determination of the 
apparent surface pKa. We have found two surface pKa values of 6.55±0.73 and 9.94±0.19 for 
an amine-modified surface, and a surface pKa of 4.37±0.59 for a carboxyl-modified surface. 
This method could be a useful tool to design pH-dependent electrostatic protein and particle 
binding/release systems, and to design surfaces with a pH-dependent surface charge for 
(bio-) analytical lab-on-a-chip or drug delivery purposes.
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Supporting Information
 We have performed the fluorescent nanoparticle adhesion assay (FNAA) on unmodified, 
piranha treated surfaces with negatively and positively charged nanoparticles. Figure S1A 
shows that negatively charged nanoparticles do not adhere to piranha treated surfaces. 
However, as show in figure S1B, there is a gradually increased adsorption of positively charged 
nanoparticles to piranha treated surfaces between pH 6-9, which is above the surface pKa 
value of the carboxyl-modified surface (pKa 4.37±0.59) found by the FNAA.
 To confirm the general applicability of the FNAA, we have applied it to two additional 
surfaces, namely a phenol-modified silicon surface and a pyridine-modified silicon surface. 
We found a pKa of 8.1 for a phenol modified surface with the positively charged nanoparticles, 
and a pKa of 6.8 for a pyridine modified surface (figure S2). 
 We have performed a contact angle titration of a carboxyl modified surface with a 10 
mM phosphate buffer (see figure S3) to check whether the type of buffer would influence 
the surface pKa value. The calculated pKa 6.05±0.64 (n=2) is very similar to that calculated 
from the contact angle titration with HEPES buffer (5.7±1.4). Finally, fluorescence microscopy 
photographs of nanoparticle adhesion are shown in figure S4.
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Figure S1: Fluorescent nanoparticle adhesion assay (FNAA) of piranha treated surfaces with (negatively charged) 
sulfate-modified fluorescent orange nanoparticles (A) and with (positively charged) CPTA-modified fluorescent 
orange nanoparticles (B).
Figure S2: Fluorescent nanoparticle adhesion assay of (left) a phenol-modified surface with positively charged 
nanoparticles and (right) a pyridine-modified surface with negatively charged nanoparticles.
Figure S3: Representative example of a contact angle titration of a carboxyl-modified silicon surface with a 10 
mM phosphate buffer.
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Figure S4: Typical fl uorescence microscopy pictures of nanoparti cle adhesion to silicon surfaces. Left  panel: 
incubati on of an unmodifi ed silicon surface with negati vely charged fl uorescent nanoparti cles (pH 6); right panel: 
incubati on of an APTES-modifi ed silicon surface with negati vely charged nanoparti cles (pH 6) (10x magnifi cati on, 
811x1070 µm, GFP fi lter set).
Abstract
 The aim of this work was to develop a nanolayered pH-sensitive 
coating method whereby proteins are coated at a suitable pH 
on the surface of chemically modified biomedical/bioanalytical 
microdevices and protein release is triggered by a pH-shift upon 
contact with physiological environment. In this work such a coating 
was developed and was applied onto microneedles. First, the surface 
of microneedle arrays was modified with basic groups with a surface 
pKa below physiological pH. This modification was a multistep 
procedure: first the surface was hydroxylated in a piranha mixture, 
then 3-aminopropyl-triethoxysilane was coupled (yielding a “pH-
independent” surface with a positive charge over a broad pH range), 
next 4-pyridinecarboxaldehyde was coupled to the obtained surface 
amine groups and finally the imine bond was reduced by sodium 
cyanoborohydride. The obtained pH-sensitive pyridine-modified 
microneedles were coated with ovalbumin at surface pKa > pH > pI 
of the protein, thus the surface of the microneedles is positively 
charged and the protein is negatively charged. The coating efficiency 
of ovalbumin was 95% for the amine-modified (pH-independent) 
and the pyridine-modified (pH-sensitive) surfaces, whereas a non-
modified surface had a coating efficiency of only 2%. After the protein-
coated microneedle arrays were pierced into the skin, having a pH > 
surface pKa of the microneedle arrays, 70% of the protein was released 
within 1 minute, whereas the protein release from pH-independent 
microneedle arrays was only 5%. In conclusion, we developed a 
procedure to efficiently coat microneedle arrays with proteins that 
are released upon piercing into human skin.
Chapter 4.2 Nanolayered chemical 
modification of silicon surfaces 
with ionizable surface groups 
for pH-triggered protein 
adsorption and release: 
application to microneedles









Journal of Materials 
Chemistry B, 1 (2013) 
4466-4477
1Division of Drug Delivery 
Technology, Leiden 
Academic Centre for Drug 
Research (LACDR), Leiden 
University, Leiden, the 
Netherlands
2Department of Soft 
Matter Chemistry, Leiden 
Institute of Chemistry 




institute of Physics (LION), 
Leiden University, Leiden, 
The Netherlands
CHAPTER 4.2: Coated microneedles




 Chemical surface modifications by self-assembled layers are applied in a broad range of 
applications, including biomedical and bioanalytical microdevices for drug delivery and the 
analysis of biological samples. Here we present a novel coating procedure for microdevices: 
a nanolayered pH-sensitive coating applied onto microdevices and the subsequent coating 
thereof with a model protein. The concept of pH-sensitive coating and release is based upon 
electrostatic interactions between the protein and the surface of the microdevice, whereby 
a protein is adsorbed to the surface at a suitable pH where the surface of the microdevice is 
charged. Subsequently, upon contact with physiological environment (pH 7.4) the surface of 
the microdevice becomes uncharged, causing the electrostatic bond to break and releasing 
the adsorbed protein.
 We apply the pH-sensitive coating technique to microneedles. Microneedles are needle 
like structures with a size in the micrometer range that are used to deliver drugs via the skin. 
The skin is an attractive organ for drug administration since the skin is an easily accessible 
organ and drug delivery via the skin is potentially pain free. However, the skin barrier located 
in the uppermost layer of the skin, the stratum corneum, limits drug delivery via this route [1, 
2]. Therefore, microneedles should be long enough to penetrate the 10-20 µm thick stratum 
corneum layer, but short enough to avoid pain sensation [1, 3].
 Protein delivery into the skin via microneedles has been achieved via various approaches 
[1, 3, 4]. Among those microneedles that are used to penetrate the stratum corneum and 
contain and deliver the drug as a single delivery system are currently of most interest. 
There are three methods to use microneedles as a single drug delivery system: 1) by using 
porous microneedles which contain a drug in solution inside the pores, 2) by using dissolving 
microneedles wherein the drug is encapsulated, and 3) by using drug-coated microneedles 
[1]. Dissolving microneedles degrade after hydration inside the skin and coated microneedles 
dissolve their coated layer upon hydration inside the skin. In this paper we focus on the 
development of coated microneedles. 
 The major benefit of using coated microneedles is that the coating process can be 
performed at ambient conditions in an aqueous environment, and that a dry coating may 
be more stable than a liquid formulation [5-7]. However, most coating procedures require 
complex coating devices which often do not allow the coating of multiple microneedle arrays 
simultaneously [6, 8, 9]. Furthermore, coating of microneedles mostly requires a selected 
set of excipients which 1) reduce the surface tension between the microneedle surface and 
the coating solution, and 2) increase the viscosity of the coating solution [5, 6, 10]. Another 
disadvantage of current coating procedures is that there is a relatively high premature drug 
loss [11]. Finally, most coating procedures require multiple dip-coating steps, often generating 
thick coatings which negatively influence the sharpness of the needle tip diameter and 
thereby compromise the penetration ability of these microneedle arrays [8, 9].
 Here, a nanolayered pH-sensitive coating was developed and applied onto the surface 
of microneedle arrays to adsorb a model protein, ovalbumin, which is released into the skin 
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upon piercing. First, the surface properties of silicon surfaces modified with a weak base, 
and the isoelectric point of ovalbumin were determined to define the pH range in which 
ovalbumin can be coated on the surface. Subsequently, the binding and release of ovalbumin 
from the chemically modified silicon surface and the antigenicity of ovalbumin after release 
were determined. Finally, after the chemical coating was applied onto the surface of in-
plane silicon microneedles with a length of 300 µm, which were coated with ovalbumin at 
optimum pH, the microneedles were assessed for morphology and release of fluorescent- 
and radioactively labeled ovalbumin in human in vitro skin.
2. Experimental
2.1 Materials
 Deionized water with a resistivity of 18 MΩ·cm, produced by a Millipore water 
purification system (MQ water), was used for the preparation of solutions and the 
cleaning of the silicon surfaces. Sulfate-modified polystyrene fluorescent orange (520 
nm/540 nm, ex/em) nanoparticles of 100 nm, human serum from human male AB plasma, 
(3-aminopropyl)triethoxysilane (APTES), ethylenediaminetetraacetic acid (EDTA), NaCl, 
CaCl2, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), hydrogen peroxide (30%), 
4-pyridinecarboxaldehyde, acetic acid, sodium cyanoborohydride, Triton X-100, Tween-20, 
and Tween-80 were purchased from Sigma Aldrich. Sulfuric acid 96-98% and acetone were 
obtained from BOOM lab equipment, and sterile phosphate buffered saline (PBS) was 
obtained from Braun. Alexa-Fluor® 488 carboxylic acid succinimidyl ester, chicken egg 
ovalbumin-Alexa-Fluor® 488, and stabilized chromochen 3,3’,5,5’-tetramethylbenzidine 
(TMB) were purchased from Invitrogen, and chicken egg ovalbumin grade VII was purchased 
from CALBIOCHEM®. Flat bottomed black 96-well plates and MICROLON® ELISA-plates 
were obtained from Greiner Bio-One, and polystyrene cuvettes (10x4x45 mm) were from 
Sarstedt. Molecular sieves 4Å 8 to 12 mesh were purchased from Acros Organics, acetonitrile 
HPLC Far UV was from LAB-SCAN analytical sciences, and methanol HPLC grade, 2-propanol 
AR, and toluene AR were purchased from BIOSOLVE. Silicon wafers <110> dsp of 0.38 mm 
thickness, cut in pieces of either 1 by 1 cm or 1 by 2.5 cm, and silicon microneedle arrays with 
either 9 or 17 microneedles per array with a surface area of 0.3 mm2 and a length of 300 
µm per microneedle were a kind gift of U-needle B.V. Bovine serum albumin (BSA) fraction 
V was obtained from Roche. Polyclonal mouse anti-ovalbumin antibody was obtained from 
LifeSpan Biosciences, Inc., Pierce® Iodination beads and Pierce® polyclonal rabbit anti-
ovalbumin antibodies conjugated with horseradish peroxidise (HRP) were obtained from 
Thermo Scientific. Iodine-125 radionuclide, 2 mCi (74 MBq), Specific Activity: ~17 Ci (629 GBq)/
mg, 10-5 M NaOH (pH 8-11) (Reductant Free), Concentration: 100 mCi/mL was obtained from 
Perkin-Elmer. Amicon® ultra centrifugal filter units with a molecular weight cut off of 30 kDa 
were obtained from Millipore™.
CHAPTER 4.2: Coated microneedles




2.2.1 Generation of a physiologically relevant surface pKa
 The modification of silicon surfaces with pyridine is a multistep procedure. The 
hydroxylation and the generation of amine groups on the surface were performed as 
previously described [12], in brief: the surface, either of silicon microneedles or silicon slides, 
was cleaned with acetone and methanol and was subsequently hydroxylated with a freshly 
prepared piranha mixture (30 v% H2O2 and 70 v% H2SO4) for 1 h at 80 °C. Then, amine-modified 
surfaces were formed by incubating the hydroxylated silicon surfaces in 2% (v/v) APTES in 
toluene for 24 h at room temperature.
 The pyridine-modified surfaces were formed in a two-step procedure. First, an 
imine bond was formed by incubating the amine-modified surface for 16 h in 100 mM 
4-pyridinecarboxaldehyde in anhydrous isopropanol with 1% (v/v) acetic acid at room 
temperature. Subsequently, the pyridine-modified surface was stabilized by reducing 
the imine bond to a secondary amine in 50 mM NaBH3CN in isopropanol for 2 h at room 
temperature. Finally, the modified silicon surfaces were washed with isopropanol (2x) and 
with methanol (3x), and dried in a vacuum oven at 50°C for 30 minutes. The modified silicon 
surfaces were stored under argon until used.
2.2.2 Reactivity of modified silicon surfaces with a fluorescent dye
 To determine whether pyridine-modified surfaces were successfully synthesized, a 
fluorescent dye was used which specifically reacts with primary amines. The non-modified, 
the amine-modified, and the pyridine-modified silicon slides of 1 by 2.5 cm were incubated for 
1 h at room temperature in 5 mL 2 μg/mL Alexa Fluor® 488 carboxylic acid succinimidyl ester 
in acetonitrile. Subsequently, the non-reacted fluorescent dye was removed by washing the 
silicon slides with acetonitrile (2x) and methanol (5x). Finally, the silicon slides were dried 
in a vacuum oven at 50°C for 30 minutes and visualized under a fluorescence microscope 
(Nikon Eclipse E600) with a mercury light source, a magnification of 100x, a GFP filter set, and 
imaged with a 10 s exposure time.
 The pictures were analyzed in ImageJ (available from rsbweb.nih.gov/ij/) with the plugin 
‘interactive 3D surface plot’, where the pixel intensity was plotted against the pixel position 
on the surface. The following settings were used: grid size 128, smoothing 3.0, max. 50%, and 
min. 4%. The derivatization efficiency of the amine-modified surface into a pyridine-modified 
surface was determined by equation 1: 
  Derivatization efficiency = 100 – [{(Im-I0)/(Ia-I0)}*100]   (Equation 1)
Here Im represents the average pixel intensity of the pyridine-modified surface, I0 represents 
the average pixel intensity of the non-modified surface, and Ia represents the average pixel 
intensity of the amine-modified surface [12].
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2.2.3 Surface analysis by atomic force microscopy
 In order to analyze the surface roughness of the coating, non-modified surfaces, pyridine-
modified surfaces, and pyridine-modified surfaces coated with ovalbumin were analyzed by 
atomic force microscopy (AFM) on a Veeco Nanoscope IIIa Multimode AFM in tapping mode 
with scan size of 1 µm2, a scan rate of 1 Hz, and an Si cantilever at 75 kHz. The data was 
analyzed in Gwyddion software version 2.25 (available from: http://gwyddion.net/).
2.2.4 Surface pKa determination by the fluorescent nanoparticle adhesion assay
 The surface pKa of pyridine-modified silicon surfaces was determined by the fluorescent 
nanoparticle adhesion assay [12]. This method determines the surface pKa by using the 
fraction of nanoparticles that is bound to the surface and the fraction of nanoparticles that 
is in solution as a function of the pH. Because pyridine is a weak base and gets positively 
charged when reducing the pH, negatively charged nanoparticles were used.
 First, 20 nanoparticle suspensions were prepared, each with a different pH in a range of 
2-12, in a 1 mM EDTA buffer with 1 µL of 2.5% sulfate-modified fluorescent orange nanoparticles 
per mL. Subsequently, two aliquots of 0.75 mL nanoparticle suspension were transferred to 
two 1.5 mL cuvettes for each pH value, wherefrom one cuvette was used as a negative control 
and the second cuvette was used to be incubated with a 1x1 cm pyridine-modified silicon 
slide. After the pyridine-modified silicon slides were incubated for 4 hour on a shaking device, 
two times 200 µL of each sample was transferred to a black 96-well plate and the emission at 
540 nm was measured with an excitation wavelength of 520 nm on a Tecan Infinite® M1000. 
Subsequently, the relative fluorescence was calculated for each pH value by dividing the 
fluorescence of the nanoparticle suspension incubated with a pyridine-modified silicon slide 
though the fluorescence intensity of a non-incubated sample at the same pH. The binding 
(100 - relative fluorescence) was plotted as a function of the pH and was fitted in Prism 5 for 
Windows according to the Henderson-Hasselbalch equation, from which the surface pKa was 
determined [12]. 
2.2.5 Determination of the isoelectric point of ovalbumin 
 The net charge of a protein plays an important role in its binding to the pyridine-
modified silicon surface. Therefore, the isoelectric point (pI) of ovalbumin was determined 
by measuring the ζ-potential as a function of the pH by laser Doppler electrophoresis on a 
Zetasizer Nano (Malvern Instruments). The ζ-potential of ovalbumin was determined in a 10 
mM phosphate buffer with a pH in the range between 3-6 and an ovalbumin concentration of 
1 mg/mL.
2.2.6 Ovalbumin binding to pyridine-modified surfaces
 To determine whether proteins are able to bind to the pyridine-modified silicon surfaces, 
the binding was investigated by using ovalbumin. Therefore, pyridine-modified silicon slides 
of 1 by 2.5 cm were incubated in 1.5 mL 1 mM EDTA buffer, pH 5.8, with different doses of 
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ovalbumin (6.25 µg, 12.5 µg, 25 µg, 50 µg, 100 µg, or 250 µg) in 2 mL cuvettes. For all ovalbumin 
doses the same amount of ovalbumin conjugated with Alexa Fluor® 488 (12.5 µg) was mixed 
with non-fluorescent ovalbumin, except the 6.25 µg and 12.5 µg dose which were solely 
fluorescent ovalbumin. As a negative control 25 µg (12.5 µg fluorescently labeled + 12.5 
µg native) ovalbumin was incubated with a piranha treated surface in 1.5 mL 1 mM EDTA 
buffer. The binding of ovalbumin to the pyridine-modified silicon surface was determined by 
measuring the concentration of non-bound ovalbumin in solution at different time points (1-
480 minutes, n=3, each dose on a different day) by fluorescence on a Tecan Infinite® M1000 
plate reader with an excitation wavelength of 488 nm and an emission wavelength of 522 nm. 
2.2.7 Ovalbumin release from pyridine-modified surfaces
 In order to examine whether ovalbumin is able to detach from the chemically modified 
silicon slides different release media were used. Therefore, APTES and pyridine-modified 
silicon slides of 1 by 2.5 cm were first coated with 25 µg fluorescently labeled ovalbumin and 
were quantified for ovalbumin adsorption as described above. Then, the silicon slides were 
transferred into 1.5 mL release media and the released amount ovalbumin was determined 
by fluorescence at time points between 1 and 60 minutes. The amount of released ovalbumin 
was divided by the adsorbed ovalbumin to calculate the release percentage. The release from 
the pyridine-modified silicon slides was assessed in the following release media: 1 mM EDTA 
pH 5.5 with 1 M NaCl; 5 mM EDTA pH 7.4; 5 mM EDTA pH 9; 1 mM EDTA pH 10; PBS; human 
serum; 1 mM HEPES pH 5.5 with 1.3 mM CaCl2; 0.1 M HCl; 1 mM EDTA pH 5.5 with 1% Triton 
X-100. The release of ovalbumin from an amine-modified surface was assessed in 5 mM EDTA 
buffer at pH 7.4 and 9.0 as a control for a “pH-independent” surface.
2.2.8 Antigenicity of released ovalbumin 
 The antigenicity of the released ovalbumin from the pyridine-modified surface was 
investigated by enzyme-linked immunosorbent assay (ELISA). Polyclonal mouse antibody 
against chicken ovalbumin was 2000x diluted in 0.05 M carbonate buffer at pH 9.6 and 
coated overnight at 4°C on a 96-well plate for ELISA (100 µL/well). Subsequently, the plate 
was washed 4 times with washing buffer (0.1x PBS with 0.05% (v/v) Tween 20) and blocked 
with 100 µL/well 1% (w/v) BSA in PBS for 1 h at 37°C. Then, 100 µL/well of solution with released 
ovalbumin and a calibration curve of ovalbumin (0.01-50 µg/mL) were prepared in 0.05% 
Tween 80, 0.5% BSA, 0.5x PBS and were incubated for 1.5 h at 37°. Next, the plate was washed 
and incubated with 100 µL/well 1000x diluted polyclonal anti-ovalbumin rabbit antibody HRP 
conjugate for 1 h at 37°C. Subsequently, the plate was washed, 100 µL TMB was added to each 
well, and after 15 minutes the reaction was stopped by adding 100 µL 2 M H2SO4 to each well 
and the absorbance was measured at 450 nm on a Tecan Infinite® M1000 plate reader. The 
released amount of ovalbumin (RELISA) was determined from the ovalbumin ELISA calibration 
curve. Furthermore, the released amount of ovalbumin of the same samples was determined 
by the intrinsic fluorescence of ovalbumin (Rintr. fluo) at an excitation wavelength of 280 nm and 
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an emission wavelength of 320 nm. Finally, the antigenicity of the released ovalbumin was 
determined by equation 2:
  Antigenicity = [RELISA/Rintr. fluo]*100%    (Equation 2)
2.2.9 Coating of microneedles
 For the assessment of the applicability of microneedles with pH-sensitive surface 
modifications, the surface of silicon microneedle arrays were modified with APTES or 
pyridine groups as described above. The in-plane microneedle arrays consist of either 
9 or 17 microneedles per array with a surface of 0.3 mm2 per microneedle, resulting in 
a total available surface area of respectively 2.7 mm2 and 5.1 mm2 per array. For chemical 
modification of the microneedles surface a highly chemical resistant coating device (figure 
1A), made of polychlorotrifluoroethylene (PCTFE), was developed by the Fine Mechanical 
Department, Faculty of Science of Leiden University. After the chemical coating was applied, 
the microneedles were transferred to a polyoxymethylene (POM) holder (figure 1B), which 
were also used as an applicator for applying the microneedles onto the skin. The chemically 
modified microneedle arrays were coated with either 0.5 µg (9 microneedle array) or 1.0 µg 
(17 microneedle array) ovalbumin in 145 µL 1 mM EDTA at pH 5.8 for 1 h in a commercially 
available 96-well plate (figure 1C). 
 The ability to modify the surface of the silicon microneedle arrays with amine groups was 
assessed by using 10 µg Alexa Fluor® 488 carboxylic acid succinimidyl ester in 2 mL acetonitrile, 
to modify the amine groups of APTES-coated microneedle arrays. These microneedles were 
then photographed under a fluorescence microscope with a magnification of 100x, a GFP 
filter set, and an exposure time of 400 ms. 
2.2.10 SEM of microneedles
 To analyze the microneedle sharpness and the coating-thickness before and after the 
different coating procedures, a thin layer of carbon was coated on the microneedles and 
subsequently analyzed by scanning electron microscopy (SEM) on a FEI NOVA nanoSEM 200.
Figure 1: Microneedle coating devices: (A) PCTFE holder loaded with microneedle arrays for applying a chemical 
coating on the microneedle surface, (B) microneedle arrays mounted in a POM holder, which is also the applicator 
used to apply the microneedles onto the skin, and (C) microneedle arrays being coated with a protein in a 
commercially available 96-well plate.
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2.2.11 Fluorescence microscopy and confocal imaging of ovalbumin delivery into in vitro human skin
 The dermal delivery of ovalbumin by the coated microneedle arrays was assessed on in 
vitro abdominal or mammary human skin, which was obtained from a local hospital within 24 h 
after cosmetic surgery, and was dermatomed to a thickness of 600 µm using a Padgett Electro 
Dermatome Model B (Kansas City, MO, USA) after the fat was removed. Pyridine pre-coated 
microneedle arrays (9 microneedles/array) coated with fluorescently labeled ovalbumin were 
three times applied on in vitro human skin for either 15, 60, or 300 seconds each time, and 
subsequently the skin was cleaned with MQ water. The ovalbumin-coated microneedle arrays 
were photographed by fluorescence microscopy (GFP filter set, 100x magnification, exposure 
time of 5 s) before and after they had pierced the human skin, and the in vitro human skin 
was analyzed by fluorescence microscopy (GFP filter set, 40x magnification, exposure time 
of 500 µs). Besides, to assess the deepness of the ovalbumin delivery inside in vitro human 
skin confocal laser scanning microscopy (CLSM) was performed with a Bio-Rad Radiance 2100 
confocal laser scanning system, equipped with a Nikon Eclipse TE2000-U inverted microscope 
with either a 4x or 20x Plan Apo lens with an argon laser at 488 nm with a 500 nm long pass 
emission filter. For controlling the confocal laser scanning system and for image acquisition 
the Laser Sharp 2000 software (Bio-Rad, Hercules, USA) was used. Images of the conduits 
created by the microneedles in in vitro skin were taken with an xz scan from 0-600 µm, with 
a depth resolution of 1.05 µm. Furthermore, xyz-images were taken every 10 µm until a depth 
of 400 µm was reached. 
2.2.12 Delivery of radioactively labeled ovalbumin into in vitro human skin
 To quantify the amount of protein that was delivered into in vitro human skin from a 
“pH-sensitive” and a “pH-independent” surface, we used radioactively labeled ovalbumin 
to bind to the surface of pyridine-modified and amine-modified microneedles. Therefore, 1 
mg ovalbumin in 1 mL PBS was labeled with 125I by incubating it with 4.6 MBq Iodine-125 in 
the presence of 4 iodination beads, according to the manufacturer’s protocol. Radio-labeled 
ovalbumin was purified by washing it three times with PBS in a 30 kDa centrifugal filter unit. 
Subsequently, microneedle arrays with 17 microneedles were coated for 1 h with 1 µg radio-
labeled ovalbumin (dissolved in 1 mM EDTA, pH 5.8), which were subsequently air-dried, and 
were applied on in vitro human skin for one minute. The γ-counts of the microneedle arrays 
before and after penetration, and of the microneedle-pierced skin were measured for 5 
minutes on a Perkin Elmer Wallac Wizard 1470 Automatic Gamma Counter.
3. Results
3.1 Surface modification and analysis of flat silicon surfaces and ovalbumin charge
 To test whether the silicon surface was successfully modified, we used Alexa Fluor® 488 
carboxylic acid succinimidyl ester, a fluorescent dye that only reacts with primary amines. 
The dye was incubated with a non-modified surface, an amine-modified surface, and an 
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amine-modified surface that was derivatized into a pyridine-modified surface. Subsequently, 
fluorescence microscopy images of these surfaces were 3D-analyzed by plotting the pixel 
intensity as a function of the position on the surface, as shown in figure 2. This figure shows 
that the silicon surfaces were successfully modified with amine groups (2C and 2D vs 2A and 
2B) and that these surfaces were subsequently successfully derivatized into pyridine groups 
(2E and 2F vs 2C and 2D) with an efficiency of 78.5±4.8% (n=3, mean ± SD) as calculated by 
equation 1. 
 Subsequently, the surface pKa of the pyridine-modified silicon surface and the pI of 
ovalbumin were determined since both the surface charge of the silicon surface and the 
charge of the protein as a function of the pH are very important for a protein to bind to a 
chemically modified ionizable silicon surface. Figure 3A shows the results of a surface pKa 
determination of a pyridine-modified silicon surface by the fluorescent nanoparticle adhesion 
assay, and figure 3B shows the pH-dependent zeta potential of ovalbumin determined by 
Figure 2: Representative 
fluorescence microscopy images 
(0.868 mm2) of (A) a non-
modified, (C) an amine-modified, 
and (E) a pyridine-modified silicon 
surface incubated with a primary 
amine reactive fluorescent dye. 
The corresponding 3D plots of the 
pixel intensity as a function of the 
position of the surface are shown 
on the right side of the image (B, 
D, F).
































A B Figure 3: (A) 
Determination of the 
surface pKa of pyridine-
modified silicon surfaces 
by the fluorescent 
nanoparticle adhesion 
assay, (B) determination 
of the isoelectric point 
of ovalbumin by laser 
Doppler electrophoresis.
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laser Doppler electrophoresis. The surface pKa of pyridine-modified surfaces determined 
by the Henderson-Hasselbalch equation was 6.91±0.30 (n=3, mean ± SD), thus at a pH < 5.9 
more than 90% of the pyridine-modified surface is positively charged. The zeta potential of 
ovalbumin was gradually decreasing between pH 3 and 7, and had a pI of 4.36±0.21 (n=3, mean 
± SD), thus having a negative charge above that pH value [13, 14]. As protein solubility and 
stability is minimal at pH≈ pI [15], an optimal adsorption of ovalbumin to pyridine-modified 
surfaces is expected in a pH range of 5.5 to 6.5. 
 To determine the surface properties of the non-modified and chemically modified surfaces 
before and after ovalbumin binding, the surfaces were analyzed by atomic force microscopy 
[13]. Non-modified surfaces were very flat with an arithmetic average of the 3D roughness of 
0.332±0.063 nm. Furthermore, when the surfaces were modified with pyridine groups  and 
subsequently coated with 5 µg/cm2 ovalbumin in 1 mM EDTA at pH 5.8 the arithmetic average 
of the 3D roughness was 0.925±0.049 nm (n=3, mean ± SD) and 0.627±0.147 nm (n=3, mean 
± SD) respectively. This indicates that after chemical modification and after coating with 
ovalbumin the surface was still very flat and comparable to the 3D roughness of surfaces 
with similar modifications with APTES described in the literature [12, 13, 16, 17].
3.2 Coating of flat silicon surfaces with ovalbumin
 Pyridine-modified surfaces (5 cm2) were coated with ovalbumin at pH 5.8, a pH value 
that assures a high positive charge on the pyridine-modified surface (pyridine groups 93% 
protonated, as calculated by the Henderson-Hasselbalch equation) and is well above 
ovalbumin’s pI resulting in a negative charge for ovalbumin. Different doses of ovalbumin, 
corresponding to surface densities up to 20 µg/cm2, were coated on the pyridine-modified 
surfaces, as shown in figure 4A. For each dose of ovalbumin the maximum coating was 
reached within 2 hours with an average coating efficiency of 95%, which was comparable 
to ovalbumin coating efficiencies on plain amine-modified silicon surfaces. However, when 
we incubated a non-modified surface with ovalbumin (25 µg/5 cm2) at pH 5.8 for 2 hours, 
the coating efficiency was only 1.85±0.93% (mean ± SD, n=3). This shows that chemical 
modification of the flat silicon surfaces drastically increases protein adsorption. 
3.3 Release of ovalbumin from flat silicon surfaces
 The release of ovalbumin from a “pH-sensitive” pyridine-modified surface was assessed 
under various conditions and was compared to that from a “pH-independent” amine-
modified surface, as shown in figure 4B and 4C. This images show that at pH 5.8, as expected, 
no ovalbumin was released from a “pH-sensitive” pyridine-modified surface. However, when 
the pH was increased to 7.4 or higher, more than 45% of the ovalbumin was released from 
the pyridine-modified surface. This was 2-3 times as much compared to the release from a 
“pH-independent” amine-modified surface at the same pH value, indicating that a “pH-
sensitive” surface promotes the release of ovalbumin. Despite the partial release, we found 
that ovalbumin did not lose its antigenicity after it was released from the chemically modified 
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surface in 5 mM EDTA at pH 7.4, being 103.0±29.8% (mean ± SD, n=3).
 Other components in the skin such as lipids, surfactants, salts and calcium ions could 
induce the release of ovalbumin from pyridine-modified surfaces. Therefore, the effect of 
these components was assessed at pH 5.8 where the pH-induced release is minimal. In figure 
4C it is shown that a high salt concentration (1 M NaCl), a surfactant (Triton X-100), and Ca2+ 
induced partial release of ovalbumin from the silicon surface (albeit substantially less than at 
neutral or alkaline pH), indicating that for skin delivery factors other than pH could also play a 
role. In contradiction to the release of ovalbumin from pyridine-modified surfaces in a 5 mM 
EDTA buffer at pH 7.4 hardly any ovalbumin was released in PBS at the same pH (2.01±0.07%), 
which is probably due to crystal formation on the pyridine-modified surfaces when PBS is 
used (data not shown). Furthermore, when an acidic solution (0.1 M HCl), which has a pH 
below the pI of ovalbumin, was used to make the pyridine surface as well as ovalbumin 
positively charged, 20% ovalbumin was released, likely due to repulsive electrostatic forces.
3.4 Application of the chemical modification and coating technology to silicon microneedle arrays
 In the previous sections we demonstrated the successful modification and subsequent 
coating with ovalbumin of flat silicon surfaces. The next step was to apply the pH-sensitive 
coating on the surface of silicon microneedle arrays. Therefore, we used a specially designed 
coating device, as shown in figure 1A. To assess the chemical modification of the microneedle 
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Figure 4: (A) Binding of different 
amounts of ovalbumin to pyridine-
modified surfaces in time at pH 
5.8 and (B) comparison between 
the release of ovalbumin from a 
5 µg/cm2 ovalbumin-coated “pH-
independent” surface (APTES, black 
bars) and from a “pH-sensitive” 
surface (pyridine, white bars) at 
physiological pH (7.4) and at a 
pH where pyridine groups should 
be completely uncharged (9.4). 
Furthermore, (C) the release 
of ovalbumin from a 5 µg/cm2 
ovalbumin-coated pH-sensitive 
surface in physiological relevant 
release media, human serum and 
PBS, is shown as well as the release 
of ovalbumin with different skin 
components at a pH where no 
release is expected (pH 5.8). Also the 
release is shown at a pH value where 
both ovalbumin and the pH-sensitive 
surface are positively charged (0.1 
M HCl).
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surface, microneedles were first modified with amine groups and subsequently a fluorescent 
dye was covalently bound (figure 5C). This image shows that the whole surface of the 
microneedles was fluorescent, indicating that the microneedle surface was successfully 
modified with amine groups. For generating the pH-sensitive coating on the surface of the 
microneedles, the amine groups on the microneedles were modified with pyridine in the 
chemical coating device (figure 1A). Then, for achieving the subsequent protein coating onto 
the pyridine-modified microneedle surface, the microneedle arrays were mounted in a holder 
(figure 1B, 1C) to coat them with ovalbumin in a 96-well plate (one array per well). The binding 
of ovalbumin to the APTES and pyridine-modified microneedles was 18.5 µg/cm2 (comparable 
to flat chemically modified silicon surfaces), corresponding to 0.50 µg and 0.94 µg ovalbumin 
on an array of 9 and 17 microneedles, respectively.
3.5 Release of ovalbumin from microneedles into in vitro human skin
 To examine the applicability of the coating technology on microneedles in vitro, we first 
investigated the effect of wear time (the time that a microneedle array stays inside the skin) 
and number of applications of one coated pH-sensitive microneedle array on the release of 
ovalbumin from the microneedles into the skin. Therefore, pH-sensitive microneedle arrays 
coated with fluorescently labeled ovalbumin (Alexa Fluor® 488) were applied three times 
with different wear times between 15 and 300 s on in vitro human skin, as shown in figure 
5A. We observed that, independent of the wear time, most of the ovalbumin was released 
after the first application (representative fluorescence microscopy images of a 3x15 s 
application into in vitro human skin, figure 5B). Furthermore, based on the fluorescence of 
the microneedles before and after skin application we conclude that most of the fluorescently 
labeled ovalbumin disappeared from the microneedles after a single application into the skin 
(figure 5D). However, when pH-independent amine-modified microneedle arrays coated with 
fluorescently labeled ovalbumin were pierced into the skin, hardly any fluorescence was visible 
in the skin samples (data not shown). Furthermore, these ovalbumin-coated microneedle 
arrays had about the same fluorescence intensity by fluorescence microscopy before and 
after they had penetrated the skin (data not shown). These results were confirmed by doing 
a similar study with radioactively labeled ovalbumin: with our pH-sensitive coating (single 
application of 60 seconds) we found that 71.2±10.0% (mean ± SD, n=3) of the ovalbumin 
was released from the microneedles into in vitro human skin. Regarding the coating and 
release efficiency of ovalbumin from the pH-sensitive coated microneedle arrays, for dermal 
vaccination a sufficient dose of coated ovalbumin can be delivered by microneedles. However, 
when we used a “pH-independent” amine-modified surface coating only 4.73±2.87% (mean 
± SD, n=3) of the radioactive ovalbumin was released from the microneedles. These data, 
combined with the release of ovalbumin from flat silicon chemically modified surfaces, show 
that pH-triggered release is crucial for effective delivery of ovalbumin into human skin. 
  Microneedles often require the use of an applicator since microneedles regularly do 
not penetrate the skin completely upon manual application onto skin [1, 18-20]. Therefore, 
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Figure 6: A) Visualization 
by confocal laser scanning 




arrays. Ovalbumin was 
fluorescently labeled with 
Alexa Fluor® 488. On the xy-
plane the surface of in vitro 
human skin is shown after 
microneedle penetration 
(40x magnification, 
2980x2384 µm), and on the 
xz plane an in-depth scan of 
ovalbumin delivery in the 
upper row of microneedle 
penetrations is shown. 
B) xyz visualization of 
ovalbumin delivery into 
a single microchannel in 
in vitro human skin (200x 
magnification, 596x477 µm).
Figure 5: (A) Pyridine-modified microneedles 
coated with 1 µg fluorescently labeled (Alexa 
Fluor® 488) ovalbumin were applied three 
times on in vitro human skin with three 
different wear times (15, 60, and 300 seconds). 
The bars represent the pixel intensity (mean ± 
SD, n=3) of the fluorescence of the microneedle 
holes filled with fluorescent ovalbumin and the 
control represents the background fluorescence 
of the skin. (B) Representative example of three 
successive microneedle piercings  (P1, P2, P3) 
with one coated microneedle array in human 
skin in vitro, with a magnification of 40x (B1) 
and 100x (B2). (C) Microneedles to which a 
fluorescent dye (Alexa Fluor® 488) is covalently 
coupled to its surface. (D) Ovalbumin-coated 
microneedle array before skin penetration (D1) 
and after 3x application for 15 seconds (D2).
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the depth of ovalbumin delivery into in vitro human skin was determined by CLSM after the 
application of ovalbumin-coated pH-sensitive microneedle arrays on human in vitro skin using 
the manual applicator. Furthermore, CLSM was used to visualize the microchannels generated 
by the pH-sensitive pyridine-modified microneedle arrays coated with ovalbumin. Figure 6A 
shows an xy-image of the surface of the skin and at the position of the microchannels an 
in-depth scan was made from the surface of the skin to a depth of 600 µm. Furthermore, 
xyz-images were made with a magnification of 200x to visualize the ovalbumin delivery into 
a single microchannel (figure 6B). Of the confocal microscopy images 3D reconstructions 
of the ovalbumin delivery into the skin were made (movie available online, http://pubs.rsc.
org/en/Content/ArticleLanding/2013/TB/c3tb20786b#!divAbstract). These images show that 
there was almost no ovalbumin present on the surface of the skin, but that it was rather 
delivered into the epidermis and dermis. Furthermore, these images show that ovalbumin 
was delivered up to 300 µm in depth, indicating that the whole microneedle had pierced the 
skin.
 To determine to what extent the coating changed the structure of the microneedles, 
the microneedles were visualized by SEM before and after the different coating procedures 
(shown in figure 7). The tip of non-modified microneedles was very sharp (diameter < 10 
nm), and therefore the application of these microneedles by using an applicator for manual 
piercing was sufficient to penetrate the skin. Also, after the surface of the microneedles 
was chemically modified with amine groups, pyridine groups, and subsequently coated with 
ovalbumin, the microneedle tip was still very sharp (diameter < 100 nm). After the coated 
microneedles were pierced into the skin, the tips of the microneedles were still very sharp 
(diameter < 100 nm), indicating that the needles stay intact after they had pierced the skin.
Figure 7: SEM images of (A) a non-modified microneedle array, (B) an amine-modified microneedle array, (C) 
a pyridine-modified microneedle array, and (D) a pyridine-modified microneedle array coated with ovalbumin 
before skin penetration and (E) after skin penetration, and (F-J) zoomed in on one of the tips of the microneedle 
arrays, respectively.
A B C D E
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4. Discussion
 Coated microneedle arrays have great potential for pain free administration of potent 
biologicals, such as therapeutic proteins and vaccines, via the skin [1, 3]. In the design of such 
devices, it is important to have a high coating efficiency as well as a high release efficiency of 
the coated drug into the skin in order to minimize the loss of expensive drug. We successfully 
developed a novel coating procedure which is based upon pH-dependent electrostatic 
interactions, whereby proteins are efficiently coated onto microneedles and efficiently 
released from microneedles into the skin. 
 For initial experiments plain silicon slides were used instead of microneedle arrays, 
because it is easier and more accurate to measure derivatization and coating efficiencies on a 
large flat surface than on the small tip of a microneedle.
 The coating efficiency of flat silicon surfaces was very high (95%) for coating densities 
up to 20 µg/cm2 (figure 4A). Moreover, ovalbumin was successfully released from the pH-
sensitive surface in a pH-dependent manner. However, under none of the incubation 
conditions (figure 4B) ovalbumin release from flat pyridine modified silicon surfaces was 
complete. One of the reasons is the presence of residual surface charge on the modified 
surfaces at physiological pH. Although 79% of the surface amine groups were derivatized 
into pyridine groups (figure 2), still 21% of the primary amine groups are unmodified. About 
97% of these primary amine groups will be protonated at physiological pH [12]. Furthermore, 
pyridine-modified surfaces have a pKa of 6.91 (figure 3B), meaning that 39.4% of the pyridine 
groups are charged at physiological pH. Combining these two effects one can calculate that 
at physiological pH 51% of the ionizable (pyridine and APTES) groups will be protonated and 
thus can still electrostatically interact with the negatively charged ovalbumin (especially 
because the negative charge of ovalbumin will be higher at pH 7.4 than at the coating pH 
of 5.8). Furthermore, these data combined with the low release with 1 M NaCl at pH 5.8 
indicates that the release mechanism of ovalbumin from pyridine-modified silicon surfaces 
was predominantly pH-dependent, rather than ionic strength dependent. Besides, this 
technology is promising for vaccination since the released ovalbumin from pyridine-modified 
silicon surfaces did not lose its antigenicity as shown by ELISA. This indicates that the native 
epitopes of ovalbumin, which are recognized by the ovalbumin specific antibodies, are still 
intact. 
 The little release of ovalbumin from “pH-independent” amine-modified flat silicon 
surfaces (figure 4B) can be explained by the fact that APTES surfaces have two pKa values 
(6.55 and 9.94), where the first pKa accounts for about 25% of the surface charge [12]. This 
implies that at pH 7.4, only 22% of the APTES surface is deionized. However, a high pH (9.4) 
of the release medium did not lead to a higher release of ovalbumin from an amine-modified 
and a pyridine-modified surface, even though at that pH value respectively 42% and 83% of the 
ionizable surface groups should be uncharged. This may be caused by an increased negative 
charge of ovalbumin at elevated pH (figure 3A), conformational changes of ovalbumin in 
the adsorbed state and/or non-electrostatic (e.g., hydrophobic) interactions contributing to 
adsorption.
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 Similar to plain silicon surfaces, the surface of microneedle arrays was successfully 
chemically modified (figure 5C) and coated with ovalbumin (figure 5D1). As determined by SEM, 
the coating thickness on flat silicon surfaces, including the cutting planes of the microneedles, 
was very small (< 20 nm) after chemical modification and after ovalbumin coating (figure 7). 
In addition, coated silicon surfaces retained a very flat surface, as determined by AFM. These 
results were similar to comparable modifications reported in the literature [12, 13, 16, 17]. 
Furthermore, the coating thickness at the cutting edges of the microneedles was larger (100-
1000 nm) after APTES coupling, indicating that APTES tends to aggregate at the edges of 
surfaces. However, ovalbumin coating on the pH-sensitive microneedles was much thinner 
than most coatings reported in the literature, which are generally 3-15 µm thick [8, 10, 11, 18]. 
Therefore, this nanolayered pH-sensitive coating retains the geometry of the microneedles 
without compromising their sharpness.
 Ovalbumin-coated pH-sensitive microneedles penetrated human skin successfully and 
delivered the fluorescently labeled ovalbumin up to a depth of 300 µm (figure 6). The major 
fraction of the fluorescently labeled ovalbumin dose was released from the pH-sensitive 
coating after a single application for 15 s into human skin (figure 5). This was confirmed 
by a radioactivity assay demonstrating that the release of ovalbumin from a pH-sensitive 
microneedle array into in vitro human skin was 71% after a single application of 60 s. This 
delivery efficiency was high compared to that of other coatings described in the literature, 
which show a release of the active compound varying between 1-91% mostly within 15 minutes, 
depending on the coating procedure [5, 7, 10, 11, 21-24]. Moreover, a relative high amount of 
active compound is lost during these coating procedures, in shrill contrast with our novel 
coating method. 
 In contrast to the pH-sensitive coating, the pH-independent coating resulted in only 
5% release of the ovalbumin from a microneedle array, which shows the necessity of the 
pH-sensitive coating for the delivery of ovalbumin. Furthermore, the release efficiency of 
ovalbumin from the microneedle arrays into in vitro human skin differed from that of flat 
silicon surfaces into a buffered solution: the release from a pH-independent microneedle 
was lower than that from a pH-independent flat surface, and the release from a pH-sensitive 
microneedle was higher than that from a pH-sensitive flat surface. These differences may be 
caused to some extent by the analytical method (fluorescence vs. radioactivity) but more 
importantly to the differences in release medium (the complex environment in human skin, 
containing lipids, calcium, and proteins, vs. a simple buffered solution), suggesting that pH is 
not the only factor contributing to the release of ovalbumin into human skin.
 Despite the protein ovalbumin showed an excellent binding onto and an excellent 
release from pyridine-modified silicon microneedles, this approach will not be suitable for 
each protein. In the case of ovalbumin, the protein bound reversibly onto the surface, but 
proteins may undergo conformational changes in the adsorbed state, aggregate and/or bind 
irreversibly onto surfaces, as reviewed by Rabe et al. [25]. Furthermore, the packing, loading 
and the reversibility of protein adsorption is dependent on many factors, including the buffer 
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composition, ionic strength, pH, temperature, type of protein (e.g. hard/soft), shape of the 
protein, and the distribution of charge and isoelectric point of the protein [25-27]. Therefore, 
for some proteins it might be beneficial to encapsulate them into micro/nano-particles prior 
to microneedle adhesion.
 Drug delivery into the skin via microneedles is minimally-invasive and potentially pain free 
and can be achieved via several approaches. However, for each approach it is important to 
minimize the amount of drug loss and to deliver the drug in a reproducible manner and fast 
(especially for patient compliance in vaccination). Therefore, this novel approach of coating 
microneedles in a pH-dependent manner has great advantages: the coating and release 
efficiencies are high, and the major part of the drug is released within 15 s. Furthermore, the 
pH-sensitive microneedle coating can be combined with a Layer-by-Layer coating, whereby 
multiple nanolayers are formed by alternate coating of positive and negatively charged 
polyelectrolytes [28, 29]. Besides, drugs that are encapsulated into micro- or nanoparticles 
can be coated on the surface of microneedles, thus this pH-sensitive coating procedure has 
a broad application ability to deliver drugs into the skin by microneedles. Furthermore, the 
developed microneedle holders for 96-well plates render the coating procedure amenable 
for high throughput screening of different coating excipients/compounds (figure 1) and the 
coating procedure can be fully automated.
5. Summary and conclusion
 Silicon surfaces were successfully modified with pyridine groups with a high derivatization 
efficiency of 79%. Because ovalbumin has a pI of 4.4 and the pyridine-modified surfaces were 
shown to have a surface pKa of 6.9, there is a coating window between pH 5.4-6.8. Pyridine-
modified silicon surfaces were coated with ovalbumin at pH 5.8 in a 1 mM EDTA buffer without 
using further excipients. This led to a high coating efficiency of ovalbumin (> 95%) with a dose 
up to 20 µg/cm2 within 2 h coating time. The in vitro release of ovalbumin at physiological pH 
was 45% within the first minute whereby the released protein retained its antigenicity. 
 Microneedles modified with the pH-sensitive surface modification and subsequently 
coated with ovalbumin, released the major fraction of ovalbumin after a single application 
of 15 s into in vitro human skin. Furthermore, the microneedle coating minimally affected the 
microneedle’s geometry and sharpness, since the coating on the cutting planes was < 20 nm 
thick and the tip diameter of the microneedles was < 100 nm after coating.
 In conclusion, this nanolayered pH-sensitive coating for microdevices may provide a 
useful tool for the delivery of potent therapeutic proteins and vaccines.
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 The aim of this work was to study the applicability of antigen-
coated pH-sensitive microneedle arrays for effective vaccination 
strategies. Therefore, a model antigen (ovalbumin) was coated 
onto pH-sensitive (pyridine-modified) microneedle arrays to test pH-
triggered antigen release by applying the coated arrays onto ex vivo 
human skin, and by conducting a dermal immunization study in mice.
 The release of antigen into ex vivo human skin from the coated 
microneedles was determined by using radioactively labeled 
ovalbumin. To investigate the induction of antigen-specific IgG, and 
CD4+ and CD8+ T-cell responses, BALB/c mice were immunized with 
antigen-coated pH-sensitive microneedles by the ‘coat and poke’ 
approach. These responses were compared to responses induced by 
the ‘poke and patch’ approach, and subcutaneous and intradermal 
vaccination with classic hypodermic needles.
 The pH-sensitive microneedle arrays were efficiently coated 
with ovalbumin (95% coating efficiency) and upon application of six 
microneedle arrays 4.27 of 7 µg ovalbumin was delivered into the skin, 
showing a release efficiency of 70%. In contrast, the ‘poke and patch’ 
approach led to a delivery of only 6.91 of 100 µg ovalbumin (7% delivery 
efficiency). Immunization by means of ovalbumin-coated microneedles 
resulted in robust CD4+ and CD8+ T-cell responses comparable to 
those obtained after subcutaneous or intradermal immunization with 
conventional needles. Moreover, it effectively induced IgG responses, 
however, it required prime-boost immunizations before antibodies 
were produced.
 In conclusion, antigen delivery into ex vivo human skin by antigen-
coated pH-sensitive microneedle arrays is more efficient than the 
‘poke-and-patch’ approach and in vivo vaccination studies show the 
applicability of pH-sensitive microneedles for the induction of both T 
cell and B cell responses.
Chapter 4.3 Ovalbumin-coated pH-sensitive 
microneedle arrays effectively 
induce ovalbumin-specific antibody 
and T-cell responses in mice
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1. Introduction
 Vaccination is one of the most cost-effective and successful approaches to prevent 
infectious diseases by preventing approximately 6 million deaths per year [1]. Besides 
vaccination against infectious diseases, therapeutic vaccines, such as anti-cancer vaccines, are 
being developed [2-4]. Despite the benefits of vaccination campaigns, however, vaccination 
does not always induce adequate immune responses [3-5]. Furthermore, subcutaneous or 
intramuscular vaccination requires medical personnel and causes pain, fear and stress in 
children and their parents [6-8]. To overcome these disadvantages, the use of microneedles 
for dermal vaccine delivery has been proposed [6, 8-10]. Moreover, dermal vaccine delivery 
has dose-sparing potential because the skin is a potent immune organ [6, 8].
 Microneedles are micron-sized structures with a length of < 1 mm, which are used to deliver 
a drug or vaccine into the skin in a minimally-invasive manner. In general, microneedles can be 
used by four different approaches to deliver a drug into the skin, as reviewed elsewhere [6, 8]. 
In this study we compare two microneedle approaches for effective vaccine delivery. In the 
‘poke and patch’ approach, microneedles are used to pierce the stratum corneum to create 
micropores. Subsequently, a patch with a vaccine formulation is applied onto the micropores 
for the vaccine to diffuse into the skin. By the ‘coat and poke’ approach, the microneedle 
surface is first coated with a vaccine that is subsequently released upon piercing of the skin. 
 Vaccine delivery by the ‘poke and patch’ approach is technically simpler than by using 
coated microneedles, since microneedle pretreatment does not require the development of 
a coating wherein the antigen´s integrity is retained. However, the ‘poke and patch’ approach 
involves a two-step delivery, i.e., first the skin is pierced and then a patch is applied on the 
site of microneedle application. In contrast, coated microneedles are a single-unit drug 
delivery system [6]. By the ‘poke and patch’ approach a relatively high dose of vaccine can be 
applied, but the patch must to be worn for a relatively long time (> 2 h) to deliver a generally 
low percentage of the vaccine into the skin [11-14]. In contrast, coated microneedles can be 
developed in such a way that the vaccine is delivered within minutes with a high delivery 
efficiency up to 30-70% [15-17], but microneedles can only be coated with a limited amount of 
vaccine [6, 15]. However, coated microneedles have the potential of dose sparing compared 
to the ‘poke and patch’ approach provided that the coating and the release are very effective 
[6, 11, 15]. 
 As previously reported, pH-sensitive microneedles offer an easy and effective way to coat 
a microneedle array with a protein that is released into the skin upon application [15]. In this 
work the surface of microneedles is modified with a weak base to obtain its pH-sensitivity. 
Subsequently, microneedles are coated at a pH value where the vaccine is negatively charged, 
thus above its isoelectric point, and the microneedle surface is positively charged, thus below 
the surface pKa. In this study we investigate the applicability of pH-sensitive microneedles 
for vaccination purposes by using ovalbumin as a model antigen. We compare the ‘coat and 
poke’ approach with the ‘poke and patch’ approach, subcutaneous and intradermal injections 
for the induction of IgG, and CD4+ and CD8+ T-cell responses.
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2. Materials and methods
2.1 Mice
 Female BALB/c mice (H2d) were obtained from Charles River (Maastricht, the 
Netherlands), which were maintained under standardized conditions in the animal facility of 
the Leiden Academic Centre for Drug Research, Leiden University. The mice were 8 weeks 
old at the start of the vaccination study and the study was carried out under the guidelines 
complied by the animal ethic committee of the Netherlands, and was approved by the 
‘Dierexperimentencommisie Universiteit Leiden (UDEC)’ under number 13065.
2.2 Generation of pH-sensitive microneedles and the coating thereof with ovalbumin
 In this study in-plane silicon microneedle arrays, each containing 17 microneedles per 
array with a microneedle length of 300 µm, as shown in figure 1, were used. The arrays, which 
were kindly provided by U-Needle B.V. (Enschede, the Netherlands), had a configuration of 8 
microneedles on the front and 9 on the back. In order to generate pH-sensitive microneedles, 
their surface was first modified with amine groups that were subsequently derivatized into 
pyridine groups, a weak base with a surface pKa≈6.9, as reported previously [15, 18]. Finally, 
pH-sensitive microneedles were coated with ovalbumin grade VII (CALBIOCHEM®) in a 96-
well plate by incubating the arrays for 2 hours in a 1 mM EDTA buffer at pH 5.8 with 10 µg/mL 
ovalbumin; this resulted in the coating of the surface of the 17 microneedles with in total 1 µg 
ovalbumin [15].
2.3 Human skin
 Abdomen ex vivo human skin was obtained from local hospitals within 24 hours after 
cosmetic surgery and was dermatomed to a thickness of 600 µm.
2.4 Microneedle application
 Microneedle arrays in this study were applied by two different approaches: the ‘coat 
and poke’ and the ‘poke and patch’ approach. For the ‘coat and poke’ approach, each pH-
sensitive microneedle array was coated with 1 µg ovalbumin and was subsequently pierced 
into the skin. After one minute the microneedle array was removed from the skin. For the 
‘poke and patch’ approach, one uncoated microneedle array was used to pierce the skin and 
subsequently a patch with 70 µL phosphate buffered saline (PBS) (163.9 mM Na+, 140.3 mM 
Cl-, 8.7 mM HPO4
2-, and H2PO4
-, pH 7.4) containing 100 µg ovalbumin was applied on the site 
of microneedle application for two hours. After dermal ovalbumin delivery by microneedles, 
the skin was extensively washed: ex vivo human skin was washed twice with a cotton swap 
soaked in PBS and tape-stripped (Scotch tape) twice; in vivo mouse skin was washed with 
lukewarm tap water.
2.5 Delivery of ovalbumin into ex vivo human skin
 To determine the amount ovalbumin that was delivered into dermatomed (600 µm) ex 
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vivo human skin by the ‘coat and poke’ and the ‘poke and patch’ approach, a calibration curve 
(1 ng - 50 µg) was prepared of radioactively labeled ovalbumin (125I) [15]. The γ-counts of the 
samples were measured for 1 minute on a Perkin Elmer Wallac Wizard 1470 Automatic Gamma 
Counter.
2.6 Immunizations
 Mice were immunized according to fi gure 2. One day prior to each immunization, the 
abdominal ventral skin of the mice was shaved. Prior to microneedle treatment mice were 
anesthetized with 150 mg/kg ketamine and 10 mg/kg xylazine. Mice were immunized thrice 
with ovalbumin (day 1, 22, and 43) and once with ovalbumin adjuvanted with CpG (ODN1826) 
(day 64). To determine the ovalbumin-specifi c IgG responses the sera of immunized mice 
were collected on day 21, 42, 63, and 74. Besides, spleens were collected on day 74 to assess 
the induction of ovalbumin-specifi c CD4+ and CD8+ T-cell responses.
 For the ‘coat and poke’ approach mice were immunized with 6 microneedle arrays/mouse 
and for the ‘poke and patch’ approach mice received a patch with ovalbumin or PBS after the 
skin was poked with one microneedle array (8 mice/group). Mice that were immunized by 
subcutaneous or intradermal injection (5 mice/group) received 5 µg ovalbumin in 100 µL and 
30 µL PBS, respectively.
Figure 1: In-plane silicon microneedle array mounted in a specially designed holder and photographed under a 
stereo microscope (0.8x magnifi cati on) (A), electron micrograph of a microneedle array (150x magnifi cati on) (B) 
and zoomed in on the ti p of a single microneedle (6000x magnifi cati on) (C).
Figure 2: Immunizati on scheme of mice
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 At the fourth immunization (day 64), mice received ovalbumin adjuvanted with CpG 
(5 mice/group) to induce antigen-specific T-cells. Prior to application of an ovalbumin-
coated microneedle array, a drop of 5 µL containing 5 µg CpG was applied onto the mouse 
skin through which one coated microneedle array was applied. Each mouse in the coated 
microneedle group was treated with six microneedle arrays per immunization. Furthermore, 
200 µg CpG was added to the patch formulation of mice that were immunized by the ‘poke 
and patch’ approach. Finally, 10 µg CpG was added to the formulations that were injected 
subcutaneously or intradermally.
2.7 Analysis of the sera for ovalbumin-specific IgG responses
 Ovalbumin specific antibodies were determined by a sandwich ELISA, as described 
previously [19]. Antibody titers were expressed as the log value of the serum dilution at the 
mid-point of a complete S-shaped absorbance-dilution curve. Non responders were given an 
arbitrary titer of 1.
2.8 Analysis of splenocytes for ovalbumin specific CD4+ responses
 Antigen-specific CD4+ and CD8+ T-cell activation was determined by measuring 
endogenous splenic CD4+/CD8+ CD69+ T-cells 10 days after the last immunization. In brief, 
splenocyte suspensions were prepared from spleens that were aseptically removed. To 
remove the erythrocytes, 2 mL of lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 1 mM EDTA-2Na, 
pH 7.2) was added to the splenocyte suspensions. After 2 minutes the cells were washed and 
resuspended in Iscove’s modified Dulbecco’s medium (IMDM) (Invitrogen Life Technologies) 
supplemented with 8% (v/v) fetal calf serum (Greiner Bioscience), 50 µM 2-mercaptoethanol, 
2 mM glutamine, 100 IU/ml penicillin, to a concentration of 25*106 cells/mL. Next, of each 
splenocyte suspension two times 2.5*106 cells were transferred to a round bottom 96-well 
plate in a volume of 200 µL, one of which was incubated with 10 µg/mL ovalbumin [20]. 
After both splenocyte suspensions were incubated overnight at 37°C with 5% CO2, the cells 
were labeled for flow cytometric analysis in PBS/ 0.1% bovine serum albumin. The following 
antibodies were used:  7-AAD (1:500) (Life Technologies); CD3V500 (1:100) (BD Biosciences); 
CD4Qdot605 (1:1000), CD8αAlexafluor700 (1:200), and CD69FITC (1:100) (eBiosciences). For the 
compensation of CD69FITC, CD3FITC was used. Of each splenocyte suspension 1*10
6 cells were 
analyzed by flow cytometry on a LSR-II (BD™). Prior to the flow cytometric measurements, 
the different colors were auto-compensated in the BD FACSDiva™ software. The gating/
analysis was performed in FowJo v10 (Supplemental Information). Finally, the percentage 
ovalbumin-specific endogenous CD4+/CD8+ T-cells was calculated from the difference in 
percentage CD4+/CD8+ CD69+ T-cells incubated with and without ovalbumin.
2.9 Statistical analysis
 Statistical analysis was performed by using Prism 5 for Windows. For the ovalbumin-
specific IgG titers and endogenous ovalbumin-specific CD4+ and CD8+ T-cell responses the 
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mean ± SEM were calculated, and the statistical significance was determined by a two-way 
ANOVA for the IgG titers and a one-way ANOVA for the CD4+ and CD8+ T-cell responses, both 
with a Bonferroni post test.
3. Results and discussion
3.1 Delivery of protein antigen
 As reported previously, silicon microneedle arrays of which the surface is modified with 
pH-sensitive groups offer a fast, easy and effective approach to deliver protein drugs, such 
as antigens, into the skin. In our previous study we have shown that positively charged pH-
sensitive microneedle arrays are coated with 1 µg ovalbumin with a coating efficiency of 
95% [15]. The amount of ovalbumin that is delivered with syringes by using conventional 
hypodermic needles is very controlled. However, the amount of ovalbumin that is delivered 
into the skin by using the ‘coat and poke’ approach or the ‘poke and patch’ approach is not 
known. Therefore, radioactively labeled ovalbumin was used to quantify the dermal delivery 
of ovalbumin by microneedles, and the results are summarized in table 1. This table shows 
that the delivery efficiency of ovalbumin by pH-sensitive microneedles is about 10-fold higher 
compared to ovalbumin delivery by the ‘poke and patch’ approach. However, the delivery 
efficiency of ovalbumin via the ‘poke and patch’ approach can be enhanced by increasing 
the microneedle length and the time that the patch is applied. It has been reported that 
delivering plain ovalbumin by the ‘poke and patch’ approach with 200, 500, and 1000 µm 
long microneedles lead to a delivery of 5%, 12%, and 23% after 24 hours, respectively [14]. In 
conclusion, in our settings using antigen-coated pH-sensitive microneedle arrays requires a 10 
fold lower amount of antigen to deliver the same dose into the skin as compared to the ‘poke 
and patch’.
3.2 Ovalbumin-specific antibody responses in mice
 In order to test the applicability of the pH-sensitive coating for vaccination purposes, 
immunization by using ovalbumin-coated pH-sensitive microneedles was compared to 
immunization by ovalbumin delivered via the ‘poke and patch’ approach, and via subcutaneous 
and intradermal injection by using conventional needles. The ovalbumin-specific serum 
IgG responses are shown in figure 3. The estimated dose of ovalbumin that is delivered by 
Table 1: The delivery of radioactively labeled ovalbumin into ex vivo human skin by the ‘coat and poke’ and the 











6 5.7 [15] 4.27±0.60 70
‘Poke and patch’ 100 Not applicable 6.91±1.52 7
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microneedles into mice was based upon the delivery into ex vivo human skin. 
 As expected, mice mock-treated with PBS did not show detectable ovalbumin-specific 
IgG antibody levels. Comparing the microneedle groups that received ovalbumin, after the 
prime 1 out of 8 mice induced ovalbumin-specific antibody responses upon microneedle 
treatment in the pH-sensitive microneedle group and none in the ‘poke and patch’ group. 
After the first boost immunization all groups that received ovalbumin showed comparable 
ovalbumin-specific IgG responses, however, the number of responders was different: in 
the ‘poke and patch’ group 5 out of 8 and in the pH-sensitive microneedle group 4 out of 
8 mice responded. Finally, all mice that received ovalbumin showed ovalbumin-specific IgG 
responses after the 2nd and 3rd boost immunization. The ovalbumin-specific IgG titers of the 
mice that received similar amounts (ca 4-7 µg) of ovalbumin by the ‘poke and patch’ approach 
or by ovalbumin-coated pH-sensitive microneedles were comparable. 
 In contrast to ovalbumin delivery by microneedles, all mice that were subcutaneously or 
intradermally injected with ovalbumin already produced ovalbumin-specific IgG antibodies 
after the prime immunization. Furthermore, the IgG titers of the mice that were immunized by 
using hypodermic needles were 10 times higher. However, immunization with microneedles 
























































Figure 3: Ovalbumin-specific 
serum IgG titers after 
microneedle-based, and 
subcutaneous and intradermal 
vaccination. Mice were 
immunized four times with time-
intervals of three weeks (prime, 
boost, 2nd boost, and 3rd boost). 
All groups, except ‘microneedles 
+ PBS’ received ovalbumin and 
at the fourth immunization the 
formulations were adjuvanted 
with CpG. Non-responding mice 
were given an arbitrary titer of 
1. Results are shown as mean ± 
SEM and statistical significance 
was determined by a two-
way ANOVA with a Bonferroni 
posttest (*** P<0.001).
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the induction time is longer and requires more successive immunizations with the 17 
microneedle arrays with a length of 300 µm.
 There have been several studies reported using microneedle-based immunization 
of ovalbumin with contradicting results. For example, Chen et al. (2013) showed that rats 
immunized with 1 mg ovalbumin by using dissolving microneedles with a length of 600 
µm gave higher ovalbumin-specific IgG levels compared to intramuscular immunization 
[21]. Raphael et al. showed that immunizing mice with 7.6 µg ovalbumin adjuvanted with 
Quil-A by using 92 µm long dissolving microneedles led to comparable ovalbumin-specific 
IgG titers as intramuscular immunization with 15 µg ovalbumin adjuvanted with Quil-A 28 
days after immunization. However, 102 days after immunization the ovalbumin-specific IgG 
responses were higher after microneedle-based immunization than after intramuscular 
immunization [22]. Guo et al. showed that mice immunized with 2 µg ovalbumin by using 
dissolving microneedles with a length of 550 µm led to comparable ovalbumin-specific IgG 
titers compared to intramuscular immunization [23]. Importantly, it has been shown that 
the microneedle length greatly influences the ovalbumin-specific IgG responses in rats 
and mice, e.g., 800-1000 µm long microneedles induced stronger IgG responses than 200-
500 µm long microneedles [14, 24], but the former ones are more likely to induce pain [8]. 
Finally, Kumar et al. showed that by applying the ‘poke and patch’ approach immunization 
with 10.5 µg ovalbumin nanoparticles resulted in slightly, but not significantly, lower IgG 
responses compared to subcutaneous immunization with the same dose. However, a dose 
of 70 µg ovalbumin led to significantly lower ovalbumin-specific IgG responses compared 
to subcutaneous immunization [14]. In conclusion, microneedle-based vaccination with 
ovalbumin by using 300 µm long microneedles resulted in robust antibody responses, 
although  lower than conventional injection, with 100% seroconversion and is likely pain-free 
upon application [8].
3.3 Ovalbumin-specific T-cell responses in mice
 After the 3rd boost immunization endogenous ovalbumin-specific CD4+ and CD8+ T-cell 
responses were evaluated by determining the upregulated expression of the activation marker 
CD69 on splenic CD4+ and CD8+ T-cells [20, 25, 26]. The percentage ovalbumin-specific CD4+ 
and CD8+ T-cells was calculated by subtracting the background signal from the percentage 
ovalbumin-incubated CD69+ cells (as shown in supplemental information SI2). Figure 4 
shows that the percentages of ovalbumin-specific CD4+ (4A) and CD8+ (4B) T-cells in mice 
that received ovalbumin were significantly higher (p<0.01) than those in PBS treated (naïve) 
mice. Furthermore, a trend was observed towards higher percentages of ovalbumin-specific 
CD4+ and CD8+ T-cells upon ovalbumin delivery by pH-sensitive microneedles compared 
to ovalbumin delivery by the ‘poke and patch’ approach, but the differences were not 
statistically significant. Moreover, immunization by using microneedles and by subcutaneous 
or intradermal immunization led to comparable percentages of ovalbumin-specific CD4+ and 
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CD8+ T-cells. In the literature it was shown that vaccination with 10 µg ovalbumin by using 600 
µm long dissolving microneedles leads to efficient anti-tumor and antiviral immune responses 
by the induction of ovalbumin-specific CD8+ and CD4+ Th1 responses [27]. Furthermore, it has 
been reported that using 110 µm long ovalbumin-coated ultra-high-density microneedle arrays 
lead to superior CD8+ T-cell responses in mice compared to intramuscular immunization [28]. 
In conclusion, these and our present results show that microneedle-based immunization is 
highly suited for inducing T-cell responses even more pronounced than IgG responses.
5. Conclusion
 In conclusion, ovalbumin delivery into ex vivo human skin by ovalbumin-coated pH-sensitive 
microneedle arrays is very efficient compared to that by the ‘poke and patch’ approach. 
Immunization by microneedles can lead to comparable IgG responses as by conventional 
subcutaneous or intradermal immunization, although requires more immunizations before 
antigen-specific antibodies are produced. To further improve the antigen-specific antibody 
responses several strategies could be explored, such as adding an adjuvant, changing the 
microneedle length, density, number, or vaccinating via a different skin site. Furthermore, 
ovalbumin-specific CD4+ and CD8+ T-cell responses are effectively induced after microneedle-
based immunization, similar to subcutaneous and intradermal immunization by conventional 
hypodermic needles. Therefore, these results show the applicability of pH-sensitive 
microneedles for controlled intradermal vaccination.





























































































Figure 4: Endogenous ovalbumin-specific CD4+ (A) and CD8+ (B) T-cells calculated by the difference between 
CD69 expression of non-stimulated and ovalbumin restimulated splenocytes (mean ± SEM). Each dot 
represents an individual immunized mouse.
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Supplemental information
 Analysis of splenocytes in FowJo v10 as follows. The lymphocytes were gated from the 
forward (FSC)-sideward scattering (SSC) dotplot (fi gure SI1A). From this population the living 
T-cells, 7-AAD negative and CD3 (AmCyan) positive, were selected (fi gure SI1B). Subsequently, 
the percentage of CD4+ (Qdot605) CD8- (AlexaFluor700) T-cells (fi gure SI1C) that was positive 
for CD69 (FITC) (fi gure SI1D) and the percentage of CD4- (Qdot605) CD8+ (AlexaFluor700) 
T-cells (fi gure SI1C) that was positive for CD69 (FITC) was determined.
Figure SI1: Gati ng strategy for the analysis of splenocytes by fl ow cytometry. Dot plots of the forward scatt ering (FSC) 
versus sideward scatt ering (SSC) (A), 7-AAD versus CD3 (AmCyan) (B), CD8 (AlexaFluor700) versus CD4 (Qdot605) (C), 
and CD4 versus CD69 (FITC).
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Figure SI2: Expression of the surface marker CD69 on CD4+ (A and B) and CD8+ (C and D) T-cells upon 
restimulation of splenocytes with ovalbumin (black bars) compared to non-stimulated splenocytes (white bars) (A 
and C). Ovalbumin-specific CD4+ T-cells calculated by the difference between the non-stimulated and ovalbumin 
restimulated splenocytes (B and D).
Abstract
 The aim of this work was to generate a tunable surface isoelectric 
point (sIEP), where the surface is modified with two molecules: a 
weak base (pyridine), carrying a pH-dependent positive charge, 
and a derivative of a strong acid (sulfate), carrying a permanent 
negative charge in a physiologically relevant pH range. To this end, 
silicon surfaces were modified with 3-aminopropyltriethoxysilane. 
These amine-modified surfaces were subsequently derivatized 
into pyridine- or sulfate-modified surfaces. Then, the surface pKa 
of pyridine-modified surfaces was determined by a fluorescent 
nanoparticle adhesion assay (FNAA). Next, these values were used to 
calculate in which ratio the chemicals must be present in the reaction 
mixture to generate a mixed pyridine/sulfate-modified surface with 
a target sIEP. After preparing surfaces with a target sIEP, a FNAA 
with positively and negatively charged nanoparticles was used to 
verify the sIEP of the generated surfaces. The FNAA revealed that 
pyridine-modified surfaces had a pKa of 6.69±0.18. When an sIEP was 
generated, negative nanoparticles bound to surfaces at pH values 
below the sIEP and positive nanoparticles bound at pH values above 
the sIEP. Furthermore, we found sIEP values of 5.97±0.88 when we 
aimed for an sIEP of 6.2, and 7.12±0.21 when we aimed for an sIEP of 
7.1. Finally, the pH-dependent binding and release of a negatively and 
positively charged (bio)polymer was investigated for a target sIEP of 
7. A negatively charged polymer (poly(I:C)) was bound at a pH < sIEP 
and released at a pH > sIEP with a release efficiency of 85±9% and 
a positively charged polymer (trimethyl chitosan) bound at a pH > 
sIEP and released at a pH < sIEP with a release efficiency of 72±9%. In 
conclusion, we established a method for preparing modified silicon 
surfaces with a tunable sIEP, which can be used for pH-dependent 
binding and release of biomacromolecules.
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 The modification of surfaces with self-assembling monolayers is used for numerous 
applications, such as bio-analytical applications, including chromatography [1], antibody 
microarrays [2], DNA and protein biosensors [3, 4], and biomedical applications, including 
nanoparticles [5, 6], and implants [7, 8]. In many of these applications biomacromolecules 
such as DNA, RNA, peptides and proteins, or drugs and (drug-containing) nanoparticles 
are immobilized by a variety of methods. These methods employ physical entrapment, 
hydrophobic interactions, covalent bonding, van der Waals interactions, and electrostatic 
interactions [2, 3, 9-11]. However, in many cases of drug delivery the compound must be 
desorbed from the surface in order to become active or to be taken up by target cells. 
Immobilization of biomacromolecules via electrostatic interactions has great potential, 
since most of these compounds are either positively or negatively charged. Furthermore, 
detachment of these compounds when adsorbed by electrostatic interactions can be 
achieved by ion competition [12] or by removing/changing the charge of the compounds and/
or the surface by a pH shift [13].
 In order to change the charged state of the surface, it needs to possess groups having at 
least one pKa, whereby the charged state of the surface is dependent on the surface pKa of 
the (acidic or basic) groups and the surrounding pH. However, according to the Henderson-
Hasselbalch equation a pH difference of 4 pH units (pKa ± 2) is required to have either a high 
(99% of the maximum) or a low (1%) surface charge. To bind oppositely charged compounds 
a high surface charge could be beneficial. For the release however, especially for large 
molecules such as biomacromolecules or polymers, even at a low surface charge of < 1%, the 
release from the surface might be hampered. Furthermore, many biomacromolecules such as 
proteins are susceptible to deformation, aggregation, and hydrolysis at pH values deviating 
substantially from physiological pH [14-16]. Therefore, a surface pKa does not always lead 
to the optimal surface properties for selective adsorption/release of biomacromolecules 
or polymers. A more sophisticated way of using electrostatic interactions for selective 
adsorption and desorption of biologically relevant compounds, is by generating a surface 
isoelectric point (sIEP). The benefit of having an sIEP, is that the surface can either be 
positively (pH < sIEP) or negatively (pH > sIEP) charged and that this change in surface charge 
takes place over a small pH range. For instance, a negatively charged compound can bind to 
a surface at pH < sIEP and is repelled at pH > sIEP. 
 Recently, Lin et al. synthesized surfaces with a tunable sIEP by changing the ratio of 
amine and carboxylic groups on gold surfaces [17], and Kuo et al. synthesized surfaces with a 
tunable sIEP on silicon surfaces by varying the ratio between amine and thiol groups on the 
surface [18]. However, surface amine groups on gold, e.g., aminothiols, are unstable because 
these molecules can undergo chemical transformation, e.g., photoassisted oxidation of 
amine groups into nitroso groups and oxidation of thiol groups into sulfonate groups [19-21]. 
Furthermore, these surfaces are only stable up to 100°C [19]. Also amine groups on silicon 
substrates have stability issues, e.g., amino alkoxysilanes, can react with carbon dioxide and 
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form imines [22, 23] thereby losing their charge.
 In this work we generated a model to generate a tunable sIEP by using two different 
surface groups, as shown in figure 1, of which one group has a pH-independent charge over 
a broad pH range and the other group has a pH-dependent charge. Therefore, a layer of 
3-aminopropyltriethoxysilane (APTES) was coated on silicon surfaces by self-assembly. These 
surfaces were then modified with pyridine groups of which the surface pKa was determined. 
The reactivity ratios of amine-modified surfaces into pyridine- and sulfate-modified surfaces 
was determined to calculate and generate surfaces with an sIEP of 6 and 7, as confirmed by 
a fluorescent nanoparticle adhesion assay (FNAA) by using positively and negatively charged 
nanoparticles.
2. Materials and methods
2.1 Materials
 Succinic anhydride, APTES, amine-modified fluorescent orange nanoparticles of 100 nm, 
sulfate-modified fluorescent orange nanoparticles of 100 nm, 4-pyridinecarboxaldehyde (4-
PCA), sodium cyanoborohydride, acetic acid, 4-formyl-1,3-benzenedisulfonic acid disodium 
salt (4-FBDA), H2O2, EDTA, rhodamine B isothiocyanate, and HPLC grade methanol were 
purchased from Sigma Aldrich. 96-98% H2SO4 was obtained from Boom lab equipment, 
1,4-dioxane was from Baker Chemicals B.V., 2-propanol Mallinckrodt analytical grade reagent 
(AR) and toluene AR were from Biosolve, and Acetonitrile HPLC Far UV was from LAB-SCAN 
Analytical Sciences. 1.5 mL polystyrene cuvettes were purchased from Sarstedt, black 96 
well plates were from Greiner, and molecular sieves 4Å and 8 to 12 mesh were from Acros 
Organics. Chitosan (Mw 120 kDa) with a degree of deacetylation of 92% was purchased from 
Primex, poly(I:C) (LMW) rhodamine was obtained from InvivoGen, and Alexa-Fluor® 488 
carboxylic acid succinimidyl ester was purchased from InvitroGen. Deionized water with a 
resistivity of 18 MΩ·cm, produced by a Millipore water purification system (MQ water), was 
used for the preparation of solutions and the cleaning of the silicon surfaces. Silicon wafers 
<110> with a thickness of 0.38 mm, cut in pieces of 1x1 cm and of 1x2.5 cm, were a kind gift of 
U-Needle B.V. 
2.2 Methods
2.2.1 Synthesis of rhodamine B labeled trimethyl chitosan (TMC)
 N-trimethyl chitosan chloride (TMC), with a degree of quaternization of 18%, was 
synthesized by methylating chitosan by iodomethane in the presence of NaOH as described 
by Hamman and Kotzé [24]. In brief, a mixture of 2 g of chitosan, 12 mL 3.75 M NaOH, 12 
mL iodomethane, and 4.8 g sodium iodine in 80 mL N-methylpyrrolidone was refluxed for 1 
hour at 60°C. Subsequently, the obtained polymer (TMC) was precipitated by ethanol and was 
washed on a fritted funnel by ethanol and diethyl ether. Next, TMC was purified by dialysis 
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against 0.17 M NaCl for 4 days and against MQ water for 2 days, and was subsequently freeze 
dried. 
 In order to quantify the polymer, TMC was dissolved in 0.1 M carbonate buffer at pH 
of 9 and was fluorescently labeled with rhodamine B isothiocyanate in a weight ratio of 
respectively 15:1 for 1 hour [25]. Next, rhodamine B labeled TMC was dialyzed against MQ 
water until rhodamin B was undetectable by fluorescence, and was finally freeze dried.
Figure 1: Schematic scheme of the principle of the generation of a tunable surface isoelectric point (sIEP) by 
modifying surfaces with positively charged groups with a pKa in a physiologically relevant pH range and with 
groups that have a permanent negative charge in the same range. After the silicon surface is oxidized with a 
piranha mixture (A), the surface is modified with APTES (B). Subsequently, this surface is derivatized into a 
pyridine-modified surface (C) of which the surface pKa is determined (D). The surface pKa and the apparent 
derivatization efficiencies to generate pyridine- (C) and sulfate-modified (E) surfaces are used to generate a 
tunable sIEP (F). Index of molecules: large gray balls (Si), black balls (C), red balls (O), blue balls (N), white balls (H), 
and yellow balls (S).
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2.2.2 Surface modification
 Chemically modified surfaces were prepared as schematically illustrated in figure 2 and 
described in detail below. In order to modify surfaces with pyridine groups for a positive 
charge and sulfate groups for a negative charge, silicon surfaces were first modified with 
APTES. This was done in a two-step procedure, as described previously [26]. Briefly: first, flat 
silicon surfaces of 1x1 cm were incubated for 30 min in a freshly prepared piranha solution 
(7 H2SO4 : 3 H2O2) at 120°C, and were then incubated in a 2% APTES solution in toluene for 
24 h to obtain amine-modified surfaces. Then, these surfaces were cured for 30 minutes 
at 120°C and were subsequently incubated for 2 hours in MQ water at 40°C to remove non-
reacted ethoxy groups. Next, the surface amine groups were derivatized into either carboxyl-
modified surfaces, pyridine-modified surfaces, or sulfate-modified surfaces. To obtain a 
carboxyl-modified surface, amine-modified surfaces were incubated for 30 min in a 20 mg/
mL succinic anhydride solution in 1,4-dioxane at 80°C. Both pyridine-modified surfaces and 
sulfate-modified surfaces were prepared by a two-step procedure. First, amine-modified 
surfaces were incubated with 15 mM of either 4-pyridinecarboxaldehyde (4-PCA) to generate 
a pyridine-modified surface, or 4-formyl-1,3-benzenedisulfonic acid disodium salt (4-FBDA) to 
generate a sulfate-modified surface, in a 1:8 isopropanol:methanol mixture with 1% acetic acid 
to which molecular sieves (0.15 g/mL) were added, for 16 h at room temperature. Finally, 
the imine bond was reduced to a secondary amine by incubating the silicon surfaces in a 
freshly prepared 50 mM sodium cyanoborohydride solution in isopropanol for 2 h at room 
temperature. The modified surfaces were stored under argon until use.
2.2.3 Fluorescent nanoparticle adhesion assay
 In order to determine the binding of nanoparticles to the chemically modified silicon 
surfaces, the unbound fraction of nanoparticles was determined as described previously 
[26]. First, a nanoparticle suspension (1 µL of 2.5% solids per mL) of either positive (amine-
modified) or negative nanoparticles (sulfate-modified) were prepared in a 1 mM EDTA buffer 
at a certain pH value. The fluorescence intensity of these nanoparticles is linearly dependent 
on a nanoparticle concentration between 0.03-2 µL nanoparticle suspension (2.5% solids)/mL 
buffer. Subsequently, two aliquots of 0.75 mL were transferred to two 1.5 mL cuvettes, to one 
of which a silicon slide was added. The cuvettes were incubated for 2 h at room temperature 
on a shaking device at 500 rpm. Next, two times 200 µL of the incubated nanoparticle 
suspensions with a silicon slide (FIsilicon) and without a silicon slide (FIcontrol) were transferred to 
a black 96 well plate and the emission at 540 nm was measured with an excitation wavelength 
of 520 nm on a Tecan Infinite® M1000. These fluorescence values were used to calculate the 
binding percentage (B), according to equation 1.
  B = (1-[FIsilicon]/[FIcontrol])*100%   (Equation 1)
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2.2.4 pKa determination of pyridine-modified surfaces
 In order to develop a model to predict and generate an sIEP, the surface charge as a function 
of the pH of each molecule that is present on the surface needs to be known. Therefore, the 
surface pKa of pyridine-modified surfaces was determined by the FNAA [26]. Since pyridine is a 
weak base and gets positively charged when reducing the pH, negatively charged nanoparticles 
were used to determine its pKa value. Therefore, the binding percentage of negatively charged 
fluorescent nanoparticles to 1x1 cm pyridine-modified silicon surfaces was determined as a 
function of the pH of the nanoparticle suspension. For each titration 20 different pH values 
were used. Subsequently, the binding percentage was plotted as a function of the pH and was 
fitted in Prism 5 for Windows according to the Henderson-Hasselbalch equation. The pH at the 
midpoint of the S-shaped curve was determined as the surface pKa.
Figure 2: Preparation of chemically modified surfaces. First, silicon surfaces were hydroxylated by a piranha 
mixture (H2SO4:H2O2). Subsequently, the hydroxylated surfaces were reacted with APTES (a), yielding an amine-
modified surface. Next, the amine-modified surfaces were modified into either carboxyl-modified surfaces by 
reaction with succinic anhydride (d), or into pyridine- and sulfate-modified surfaces by reaction with 4-PCA (b) 




 In order to generate an sIEP by mixing two chemicals, it is important to know in which 
ratio these chemicals react with amine-modified surfaces, since the ratio of the two chemicals 
on the surface determines the charge and thereby the sIEP. Therefore, 4-PCA (pyridine) and 
4-FBDA (sulfate) modified silicon slides were incubated with a fluorescent dye that only 
reacts with primary amines, i.e., only the non-derivatized amine groups on the surface are 
fluorescently labeled. This was done by incubating the chemically modified surfaces with 
2 µg/mL Alexa-Fluor® 488 carboxylic acid succinimidyl ester in acetonitrile in the dark for 
1 hour at room temperature [26, 27]. Subsequently, the chemically modified surfaces were 
photographed by fluorescence microscopy (Nikon Eclipse E600 with a mercury light source, 
a magnification of 100x, a GFP filter set, and imaged with a 10 s exposure time). The pixel 
intensity of the fluorescence microscopy images of 4-FBDA, 4-PCA, APTES, and piranha 
treated surfaces was calculated in ImageJ (available from rsbweb.nih.gov/ij/). Subsequently, 
these pixel intensities were used to calculate the derivatization efficiency (DE) of amine-
modified surfaces into 4-PCA (pyridine) or into 4-FBDA (sulfate) according to equation 2. 
  Derivatization efficiency = 100 – ([(Im-I0)/(Ia-I0)]*100)  (Equation 2)
 Here Im represents the average pixel intensity of 4-PCA (pyridine) or 4-FBDA (sulfate) 
modified surfaces, I0 represents the average pixel intensity of the non-modified (piranha 
treated) surfaces, and Ia represents the average pixel intensity of the amine-modified surfaces 
[26, 27]. The reactivity ratio (RR) was calculated as follows:
  RR = DE4-PCA (pyridine) / DE4-FBDA (sulfate)   (Equation 3)
2.2.6 Comparative nanoparticle adhesion
 The adhesion of both positively and negatively charged nanoparticles was determined 
as a function of time to ensure that both nanoparticles adsorb to an oppositely charged 
surface in a comparable manner. In order to compare the binding properties, such as binding 
percentage and binding time, to an oppositely charged surface, silicon surfaces modified with 
a compound with one positively charged group (APTES, charge +1) and with one negatively 
charged group (carboxyl, charge -1, derivatization efficiency > 95% [26]) were prepared. Next, 
positively charged nanoparticles were incubated with a 1x2.5 cm (5 cm2) carboxyl-modified 
silicon surface (pKa=4.37 [26]) at pH 10, to ensure a complete deprotonation of the surface 
carboxylic groups. Conversely, negatively charged nanoparticles were incubated with a 
1x2.5 cm (5 cm2) amine-modified silicon surface (pKa=6.55 and 9.94 [26]) at pH 3, to ensure a 
complete protonation of the surface amine groups. Both chemically modified silicon surfaces 
were incubated with 1.5 mL nanoparticle dispersions in a concentration of 1 µL nanoparticles 
(2.5% solids) per mL. Finally, the binding percentage of the positively charged nanoparticles 
to the carboxyl-modified surface and the binding percentage of the negatively charged 
CHAPTER 4.4: Coated microneedles
Generation of a tuneable surface 
isoelectric point
123
nanoparticles to the amine-modified surface were determined in a time frame of 2 hours.
2.2.7 Preparation of modified silicon surfaces with a tunable surface isoelectric point
 In order to generate an sIEP of choice (target sIEP), the predetermined surface pKa of 
pyridine-modified surfaces and the reactivity ratio were used to calculate the required relative 
amounts of 4-PCA (pyridine) and 4-FBDA (sulfate) in the reaction mixture, as explained below. 
First, according to the Henderson-Hasselbalch equation, the fraction of protonated pyridine 
(αBH+) is calculated for the pH equal to the target sIEP (pH (target sIEP)) according to equation 4:
  αBH+ = 1 / (1 + 10
 pH (target sIEP) – pKa)   (Equation 4)
 At the target sIEP, the number of positively charged groups (BH+target sIEP) should equal 
the number of negatively charged groups (A-). Taking into account the differences in 
derivatization efficiencies of 4-PCA and 4-FBDA and assuming a net charge of -2 for 4-FBDA 
(which has two sulfonyl groups (pKa < 1)), we calculated the required ratio of the 4-FBDA and 
4-PCA concentration in the reaction mixture according to equation 5:
  [4-FBDA] / [4-PCA] = αBH+ * RR / 2   (Equation 5)   
 
 Finally, the concentrations [4-PCA] and [4-FBDA] for a target sIEP were calculated in 
such a way that [4-PCA] + [4-FBDA] = 50 mM. 
 According to the procedure described above, surfaces were prepared with a target 
sIEP of 6.2 and 7.1. To determine the sIEP, a FNAA was performed at 14 different pH values 
with either positively or negatively charged nanoparticles and the relative fluorescence was 
determined as a function of the pH. This assay was performed trice for each target sIEP. 
Subsequently, the sIEP was determined as described below: 
 The binding of positive and negative nanoparticles was calculated in Prism 5 for 
Windows from the binding “log vs response-variable slope” curves, by subtracting the 
top asymptote from the relative fluorescence values to correct for non-specific binding. 
Subsequently, the sIEP was determined as the intersection of the “log vs response-variable 
slope” curves of the binding. 
 Next, the binding of fluorescently labeled nanoparticles onto the surface was sorted for 
every 0.3 pH units. Then, the binding of the positively charged nanoparticles was subtracted 
from the binding of the negatively charged particles for every sorted pH value and was 
normalized to have values between -1 and 1. This value was defined as the arbitrary surface 
charge, which was plotted as a function of the pH. 
 To visualize the fluorescent nanoparticle adhesion onto the sIEP surfaces fluorescence 
microscopy was used (Nikon Eclipse E600 with a mercury light source, a magnification of 
100x, a GFP filter set, and imaged with a 5 s exposure time).
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2.2.8 pH-dependent binding and release of a positively and negatively charged polymer
 In order to test the applicability of the pH-sensitive coating/release system for e.g. 
pharmaceutical applications, a surface was prepared with a target sIEP of 7.1 as described 
above. Subsequently, a negatively or positively charged polymer was coated onto the sIEP=7 
surface in 0.75 mL of a 1 mM EDTA solution for 1 hour at room temperature at a pH of 5.7 and 
8.6, respectively. The negatively charged polymer poly(I:C) (a synthetic analog of dsRNA) was 
coated onto the sIEP=7 surface in concentrations of 10 µg/mL or 1 µg/mL (pH < sIEP), and the 
positively charged polymer TMC was coated onto the sIEP=7 surface in concentrations of 100 
µg/mL or 10 µg/mL (pH > sIEP). Both polymers were fluorescently labeled with rhodamine 
B, the fluorescence of which was measured at an excitation wavelength of 550 nm and 
an emission wavelength of 580 nm. The amount of bound polymer was determined by 
measuring the unbound fraction of polymer and applying equation 1. Next, poly(I:C) and TMC 
coated sIEP=7 surfaces were incubated in 0.75 mL of a 5 mM EDTA solution for 30 minutes at 
room temperature at a pH of 8.6 and 5.5, respectively. Subsequently, the released amount 
of polymer was determined in the release solution by fluorescence as described above. The 
percentage of released polymer was calculated by dividing the released amount of polymer 
by the amount of bound polymer.
3. Results and discussion
3.1 pKa and reactivity ratio determination
 In order to develop a tunable sIEP, whereby one molecule with a permanent charge 
over a biological relevant pH range and one molecule with a pKa within that range is used, 
the surface pKa of that molecule needs to be known. Therefore, a FNAA was performed on 
pyridine-modified silicon surfaces at different pH values between pH 4-9. Figure 3 shows the 
data of all individual pKa determinations combined, whereby each point is the average binding 
at five subsequent pH values. According to the Henderson-Hasselbalch equation a curve was 
fitted to each individual titration (n=3), and a surface pKa of 6.69±0.18 (mean ± SD, n=3) was 
found for pyridine-modified surfaces. This surface pKa did not differ from the value that we 
have reported previously (6.91±0.30 (mean ± SD, n=3)) [27], which shows the reproducibility 
of this surface modification, even when 4-PCA is reacted with APTES surfaces in a different 
solvent mixture; 1:8 isopropanol:methanol versus isopropanol only.
 After the pKa of pyridine-modified surfaces was determined, the derivatization efficiencies 
of 4-PCA (pyridine) and 4-FBDA (sulfate) were determined. Surfaces were incubated with a 
fluorescent dye that only reacts with primary amines, thus only the non-derivatized amine 
groups are fluorescently labeled. After the surfaces were imaged by fluorescence microscopy, 
the average pixel intensity was used to calculate the derivatization efficiencies according to 
equation 2. For 4-FBDA (sulfate) modified surfaces a derivatization efficiency of 86.7±3.2% 
and for 4-PCA (pyridine) a derivatization efficiency of 75.2±6.5% (mean ± SD, n=3) was found, 
which was comparable to the value that was reported previously for 4-PCA (78.5%) [27]. From 
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the derivatization efficiencies the reactivity ratio (4-PCA:4-FBDA) was calculated to be 0.87 by 
applying equation 3.
3.2 Nanoparticle adhesion to a positively or negatively charged surface
 In order to test whether the intersection of positively charged nanoparticles and 
negatively charged nanoparticles can be used to determine the sIEP, both types of particles 
need to bind in a comparable way. Therefore, silicon surfaces with a charge (Q) of +1 (amine-
modified surface) and with a charge of -1 (carboxyl-modified surface) were synthesized, 
rather than a 4-FBDA (sulfate-modified) surface which has two negatively charged groups. 
Subsequently, the positive and negative nanoparticles were incubated with the carboxyl- and 
pyridine-modified surfaces, respectively, as shown in figure 4. This figure shows that both 
positively and negatively charged nanoparticles bind to a comparable extent, and therefore 
these particles can be used to determine the sIEP. 
3.3 Preparation and determination of the surface isoelectric point of modified silicon surfaces
 After the required unknown parameters were determined (pKa=6.69, RR=0.87), two 
reaction mixtures with different ratios of 4-PCA and 4-FBDA were calculated according to 
equation 5. For a surface with a target sIEP of 6.2 and 7.1 a [4-FBDA]/[4-PCA] ratio of 0.320 
and 0.127 were calculated, respectively. Subsequently, for the preparation of modified silicon 
surfaces with a target sIEP of 6.2, a reaction mixture with 37.88 mM 4-PCA and 12.12 mM 
4-FBDA was used, and for the ones with a target sIEP of 7.1 a mixture of 44.38 mM 4-PCA and 
5.62 mM 4-FBDA was used. Next, a FNAA was performed, showing sIEP values that were very 
close to the ones we aimed for (figure 5). The sIEP was calculated by the intersection of the 
nanoparticle binding curves. This led to a calculated sIEP of 5.97±0.88 and 7.12±0.21 (mean ± 
SD, n=3) for a target sIEP of 6.2 and 7.1, respectively (representative examples figure 5A and 
5B for a target sIEP of 6 and 7). Subsequently, from the binding of the positively and negatively 
charged nanoparticles the arbitrary surface charge was calculated, as described above (2.2.7) 
which is shown in figure 5C and 5D, for a target sIEP of 6.2 and 7.1, respectively. These images 
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Figure 3: pKa determination of pyridine-
modified surfaces by a fluorescent 
nanoparticle adhesion assay with negatively 
charged nanoparticles. The binding of 
nanoparticles is plotted against the pH and 
the pKa corresponds to the pH value at 
the mid-point of the S-shaped curve that 
was fitted according to the Henderson-
Hasselbalch equation.
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Figure 5: Fluorescent nanoparti cle adhesion with positi vely (pos NP) and negati vely (neg NP) charged 
nanoparti cles on surfaces with a surface isoelectric point (sIEP) of 6 (A, C) or 7 (B, D), a representati ve 
ti trati on showing the binding (A, B), and the arbitrary surface charge calculated from the positi vely and 
negati vely charged nanoparti cles for a chosen target sIEP (C, D).
Figure 6: Fluoresce microscopy imaging of silicon surfaces with an isoelectric point of 7 aft er incubati on with 
positi vely charged fl uorescent nanoparti cles (Pos NPs) or with negati vely charged fl uorescent nanoparti cles 
(Neg NPs) at diff erent pH values.
Nanoparticle adhesion














Figure 4: The adhesion of negati vely charged 
nanoparti cles (neg NP) at pH 3 onto a positi vely charged 
(amine) surface and the adhesion of positi vely charged 
nanoparti cles (pos NP) at pH 10 onto a negati vely 
charged (carboxyl) surface as a functi on of ti me.
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clearly show the transition between a positively charged and a negatively charged surface, 
and further emphasize that the sIEP value was successfully tuned to an aimed value.
 After surfaces with a target sIEP of 7.1 were incubated with either positively or negatively 
charged nanoparticles at different pH values, the surfaces were photographed under a 
fluorescence microscope, as shown in figure 6. These images show that there is a turning 
point of negatively charged nanoparticle adhesion towards positively charged nanoparticle 
adhesion between pH 6 and 7. In conclusion, figure 5 and 6 show that by generating an sIEP, 
dependent on the pH either positive or negative nanoparticles bind to the surface, and that 
the surface sIEP can be tuned to a value of choice, provided that the pKa and the sIEP are 
sufficiently close to each other, i.e., less than one pH unit.
3.4 Proof of concept: pH-dependent binding and release of a positively and negatively charged polymer
 In order to test the applicability of surfaces with an sIEP for pH-dependent capture and 
release of charged molecules, we chose to prepare a surface with an sIEP of 7. A negatively 
(poly(I:C)) and positively (TMC) charged polymer were selected to bind to these surfaces. As 
shown in figure 7A, poly(I:C) was coated onto sIEP=7 surfaces (2 cm2) at a pH < sIEP (pH=5.7) 













































































































Figure 7: Poly(I:C) and TMC binding 
onto surfaces with an isoelectric point 
of 7 at a pH value of respectively 
5.7 and 8.6. poly(I:C) was coated 
in a concentration of 10 or 1 µg/
mL and TMC in 100 or 10 µg/mL (hi 
and lo concentration, respectively). 
Subsequently, poly(I:C) and TMC 
were released at a pH of 8.6 and 
5.5, respectively  (A). The release 
of poly(I:C) and TMC calculated in 
percentages (B).
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(mean ± SD, n=3), respectively. Subsequently, these surfaces were incubated for 30 minutes 
in a release solution with pH > sIEP (pH=8.6), which led to a release of 549±20 ng and 222±15 
ng (mean ± SD, n=3), respectively. Furthermore, figure 7A shows that the binding of TMC 
at a pH > sIEP (pH=8.6) was 6.77±1.61 µg and 1.78±0.48 µg (mean ± SD, n=3) at a coating 
concentration of 100 and 10 µg/mL, respectively. Subsequently, these TMC coated surfaces 
were incubated for 30 minutes at a pH < sIEP (pH=5.5), which led to a release of 3.13±1.99 µg 
and 0.920±0.187 µg (mean ± SD, n=3), respectively. Figure 7B shows the release of poly(I:C) 
and TMC in percentages of the coated dose, which were respectively 85±9% and 76±8% (mean 
± SD, n=3) for poly(I:C), and 72±9% and 53±12% (mean ± SD, n=3) for TMC for a high and low dose 
of coated polymer. The generation of tunable sIEP surfaces can be applied onto biomedical 
microdevices, such as microneedles, for pH-sensitive coating of microneedles with a drug 
and subsequently releasing the drug into the skin by a pH-shift [27]. In conclusion, these data 
show the applicability of an sIEP coating in a physiological relevant pH range for controlled 
binding and subsequent release of charged (bio)macromolecules.
4. Conclusion
 In this work we have shown to be able to generate surfaces with a predefined sIEP. For 
the generation of an sIEP it is important to choose two oppositely charged compounds, one 
of which should have a pKa in the range of the desired sIEP. After choosing the compounds, 
the surface pKa of the molecules that are coupled to the surface and the derivatization 
efficiencies of the different molecules need to be determined. Furthermore, we have shown 
to be able to bind positively and negatively charged (bio)macromolecules and subsequently 
release them in a pH-dependent manner. In conclusion, this data shows the tunability of 
silicon surfaces towards a chosen sIEP by using a specific ratio of two different molecules, 
which may have bio-analytical and bio-medical applications, such as drug delivery. 
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Abstract
 Purpose The aim of this work was to coat pH-sensitive microneedle 
arrays with inactivated polio vaccine (IPV) particles and N-trimethyl 
chitosan chloride (TMC) via electrostatic interactions, and assess the 
immunogenicity of the polyelectrolyte multi-nanolayer coating after 
topical application of the coated microneedles in rats. 
 Methods The surface of 200 µm long microneedles was first 
chemically modified with pH-sensitive (pyridine) groups and then 
coated with negatively charged IPV and a positively charged 
polymeric adjuvant (TMC). To obtain a sufficient high antigen dose, 
ten layers of IPV were alternately coated with TMC. The binding of 
IPV and TMC onto pH-sensitive microneedles was quantified and 
visualized by using fluorescently labeled TMC and IPV. The release of 
IPV and TMC from the microneedles was evaluated in ex vivo human 
skin by fluorescence and the immunogenicity was assessed after 
topical application of the coated microneedles in rats.
 Results pH-sensitive microneedles were homogeneously coated 
with ten alternated layers of IPV and TMC, resulting in 45 DU IPV and 
700 ng TMC per microneedle array. Fluorescence microscopy imaging 
revealed that both IPV and TMC were released into ex vivo human 
skin upon application of the coated microneedles. Finally, the in vivo 
application of IPV-TMC coated pH-sensitive microneedles in rats led to 
the induction of IPV specific antibody responses, showing the release 
and immunogenicity of the coating in vivo.
 Conclusion Topical administration of pH-sensitive microneedles 
coated with polyelectrolyte multi-nanolayers of antigens and 
oppositely charged polymeric adjuvants may be a useful approach for 
microneedle-based vaccination.
Chapter 4.5 Layer-by-layer assembly of 
inactivated poliovirus and 
N-trimethyl chitosan on 
pH-sensitive microneedles 
for dermal vaccination






1 Division of Drug Delivery 
Technology, Leiden Academic 
Centre for Drug Research 
(LACDR), Leiden University
2 Institute for Translational 
Vaccinology (Intravacc)
CHAPTER 4.5: Coated microneedles
Layer-by-layer assembly of IPV and TMC
131
1. Introduction
 The skin is an attractive site for drug administration because the skin is easily accessible 
and dermal drug delivery is potentially pain free [1-3]. However, the top layer of the skin, 
the stratum corneum, is an impermeable barrier that keeps foreign entities, including drugs, 
from entering the skin. Therefore, several drug delivery systems and devices have been 
developed to overcome the stratum corneum barrier [4-7]. One of the promising systems 
are microneedles. Microneedles are needle-like structures that are no longer than 1 mm 
and are used to pierce the stratum corneum to facilitate the delivery of a drug into the skin. 
Microneedles should be long enough to pierce the stratum corneum, but preferably short 
enough to avoid bleeding and pain sensation. Microneedles have been under development 
for the past two decades for minimally-invasive dermal drug delivery [8-11].
 Microneedles have been used by different approaches to deliver a drug into the skin, 
as reviewed elsewhere [8, 9]. One of these approaches is the ‘coat and poke’ approach. By 
this approach microneedles are first coated with a drug. These drug coated microneedles 
are subsequently used to pierce the skin. After piercing the coating is hydrated, leading to 
the release of the drug from the microneedles into the skin. An advantage of using coated 
microneedles is that they are a single-unit drug delivery system. Another benefit of using the 
‘coat and poke’ approach is that after coating the strength of the microneedles is retained 
[8-10]. However, one major disadvantage of using coated microneedles is that only small 
amounts of drugs can be coated onto the microneedles. Therefore, this approach is only 
applicable to very potent drugs such as vaccines. Besides, to coat sufficient amounts of drugs, 
often thick layers are required as often surfactants and polymers are included in the coating 
formulation, which may result in a decrease in microneedle tip sharpness. This impairs the 
penetration ability of the microneedles into the skin [9, 12, 13].
 During the past few years two different approaches have been developed to obtain 
ultrathin drug coatings in the nanometer range onto microneedles. The first approach is based 
on a nanolayered (< 20 nm) pH-sensitive surface modification that only minimally impairs 
the sharpness of atom sharp microneedles [14]. These pH-sensitive (pyridine-modified) 
microneedles were coated with ovalbumin at a pH value (5.8) that is below the pKa (6.9) 
of pyridine surfaces and above the isoelectric point of ovalbumin (4.4). Upon application 
of these coated microneedles ovalbumin was efficiently released (70%) by a pH shift into ex 
vivo human skin (physiological pH of 7.4) [14]. The second approach is by using a layer-by-
layer assembly to generate polyelectrolyte multi-nanolayers [15-17]. Polyelectrolyte multi-
nanolayers are formed by alternately coating a negatively and positively charged compound 
onto microneedles. This approach has been used for the dermal delivery of DNA [16, 17], 
nanoparticles [15, 16], and proteins [17]. Combining these approaches can lead to ultrathin 
coatings to coat sufficient amounts of drugs onto the microneedle surface that are efficient 
release upon topical application while retaining the microneedle sharpness.
 In this study we combined a layer-by-layer assembly with the previously reported pH-
sensitive surface modification to coat silicon microneedle arrays. The surface of 200 µm long 
microneedles was first chemically modified with pH-sensitive (pyridine) groups that were 
subsequently coated with negatively charged inactivated polio vaccine (IPV) particles and 
a positively charged polymeric adjuvant, N-trimethyl chitosan chloride (TMC), by a layer-by-
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layer approach. The release of IPV and TMC from the microneedles was evaluated in ex vivo 
human skin and the immunogenicity was assessed after topical application of the coated 
microneedles in rats.
2. Materials and methods
2.1 Preparation, characterization and quantification of TMC and IPV
 TMC with a degree of quaternization of 18% and fluorescently labeled with rhodamine B 
(TMCrhod.B) was synthesized as previously described [18]. In brief, 120 kDa chitosan (Primex) 
was methylated by iodomethane in the presence of NaOH and was labeled with rhodamine 
B isothiocyanate. Subsequently, TMCrhod.B was purified by dialysis and freeze dried. Plain 
IPV (serotype 1) and fluorescently labeled (Alexa Fluor® 488) IPV (IPVAF-488), obtained from 
Intravacc, were used for immunization and visualization, respectively. Plain IPV, IPVAF-488, and 
TMCrhod.B were quantified by measuring the fluorescence on a Tecan Infinite® M1000 plate 
reader. TMCrhod.B was excited at 550 nm and detected at 580 nm. Plain IPV was quantified by 
ELISA or intrinsic fluorescence (emission of 330 nm at an excitation wavelength of 280 nm) 
and IPVAF-488 was excited at 488 nm and its emission detected at 522 nm. Plain IPV, IPVAF-488, 
and TMCrhod.B were quantified by fluorescence by using a calibration curve that was linear 
between 100 ng/mL and 10 µg/mL for each of the compounds. To determine the antigenicity 
of IPV, the D-antigen (representing native polio particles) was analyzed by an enzyme-linked 
immunosorbent assay (ELISA) as previously described [19]. The samples were compared to 
a reference suspension (non-treated plain IPV) that was diluted to the same concentration 
as the samples. 1 DU IPV contains ~13 ng viral protein [20]. Finally, the zeta potential of plain 
IPV (0.5 mg/mL) in a 10 mM phosphate buffer at pH 5.8 was measured by laser Doppler 
electrophoresis on a Zetasizer Nano (Malvern Instruments).
2.2 Chemical modification of microneedles
 The surface of microneedles (576 microneedles on a backplate of 5x5 mm, Robert Bosch 
GmbH) was chemically modified to obtain pH-sensitive microneedles (pyridine-modified) that 
have a surface pKa of 6.9 [14]. First, the microneedle surface was hydroxylated by incubation 
with a freshly prepared piranha solution (H2SO4:H2O2 7:3 (v/v)) for one hour at 120°C. Next, 
the microneedle surface was modified with amine groups by incubating the top side of 
the microneedle arrays with 15 µL of a 2% (v/v) APTES (Sigma Aldrich) solution in toluene at 
room temperature. To introduce surface roughness on the microneedles 0.1% (v/v) H2O was 
added to the APTES solution. Furthermore, to prevent evaporation of the APTES solution, 
the microneedles were kept in a chamber wherein the air was saturated with toluene. After 
24 hours the microneedles were cured for 30 minutes at 120°C and were incubated for two 
hours at 40°C in Milli-Q water to remove unreacted ethoxy groups, obtaining amine-modified 
microneedles. Subsequently, these amine-modified microneedles were incubated overnight 
in 100 mM 4-pyridinecarboxaldehyde (Sigma Aldrich) in anhydrous isopropanol at room 
temperature. Finally, to form a stable secondary amine, the microneedles were incubated in 
50 mM sodium cyanoborohydride (Sigma Aldrich) in isopropanol for two hours. The obtained 
pH-sensitive, pyridine-modified microneedles were stored under vacuum until use.
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2.3 Location of pH-sensitive groups on the microneedle surface
 To assess whether the chemical (amine) modification was successful, a fluorescent dye 
was used that only reacts with primary amines. Therefore, 15 µL of 10 µg/mL Alexa Fluor® 
488 carboxylic acid succinimidyl ester (Invitrogen) in anhydrous acetonitrile was reacted 
to amine-modified microneedles in the dark for one hour at room temperature. Finally, the 
microneedles were washed twice with acetonitrile and five times with methanol to obtain 
fluorescent-modified microneedles.
 To visualize the location of pH-sensitive (pyridine) surface groups, fluorescently labeled 
negatively charged nanoparticles (Sigma Aldrich) were coated onto the positively charged 
microneedle surface. To this end, pH-sensitive microneedles were incubated with 50 µL of a 1 
µL/mL sulfate-modified fluorescent red nanoparticle dispersion (2.5% solids) (Sigma Aldrich) 
in a 1 mM EDTA buffer at pH 5.8. At this pH value the pyridine groups are positively charged 
[14]. After one hour the microneedles were washed in 1 mL 1 mM EDTA buffer at pH 5.8, 
obtaining nanoparticle-coated pH-sensitive microneedles.
 The fluorescent-modified microneedles and the nanoparticle-coated pH-sensitive 
microneedles were visualized by using fluorescence microscopy (Nikon Eclipse E600) and 
confocal laser scanning microscopy (CLSM) with a depth resolution of 1.05 µm on a Nikon 
Eclipse TE2000-U with a Bio-Rad Radiance 2100 confocal laser scanning system [14]. An argon 
laser (488 nm) was used for the visualization of fluorescent-modified microneedles with a 
500 nm long pass emission filter and a helium neon laser (543 nm) was used to visualize 
nanoparticle-coated pH-sensitive microneedles with a 570 nm long pass emission filter. Non-
modified microneedle arrays were imaged as a negative control.
2.4 Layer-by-layer coating of IPV and TMC onto microneedles
 pH-sensitive microneedles were coated with either plain IPV or IPVAF-488 and TMCrhod.B by 
a layer-by-layer approach. The layer-by-layer approach is based on electrostatic interactions 
between oppositely charged polyelectrolytes and was performed as schematically presented 
in figure 1. pH-sensitive (pyridine-modified) microneedle arrays were used (1). To obtain a 
positive surface charge onto the pH-sensitive microneedles, the coating was performed at pH 
5.8 in a 1 mM EDTA buffer. The top side of the surface-modified microneedle arrays was coated 
Figure 1: Schematic presentation of the layer-by-layer coating procedure of microneedles. The procedure starts 
by modifying the surface of microneedle arrays with pH-sensitive groups (1). Next, the microneedles are coated 
with a layer of plain IPV or IPVAF-488 (2) and are subsequently washed and dried (3). Then, the microneedles are 
coated with a layer of TMCrhod.B (4), washed and dried (5). Steps 2-5 are performed ten times.
(1) Chemically modified
      microneedle array





(4) Cationic polymer (5) Drying
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with a layer of IPV by incubating the microneedles with either 50 µL of a 10 µg/mL plain IPV 
or IPVAF-488 suspension (2). After one hour the microneedles were washed with 500 µL 1 mM 
EDTA at pH 5.8. After the microneedles were dried under a stream of pressurized air (3), they 
were incubated for one hour with 50 µL of a 10 µg/mL TMCrhod.B solution (4). Subsequently, 
the microneedles were washed and dried as described above (5). Steps 2-5 were performed 
ten times to obtain pH-sensitive microneedles coated with ten alternating layers of IPV (plain 
or fluorescently labeled) and TMCrhod.B. The amount of IPV and TMCrhod.B that bound onto the 
microneedle surface was quantified by measuring the unbound fraction of IPV and TMCrhod.B 
in the wash samples.
2.5 Visualization of IPV-TMC layer-by-layer coated microneedles
 To visualize the pH-sensitive TMC-IPV coated microneedle arrays CLSM was performed 
with a depth resolution of 5 µm/step on a Nikon TE 2000-e with a 20x Plan APO objective. An 
argon laser (488 nm) was used for the visualization of IPVAF-488 with a 530/50 emission filter 
and a diode-pumped solid-state laser (561 nm) with a 590/50 emission filter was used for 
the visualization of TMCrhod.B. Image acquisition and processing was performed by using NIS 
elements. Besides, the structure, geometry, and the surface morphology of the microneedle 
arrays were analyzed by using scanning electron microscopy (SEM) on a FEI NOVA nanoSEM 
200.
2.6 Microneedle application onto ex vivo human skin
 Ex vivo human skin was supplied by local hospitals within 24 hours after cosmetic 
surgery and was dermatomed to a thickness of 600 µm [14]. Next, the skin was stretched 
on Styrofoam that was covered with parafilm. After the pH-sensitive IPVAF-488 - TMCrhod.B 
coated microneedle arrays were attached onto the skin by using dermal tape (Leukosilk), 
an impact-insertion applicator [21] was used to pierce the microneedles into the skin at 3 
m/s. After five minutes the microneedles were removed and the skin surface was visualized 
by fluorescence microscopy by using a GFP and CY3 filter set for the visualization of IPVAF-488 
and TMCrhod.B, respectively. The IPV-TMC coating on the microneedles was examined by 
fluorescence microscopy before and after skin application. Besides, 10 µm thick cryosections 
(Leica Cryostat) of the microneedle treated skin were made of which the nuclei were stained 
with VectaShield® mounting medium with DAPI (Vector Lab). Finally, the cross sections were 
visualized by fluorescence microscopy using a DAPI, GFP, and Cy3 filter set.
2.7 Immunization study
 Female Wistar Han rats (10 per group, 175-250 g, Charles River) were immunized twice 
with intervals of three weeks by intramuscular injection with 5 DU plain IPV (corresponding 
with 65 ng viral protein) or PBS (100 µL/hind leg), or by applying three plain IPV-TMCrhod.B coated 
microneedle arrays (containing 45 DU IPV on the microneedles and backplate per array) for 
one minute on the ear pinna. Sera were collected 3 weeks after the boost immunization. 
Animals were maintained under standardized conditions in the animal facility of the Leiden 
Academic Centre for Drug Research, Leiden University. The study was carried out under the 
guidelines complied by the animal ethic committee of the Netherlands and was approved by 
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the “Dierexperimentencommisie Universiteit Leiden (UDEC)” under number 12084. 
2.8 IgG ELISA
 To determine the D-antigen (representing native polio particles) and C-antigen 
(representing precursor or partially denatured polio particles) IPV-type-1 specific serum IgG 
responses, the sera of immunized rats were analyzed by ELISA as previously described [22]. 
Endpoint titers were determined by 4-parameter analysis using the Gen5™ 2.0 data analysis 
software (BioTek Instruments, Inc., Winooski, VT) and defined as the reciprocal of the serum 
dilution producing a signal identical to that of antibody-negative serum samples at the same 
dilution plus three times the standard deviation [20, 23].
3. Results and discussion
3.1 Charge of IPV at coating pH
 In our previous study we have shown that coating of a model antigen (ovalbumin) onto 
pH-sensitive (pyridine-modified) microneedles was efficiently performed above its isoelectric 
point, at pH 5.8 [14]. The ζ-potential of plain IPV at the same pH value in 1 mM EDTA buffer 
was measured to verify whether these conditions may also be suitable for the coating of IPV 
onto pH-sensitive microneedles. The isoelectric point of IPV is unknown but likely lower than 
that of live poliovirus type 1 (6.2 [24]) since formaldehyde (used to inactivate the virus) reacts 
with amine groups. This is expected to result in a decrease of the isoelectric point of proteins 
by several pH units [25]. Indeed, laser Doppler electrophoresis performed at pH 5.8 revealed 
a ζ-potential of -7.75±0.88 mV (mean ± SD, n=3), demonstrating that the isoelectric point of 
IPV is below 5.8.
3.2 pH-dependent stability of IPV
 Another requirement of pH-sensitive coatings is that the antigen’s antigenicity should 
be retained at coating pH. Therefore, the pH-dependent stability of IPV was investigated, as 
reported in figure 2. Figure 2 shows that IPV was stable between pH 4 and 11 in a 1 mM EDTA 
buffer for at least one hour, indicating that IPV can be coated onto microneedles at a broad 
pH range. Only at pH 12, the highest pH tested, IPV completely lost its antigenicity. 
















Figure 2: Stability of a 300 ng/mL IPV suspension 
(expressed as DU/ml) after it was incubated for one 
hour at different pH values in a 1 mL 1 mM EDTA buffer. 
The dotted line is the D-antigen concentration that was 
measured in the reference suspension.
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3.3 Location of pH-sensitive groups on the microneedle surface
 Fluorescence imaging showed that the surface of amine-modifi ed microneedle arrays (by 
APTES coupling), incubated with a fl uorescent dye that only reacts with primary amines, was 
successfully modifi ed with amine groups (fi gure 3A). Besides, CLSM revealed that the amine 
groups are mostly present on the tip of the microneedles (fi gure 3B and 3C), which could be 
explained because APTES tends to aggregate at the edges of surfaces [14]. No fl uorescence 
was observed when non-modifi ed microneedles were incubated with the amine-reactive 
fl uorescent dye (data not shown).
 To visualize whether the next step in the surface modifi cation was successful, which is 
the introduction of pH-sensitive (pyridine) groups, fl uorescently labeled negatively charged 
sulfate-modifi ed fl uorescent nanoparticles were coated onto the pH-sensitive microneedles 
at pH 5.8, a pH at which the surface pyridine groups are positively charged [14, 18]. The coated 
microneedles were visualized by CLSM (fi gure 3D). This fi gure shows that the pH-sensitive 
surface groups were mainly present on the tip of the microneedles. These results are in line 
with a previous study in which the surface of silicon microneedles with a diff erent geometry 
were successfully modifi ed with amine and pyridine groups [14]. This indicates that this 
modifi cation procedure is a generic method for modifying the surface of silicon microneedle 
arrays.
3.4 Layer-by-layer coating of IPV and TMC onto microneedles
 In order to coat pH-sensitive microneedles with a high dose of IPV, the microneedles were 
coated by a layer-by-layer approach. Since pH-sensitive microneedles are positively charged 
Figure 3: Representati ve fl uorescence images of chemically modifi ed microneedle arrays that contain 24x24 
microneedles per array. An amine-modifi ed microneedle array that was incubated with an amine-reacti ve 
fl uorescent dye photographed by fl uorescence microscopy from the side (A), confocal laser scanning microscopy 
(CLSM) of 6x6 microneedles (B) and zoomed in on the ti p of a single microneedle (C).  CLSM of a 100 nm 
nanoparti cle-coated pH-sensiti ve microneedle array (D).
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at the coating pH (5.8), the first coating was performed with IPV (plain IPV or IPVAF-488), which 
is negatively charged at this pH (see section 3.1). Subsequently, the IPV covered surface 
was coated with positively charged TMCrhod.B. This alternated coating of IPV and TMCrhod.B 
was performed ten times and between each coating step the amount of IPV and TMCrhod.B 
was quantified, as shown in figure 4. There was a linear relationship between the number 
of layers and the amount of IPV (IPVAF-488: R
2=0.98; plain IPV (intrinsic fluorescence): R2=0.92; 
and plain IPV (ELISA): R2=0.98) and TMCrhod.B (R
2=0.97) that are coated onto the microneedle 
surface. Furthermore, figure 4 shows that IPV (as determined by intrinsic fluorescence and 
ELISA) and IPVAF-488 (as determined by the fluorescence of Alexa Fluor® 488) bound in a 
comparable manner onto the microneedle surface. However, the amount of plain IPV that 
was coated onto the microneedles as determined by ELISA was 25% lower compared to the 
amount as determined by the intrinsic fluorescence of IPV. This could indicate that 75% of the 
microneedle-coated IPV is the D-antigenic form. Finally, this figure shows that comparable 
amounts of IPV and TMCrhod.B were coated onto the microneedles.
3.5 Visualization of IPV-TMC coated microneedles
 The CLSM results shown in figure 5 demonstrate that both IPV (5A) and TMC (5B) were 
homogeneously coated (5C) onto the surface of pH-sensitive microneedle arrays by a layer-
by-layer approach. Besides, SEM was used to visualize the microneedle geometry and the 
morphology of the coating, as shown in figure 6. This figure shows an overview of a part 
of a microneedle array that contains 576 microneedles on a backplate of 5x5 mm (6A) and 
increasingly zoomed-in pictures on the surface of a microneedle before (figure 6B1-6B3, 
respectively) and after coating (figure 6C1-6C3, respectively). The surface morphology was 
clearly changed from a smooth into a rougher one after it was coated with 10 layers of IPV 
alternated with TMC (figure 6C3) compared to non-modified microneedles (figure 6B3). 
Finally, this figure reveals that modification of microneedles with pH-sensitive groups and the 
subsequent coating thereof with ten layers of IPV alternated with TMC does not visibly impair 
microneedle sharpness. In contrast, coatings based on different procedures (e.g., multiple 
dip coating steps with highly viscous solvents) generally lead to thick coatings/reduced 
microneedle sharpness and thereby might compromise the penetration ability of microneedle 
arrays [12, 13]. Therefore, these results illustrate the advantage of coating procedures that 
are based on polyelectrolyte nanolayers and pH-sensitive electrostatic interactions.
3.6 Microneedle application onto ex vivo human skin
 To determine whether the IPV-TMC multilayers can be released from the surface of pH-
sensitive microneedles into the skin, the coated microneedle arrays were applied onto ex 
vivo human skin. As shown in figure 7, both IPVAF-488 (7A) and TMCrhod.B (7B) were delivered 
into the skin in the conduits (C). Besides, hardly any fluorescence was visible on the tips of 
the microneedles after topical application (data not shown). However, we were unable to 
quantify the amount of IPV and TMC that was released from the microneedles into the skin 
(because of the auto fluorescence of the ex vivo human skin). To quantify the released amount 
of IPV and TMC into the skin, radioactively labeled analogues should be used [26]. To confirm 
that IPVAF-488 and TMCrhod.B were indeed delivered into the skin rather than onto the stratum 
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Figure 4: Cumulati ve dose 
of IPV and TMC during the 
coati ng of pH-sensiti ve 
microneedle arrays with 
IPV alternated with TMC. 
Each layer # consisted of 
one coati ng with either 
plain IPV or IPVAF-488 
(negati vely charged) and 
one coati ng with TMCrhod.B 
(positi vely charged). Bars 
are represented as mean 
± SD, n=3.
Figure 5: 
Representati ve CLSM 
images of pH-sensiti ve 
microneedles that 
were coated by a layer-
by-layer approach 
with 10 layers of IPV 
alternated with TMC: 
IPVAF-488 (A), TMCrhod.B 
(B), and an overlay of 
these images (C).
Figure 6: Representati ve 
SEM images of non-
modifi ed microneedles 
(A and B) and pH-
sensiti ve microneedles 
coated with ten layers of 
IPV alternated with TMC 
(C) at a magnifi cati on of 
500 (1), 1000 (2), and 
8000 ti mes (3).
Figure 7: Representati ve fl uorescence microscopy images of IPV-TMC-coated pH-sensiti ve microneedles that 
have been applied for 5 minutes onto ex vivo human skin. Images from the stratum corneum side of the skin 
with a GFP fi lter for IPVAF-488 (A) and a Cy3 fi lter for TMCrhod.B (B) that are overlaid (C), and cross secti ons of the 
microneedle penetrated skin (D and E), showing IPVAF-488 (green), TMCrhod.B (red) and DAPI stained nuclei (blue) in 
the epidermis (Epi) and dermis (Der).
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corneum, cryosections of the pierced skin were made (7D and 7E). This figure shows that IPV 
and TMC were indeed succesfully delivered into the skin, and that the delivery was both in 
the viable epidermis and in the top layer of the dermis. In conclusion, TMC-IPV multilayers are 
succesfully released into ex vivo human skin within five minutes of microneedle application.
3.7 Immunization of rats with IPV-TMC coated microneedles
 Two distinct antigenic forms of IPV exist: the C-antigen, which is expressed on non-
infectious polio particles like some viral precursor forms as well as stressed virus or 
vaccine, and the D-antigen, which is expressed on native infectious polio virus [27]. The 
D-antigen of IPV is the immunorelevant structure, which is responsible for the induction 
of virus neutralizing antibodies upon immunization [19, 20]. To assess whether IPV-TMC 
coated pH-sensitive microneedles can be used for vaccination, an immunization study 
in rats was performed. Figure 8 shows that immunization of rats with plain IPV-TMCrhod.B 
coated microneedles successfully led to the induction of IPV-specific antibody responses. 
Despite the low anti-D-antigen responses, this figure shows that using antigen-TMC coated 
microneedles can be used for vaccination because high and robust anti-C-antigen antibodies, 
similarly as compared to intramuscular immunization, were induced upon vaccination. 
However, the D-antigen antibodies upon immunization with coated microneedles were 
lower compared to intramuscular immunization, which could indicate that the D-antigen 
was partly converted into C-antigen during its coating onto the microneedle surface. This 
highlights the importance of choosing the proper antigen/stabilizing the antigen for coating 
pH-sensitive microneedles, e.g., IPV is very sensitive to surface induced degradation (if IPV 
is directly coated onto ELISA plates, it immediately converts into C-antigen). To retain the 
D-antigen during coating, IPV should be stabilized, e.g., by encapsulation into nanoparticles. 
Besides, our IPV stock also contained C-antigen, as indicated by the anti-C-antigen responses 
upon intramuscular immunization. This is atypical since C-antigen is being removed during the 
purification. Therefore, it is likely formed during longtime storage (the batch was expired for 
human use) and/or the coating process. D- to C-antigen conversion as a result of the coating 
procedure may occur easier in aged material. In addition, as coating of plain IPV determined 
by D-antigenicity was high, another explanation could be that the C-antigen is better released 
than the D-antigen (e.g., has a different charge). However, this coating method could be 
a suitable approach for microneedle-based vaccination when using a more stable antigen/























Figure 8: Inactivated poliovirus (IPV) 
type-1 specific serum IgG titers against 
C- and D-antigen upon immunization via 
coated microneedles or intramuscular (IM) 
injection. Non responders were given an 
arbitrary titer of 10.
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4. Conclusion
 Microneedles were successfully chemically modified with pyridine groups, which are 
mainly present on the tips of the microneedles. These pH-sensitive microneedles were 
coated at a pH value where IPV is negatively charged and the surface of microneedles is 
highly positively charged, enabling a good binding of IPV onto the surface. Furthermore, we 
have shown that ten layers of IPV alternated with TMC were successfully and homogeneously 
coated onto the surface of pH-sensitive microneedles and that this coating only minimally 
impairs microneedle sharpness. Besides, we have shown that IPV and TMC were released into 
the conduits formed after application of IPV-TMC coated pH-sensitive microneedles onto ex 
vivo human skin. Finally, the in vivo application of IPV-TMC coated pH-sensitive microneedles 
in rats led to the induction of both C- and D-antibody responses, the former non-inferior to 
intramuscular immunization, showing the release and immunogenicity of the coating in vivo.
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 Purpose The aim of the study was to develop a cheap and fast 
method to produce hollow microneedles and an applicator for 
injecting vaccines into the skin at a pre-defined depth and test the 
applicability of the system for dermal polio vaccination.
 Methods Hollow microneedles were produced by hydrofluoric 
acid etching of fused silica capillaries. An electromagnetic applicator 
was developed to control the insertion speed (1-3 m/s), depth (0-1000 
µm), and angle (10°-90°). Hollow microneedles with an inner diameter 
of 20 µm were evaluated in ex vivo human skin and subsequently 
used to immunize rats with an inactivated poliovirus vaccine (IPV) 
by an intradermal microinjection of 9 µL at a depth of 300 µm and an 
insertion speed of 1 m/s. Rat sera were tested for IPV-specific IgG and 
virus-neutralizing antibodies.
 Results Microneedles produced from fused silica capillaries 
were successfully inserted into the skin to a chosen depth, without 
clogging or breakage of the needles. Intradermal microinjection 
of IPV induced immune responses comparable to those elicited by 
conventional intramuscular immunization.
 Conclusions We successfully developed a hollow microneedle 
technology for dermal vaccination that enables fundamental 
research on factors, such as volume, insertion depth, and insertion 
angle, on the immune response.
Chapter 5 Novel hollow microneedle 
technology for depth controlled 
microinjection-mediated dermal 
vaccination: a study with polio 
vaccine in rats
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 Conventional vaccinations are performed by intramuscular or subcutaneous injections, 
causing pain and stress especially in toddlers and children. In addition, needlestick injuries 
and re-use of needles in developing countries carry the risk of transmitting biohazardous 
pathogens like hepatitis B and HIV. Because of the natural function of the skin, it is a highly 
immunologically active site. Therefore, it is not surprising that intradermal injections result 
in potent immune responses, but they are relatively difficult to perform and very painful 
[1]. Advances in microfabrication techniques are making intradermal injections using 
microneedles a feasible alternative to traditional injections. Microneedles can be used to only 
penetrate a shallow part of the skin (i.e. < 300 µm), thereby offering the possibility to deliver 
a vaccine into the epidermis or dermis, which is expected to yield a potent immune response. 
The minimally-invasive, potentially pain free nature and ease of the injections can reduce the 
risk of infections and alleviate the need for trained personnel [2-4].
 One of the vaccines for which microneedle-based delivery would be advantageous is 
inactivated polio vaccine (IPV), as outlined below. Poliomyelitis, or polio, is a crippling and 
life-threatening disease that has been very effectively combated by widespread vaccination 
[5]. The majority of the vaccinations that helped to largely eradicate this disease have been 
performed using the oral polio vaccine (OPV) [6]. While very effective and easy to administer, 
this live attenuated vaccine can in rare cases revert to a pathogenic form and cause vaccine-
associated paralytic poliomyelitis [7]. With reduced incidence of wild poliomyelitis and the 
associated change in risk/benefit considerations, the use of IPV has become the vaccination 
method of choice [8, 9]. While being a safer vaccine, IPV cannot be administered orally but is 
usually delivered using intramuscular or subcutaneous injection. Because of the widespread 
use of injected polio vaccines, switching to microneedles for less-invasive injections could 
benefit a large population by reducing infection risk and pain. Additionally, alleviating the 
need for trained personnel and dose sparing injections could reduce the costs of large 
vaccination programs [10, 11].
 Among the available microneedles, hollow microneedles are especially attractive 
because the dose and the rate of drug delivery is controlled and there is no or limited need to 
reformulate the vaccine [2]. Hollow microneedles are commonly produced by pulling heated 
glass capillaries, using micromachining, or using microfabrication technologies on silicon 
wafers [12-15]. Pulled capillaries, however, may suffer from a low reproducibility in tip shape, 
low throughput production process and clogging problems because of a narrowing inner 
diameter towards the tip. While silicon needles can alleviate many of these problems, their 
production is complex and prohibitively expensive for routine use.
 In this paper we present a novel microneedle fabrication method based on wet etching 
of capillaries that is cheap and easy to scale up. Batchwise fabrication of 100 microneedles can 
be performed in a lab without specialized equipment and the process can easily be adapted 
to the production of larger batches or even to a continuous process. The microneedles have 
a constant inner diameter, preventing clogging, and a tip shape that can be tuned with the 
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etch time. To ensure controlled and reproducible injection, we present a novel microneedle 
applicator. The penetration depth can be adjusted as well as the angle of insertion, the 
injection speed and time. We demonstrate reproducible injections in human skin in vitro 
and successful intradermal vaccination of rats with IPV using these hollow microneedles in 
combination with the applicator. This minimally-invasive, potentially pain free vaccination 
method resulted in a similar immune response as conventional intramuscular vaccination, 
showing the potential of etched microneedles for intradermal vaccination.
2. Materials and methods
2.1 Production of microneedles
 Polyimide coated fused silica capillaries (Polymicro, Phoenix AZ, USA, 375 µm outer 
diameter, 20 µm inner diameter) were wet etched into microneedles. First, the lumen of 
the capillaries was filled with silicone oil AK350 (Boom Chemicals, Meppel, the Netherlands) 
to protect the inside of the capillary from the etchant. Subsequently, to etch the capillaries 
into microneedles, batches of up to 81 capillaries were mounted in a holder with one end 
suspended in 49% (w/w) HF, as shown in figure 1. The length of the capillary that is immersed 
in HF could be adjusted by the level of HF in the container as well as by the position of the 
screws of the holder during mounting. The shape of the microneedle tip was investigated 
as a function of etching time up to 30 hours. The microneedles chosen for the intradermal 
injections were etched for 4 hours. In order to connect the microneedles to the applicator, 
the sharp capillaries were glued into Luer adapters using medical grade glue (Loctite M-31 CL, 
Henkel, Düsseldorf, Germany). Luer adapters were acquired by removing the needle from 
Microlance® 26G hypodermic needles (BD, Franklin Lakes, NJ, USA). Finally, the polyimide 
coating was removed from the microneedles by submersion of the etched capillaries into hot 
sulfuric acid (96-98%, Boom chemicals, Meppel, the Netherlands) for 5 min at 200°C, and the 
silicone oil was removed by flushing the microneedles with acetone.
 To assess the reproducibility of the tip shape, the tip angle of 55 microneedles with 20 
µm inner diameter was measured after 4 hours etching. Image analysis was performed using 
ImageJ (available from rsbweb.nih.gov/ij/).
Figure 1: A batch of 81 fused silica capillaries mounted in a 
polyethylene holder and placed over a Teflon container with 
49% HF. All needles are etched simultaneously by immersion 
in 49% HF. Immersion depth can be adjusted by the HF level 
in the container and the screw positions of the holder during 
mounting.
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 In order to enable insertion of the microneedles into the skin to a controlled depth in 
a reproducible way, an applicator for hollow microneedles was developed. The flexibility 
of the skin can hamper skin penetration and reduce the depth accuracy of injections. The 
insertion speed, insertion depth, and angle of insertion are important factors to overcome 
this and achieve successful depth controlled penetration and drug delivery. As shown in 
figure 2, the applicator uses an electromagnet (a) to insert the microneedle mounted on the 
Luer connection (c) into the skin. The electromagnet is actuated using a controllable power 
source. Application of a variable current through the electromagnet allows for a tuned 
insertion speed from 1-3 m/s [16]. Furthermore, the controlled power supply regulates the 
wear time, to accurately and reproducibly control the time the microneedle is kept inside 
the skin. For injection, the skin is placed on a platform positioned below the injector (g). The 
penetration depth is controlled by a guide-plate (d) that can be adjusted with a micrometer 
actuator (b). The position of the guide-plate is adjusted so that the microneedle protrudes 
the desired distance through the hole in the plateau when the electromagnet is actuated. 
Before injection the injector is lowered so the guide-plate rests on top of the skin. Upon 
actuation the needle is inserted into the skin at the desired speed and depth, as controlled 
by the current and plateau position. Additionally the entire applicator can be tilted along 
a graduated rail (e) for angled insertion (10°-90° relative to the skin). Insertion at a shallow 
angle can be used to insert a greater length of the needle into the skin, without penetration 
into deeper skin layers. The hollow microneedles were attached to a syringe pump that was 
equipped with a gas tight Luer lock 100 µL syringe and connected to a fused silica capillary 
with a diameter of 100 µm (f) to allow tuning of the liquid delivery rate. 
Figure 2: A microneedle applicator was 
developed using an electromagnet (a) to 
insert a microneedle (c) into the skin at 
controlled speed. A micrometer actuator (b) 
is used to adjust the level of a guide-plate (d) 
to ensure proper positioning and penetration 
depth of the microneedle. A graduated rail 
(e) can be used to tilt the entire applicator 
for angled insertion. The microneedle is 
connected to a syringe pump with a capillary 
(f) for vaccine delivery. Close-up of the guide-
plate with a through hole for the needle (g). 
Microneedle applicator injecting a vaccine 
into the skin of an anesthetized rat (h).
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2.3 Determination of microneedle insertion depth
 To determine the microneedle insertion depth, fluorescently labeled human skin was 
used. Ex vivo abdominal or mammary human skin, which was obtained within 24 h after 
cosmetic surgery, was dermatomed to a thickness of 1200 µm using a Padgett Electro 
Dermatome Model B (Kansas City, MO, USA) after the fat was removed. The dermatomed 
skin was incubated overnight on filter paper soaked with 10 µg/mL fluorescein (Fluka®, Sigma-
Aldrich, Steinheim, Germany) with the stratum corneum side to the surface in a Petri dish 
at 4°C. Before the skin was used for experiments, it was stretched on a piece of expanded 
polystyrene covered with parafilm, and thereafter the surface of the skin was cleaned 3 times 
with phosphate buffered saline (PBS) (Braun, Melsungen, Germany, pH 7.4, 163.9 mM Na+, 
140.3 mM Cl-, 8.7 mM HPO4
2-, and H2PO4
-). Subsequently, a microneedle was connected to the 
Luer connection on the microneedle applicator (figure 2c) and the micrometer actuator (figure 
2d) was adjusted to a chosen depth up to 400 µm. In order to accurately set the insertion 
depth, the microneedle position was calibrated. First, the electromagnet was actuated and 
the microneedle was positioned to be flush with the plateau using the micrometer actuator 
(figure 2a). This was done by laser alignment, by which a laser was put perpendicular to the 
guide-plate of the applicator (figure 2d). When a microneedle protrudes past the guide-plate 
the laser light is scattered at the tip of the microneedle, therefore the needle was determined 
to be flush with the guide-plate at the point where no light scattering was observed at the 
microneedle tip. After this calibration of the microneedle position, the microneedle actuator 
was adjusted to a depth of 100, 200, 300, or 400 µm, and was subsequently pierced into the 
fluorescently labeled human skin. For each chosen depth 3 microneedles were used to pierce 
the skin and each microneedle stayed in the skin for 5 s. After the microneedles had pierced 
the fluorescently labeled skin, the microneedles were analyzed by bright-field microscopy 
and by fluorescence microscopy (Nikon Eclipse E600, mercury light source, GFP filter set) 
at 100x magnification and imaged with a 1 s exposure time. Subsequently, the bright-field 
and fluorescence microscopy images were overlaid in ImageJ, and the insertion depth was 
expressed as the measured length between the tip of the microneedle and the part up to 
where the fluorescence was visible.
2.4 Microinjection into skin
 To visualize the intradermal injections, a 10 µg/mL fluorescein solution in PBS was 
injected into human ex vivo skin at different depths (100-400 µm). The skin was stretched on 
Styrofoam covered with parafilm, and the injection depth was adjusted as described above. 
The microneedle was connected to a syringe pump with a flow rate of 2 µL/min to deliver 3 µL 
of the fluorescein solution. As a negative control 3 µL of the fluorescein solution was dispensed 
on top of the skin. Furthermore, diffusion of the injected compound into surrounding tissue 
was assessed by imaging the fluorescence in the skin at several time points after injection. 
The fluorescence was imaged using a Microsoft Lifecam HD with a 480±5 nm light source 
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(LED, Conrad) and a 520-540 nm band pass interference filter.
 To confirm that microneedle insertion leads to dermal delivery of the injectable, 
microinjections of 0.4% trypan blue (Sigma) into ex vivo skin were performed at a protrusion 
depth of 300 µm. Microneedles were inserted into either human or rat skin and subsequently 
a microinjection of respectively 0.5 µL or 3 µL was performed. Next, 10 µm thick cryosections 
(Leica Cryostat) of the injected human skin and 5 µm thick cryosections of rat skin were made. 
Subsequently, the cryosections were stained by hematoxylin and eosin (H&E). Finally, the 
skin was photographed under a stereo microscope (Zeiss Stemi 2000-c) at a magnification of 
5x. 
2.5 Immunization
 To examine the applicability of the hollow microneedles for vaccination purposes, a 
comparison was made between vaccination of rats by intradermal injection with microneedles, 
and intradermal and intramuscular injection with a conventional needle.
 Female Wistar Han rats (175-250 g) were obtained from Charles River (Maastricht, the 
Netherlands) and were maintained under standardized conditions in the animal facility of 
the Leiden Academic Centre for Drug Research, Leiden University. The study was carried out 
under the guidelines complied by the animal ethic committee of the Netherlands and was 
approved by the “Dierexperimentencommisie Universiteit Leiden (UDEC)” under number 
12084. Rats (10 per group) were immunized with either 5 or 15 DU (1/8th  and 3/8th human dose, 
respectively) IPV-type-1 (1 DU≈13 ng virus protein) [17] intradermally by hollow microneedles at 
an protrusion depth of 300 µm and a flow speed of 2 µL/min for 4.5 minutes. For comparison, 
rats were immunized with 5 DU IPV/50 µL intradermally on the ventral abdominal skin with 
a 30G needle and with 5 DU IPV/200 µL intramuscularly with a 26G needle (100 µL/hind leg). 
As a negative control rats were injected intramuscularly with 200 µL PBS (100 µL/leg). All rats 
were anesthetized during the immunization with 50 mg/kg ketamine (Nimatek® (100 mg/
mL ketamine, Eurovet Animal Health B.V., Bladel, the Netherlands)) and 5 mg/kg xylazine 
(Rompun® (20 mg/mL xylazine, Bayer B.V., Mijdrecht, the Netherlands)) by intraperitoneal 
injection. Three weeks after immunization blood samples were collected and the rats were 
sacrificed. This immunization scheme is identical to the regular IPV potency assay [18].
2.6 IgG ELISA
 Polystyrene 96 wells microtiter plates (Greiner Bio-One, Alphen a/d Rijn, the Netherlands) 
were coated overnight at 4°C with bovine anti-poliovirus type 1 serum (RIVM, Bilthoven, The 
Netherlands) in PBS pH 7.2 (Gibco from Invitrogen, Paisley, UK). After washing with 0.05% 
Tween 80 (Merck, Darmstadt, Germany) in tap water, 100 μL/well monovalent IPV vaccine type 
1 (4.5 DU/well) diluted in assay buffer, PBS containing 0.5% (w/v) Protifar (Nutricia, Zoetermeer, 
the Netherlands) and 0.05% (v/v) Tween 80 (Merck, Darmstadt, Germany), was added. After 
incubation at 37°C for 2 hours, threefold dilutions of sera samples in assay buffer were added 
150
(100 μL/well) and incubated at 37°C for 2 hours. After washing, plates were subsequently 
incubated at 37°C for 1 hour with horseradish peroxidase (HRP)-conjugated goat-anti-rat IgG 
(Southern Biotech, Birmingham, AL) as detection antibody (4000 fold dilution, 100 μL/well). 
Plates were extensively washed and 100 μl/well TMB substrate solution, containing 1.1 M 
sodium acetate (NVI, Bilthoven, the Netherlands), 100 mg/mL 3,3’,5,5’-tetramethylbenzidine 
(Sigma-Aldrich, St. Louis, MO), and 0.006% (v/v) hydrogen peroxide (Merck, Darmstadt, 
Germany), was added. After 10-15 minutes, the reaction was stopped with 100 µL/well 2 M 
H2SO4 (NVI, Bilthoven, the Netherlands) and absorbance was measured at 450 nm by using a 
Biotek L808 plate reader.
 Endpoint titers were determined by 4-parameter analysis using the Gen5™ 2.0 data 
analysis software (BioTek Instruments, Inc., Winooski, VT) and defined as the reciprocal of 
the serum dilution producing a signal identical to that of antibody-negative serum samples at 
the same dilution plus three times the standard deviation [17, 19].
2.7 Virus neutralizing antibodies
 Virus neutralizing (VN) antibodies against poliovirus type 1 were measured as described 
elsewhere  [19]. In brief, the sera were inactivated at 56°C for 30 min prior to testing, of 
which 2 fold serial dilutions were made (21 to 224). These dilutions were incubated with 100 
cell culture infectious dose 50% (CCID50) of wild type poliovirus type 1 (Mahoney) for 3 hours 
at 36°C and 5% CO2, and the resulting mixtures were subsequently used to inoculate 1·10
4 Vero 
cells. Virus-neutralizing antibody titers were determined after 7 days by staining the cells with 
crystal violet and expressed as the last serial dilution with an intact monolayer.
2.8 Statistical analysis
 The statistical analysis was performed using Prism 5 for Windows, where the mean ± SEM 
(n=10) of the IgG and VN titers were calculated. As our data was not-normally distributed, 
Kruskall-Wallis tests with a Dunns post-hoc test were performed to calculate the statistical 
significance.
3. Results and discussion
3.1 Production of microneedles: Influence of etch time
 The microneedle geometry was observed to be dependent on etch time. The 
representative different tip shapes that were obtained after 1, 2, 4, 9, 22 and 29 hours of 
etching (n=3) are depicted in figure 3. Less than four hours of etching resulted in blunt needles 
with strong etching of the lumen of the capillary. Etch times between 4 and 22 hours resulted 
in increasingly long, thin needles of up to 4 cm. Longer etching resulted in fully dissolving 
extended portions of the capillary, leaving a short microneedle with an irreproducible tip 
shape.
 When using a constant etch time reproducibly shaped microneedles were obtained. 
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After 4 hours of etching, microneedles with a tip angle of 15.0°±2.8° were obtained (mean ± 
SD of 55 microneedles, see supplementary information, figure S1, for angle distribution).
 The observed lumen shapes are caused by displacement of the silicone oil. At the start 
of etching a small amount of HF is sucked into the lumen by capillary force, etching a short 
length from the inside. After 4 hours this portion is fully etched away, leaving only the part of 
the capillary that was protected from inside etching (figure 3c, h).
 The outer shape of the needle can be explained by the interaction between the HF and 
the polyimide coating. The coating is slightly permeable to HF. When HF permeates through 
the coating it slowly etches the fused silica and delaminates the coating and the fused silica. 
When the coating is separated from the capillary, HF is sucked in between by capillary force. 
This HF results in the strong etching that determines the final tip shape. As HF supply through 
the coating is small, mass transport by diffusion from the tip is limiting the etch rate, resulting 
in slower etching further away from the tip. This gradient in etch rate results in the sharp tip 
of the microneedle.
 Gluing the microneedles into Luer adapters resulted in needles that can be used and 
connected with the ease of conventional needles (figure 3g).
 The relatively short needles obtained by 4 hours of etching were most suitable for 
injection into the skin because of their rigidity and robustness. While not suitable for injections 
into the skin, the extremely long needles can be useful for other applications. The ultra-high 
aspect ratio of these needles (4 cm long, 20 µm tip diameter, figure 3i) could be very useful 
for deep penetration into soft fragile tissue, e.g., for intracerebral injections.
Figure 3: Representative 
images of the influence of 
etch time on the tip shape of 
hollow microneedles etched 
from capillaries after 1, 2, 
4, 9, 22, 29 hours all taken 
at the same magnification 
(a-f, respectively); a capillary 
etched for 4 hours mounted 
into a Luer hub after removal 
of the polyimide sleeve, used 
for dermal drug delivery (g); a 
typical needle tip opening of 
microneedles after 4 hours of 
etching (h); a typical hollow 
microneedle etched for 22 
hours next to a standard 30G 
needle, a microneedle etched 




Figure 5: Fluorescence visualization of fluorescein 
microinjections into ex vivo human skin. Control injections 
(fluorescein dispensed on top of the skin) result in 
solvent evaporation over time and, consequently, loss of 
fluorescence, while 300 µm deep injections show no leakage 
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Figure 6: Representative microinjections of trypan blue solution into ex vivo skin. Four subsequent 10 µm thick 
cryosections following a 0.5 µL microinjection into ex vivo human skin before (A) and after hematoxylin and eosin 
(H&E) staining (B). Four subsequent 5 µm thick H&E stained cryosections following a 3 µL microinjection into ex 
vivo rat skin (C). The scale bar is 0.2 mm.
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 Microneedle applicators are needed for controlled and reproducible microneedle 
application and reduce the required insertion forces to pierce the stratum corneum for both 
solid and hollow microneedles [1, 2, 16, 20-24]. The microneedle applicator used in this work 
was designed for in- and ex vivo microinjections with easily adjustable insertion speed, depth, 
angle, and fl ow rate. Robust performance was observed, i.e., at an insertion speed of 1 m/s no 
damage of the needles was observed.
 In order to construct the system to be completely air free, gas tight syringes and Luer 
lock connections combined with pressure resistant fused silica tubing were used. This enables 
constant fl ow generation at high pressures. As such, the system could be used at relatively 
high fl ow rates without using hyaluronidase (2 µL/min, as compared to literature values of 
single microneedle injections of 50-300 nL/min) [21, 25, 26]. Flow rates of other systems 
described in the literature might have been limited by the maximum applicable pressure in 
systems using common fl exible tubing and diff erent pump types [12, 15, 21, 25, 27, 28].
 The full tunability of the device is very valuable in a research setting, where varying 
injections into diff erent skin types and layers are required, e.g., to examine the immune 
responses as a function of the microneedle insertion depth or injection volume. Whilst 
completely compatible with use for intradermal microinjections in in vivo arms of humans, 
the freestanding setup of the device is particularly suitable for use in animal studies, as it 
allows for easy handling of the animals. When used for vaccination of humans, a much simpler 
applicator with a fi xed insertion speed and angle could easily be envisioned. Using a spring 
loaded, fi xed angle applicator would result in a hand held device suitable for a clinical setting.
3.3 Determination of microneedle insertion depth
 It is important to control the depth of hollow microneedle insertion into the skin, since 
this defi nes whether or not the microneedle injection causes pain and/or bleedings. Fig. 4a-c 
depicts micrographs of microneedles after insertion into fl uorescently labeled ex vivo human 
skin with a velocity of 1 m/s. The distance between the fl uorescent dye transferred from 
the skin and the tip of the needle was used to measure penetration depth. Figure 4d shows 
that the measured microneedle insertion depth was on average 110±36 µm (mean ± SD, 
Figure 4: Determinati on of the depth of microneedle 
inserti on. Aft er hollow microneedles were pierced into 
fl uorescein labeled human skin, one picture of the hollow 
microneedle was taken by using bright-fi eld microscopy 
(A), and another picture on the same positi on was taken by 
fl uorescence microscopy (B). Subsequently, the bright-fi eld 
and fl uorescence microscopy pictures were overlaid (C) from 
which the depth of microneedle inserti on was measured and 
plott ed against the length of the microneedle protruding 
below the guide-plate (D). Each point in panel D represents 
the average (± SD) of three individual microneedle inserti ons.
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n=4) deeper than the length of the microneedle protruding past the guide-plate. This offset 
towards a deeper microneedle insertion than the aimed depth could be due to the pressure 
that is applied by the microneedle applicator guide-plate onto the skin, causing the skin to 
bulge into the opening in the plateau (figure 2G). However, when corrected for this offset, 
this applicator for hollow microneedles enables us to accurately and reproducibly insert a 
microneedle into the skin at a predetermined depth. A linear correlation (R2=0.979) between 
the protrusion length and insertion depth was observed with an average RSD of 16%. The 
shown depth accuracy is sufficient to selectively inject into the dermis in rats and would allow 
for even more control in the relatively thick human skin. In addition to the presented results, 
strain measurements during insertion could be considered for subsequent research to judge 
the penetration into the different layers of the skin.
3.4 Microinjection into skin
 Intradermal injections were visualized by injection of 3 µL fluorescein at a flow speed 
of 2 µL/min into ex vivo human skin. Successful injections were observed at all the injection 
depths that were tested (100-400 µm). As depicted in figure 5, fluorescence from the 
injected fluorescein was observed below the surface of the skin. No leakage was observed 
and fluorescence was maintained for prolonged periods of time. The negative control of 
fluorescein dispensed on top of the skin showed fast evaporation of the solvent, causing 
rapid loss of fluorescence intensity. No significant difference in fluorescence intensity 
between penetration depths from 100-400 µm was observed in the skin (data not shown). 
Furthermore, no clogging of the microneedles was observed even when the microneedles 
were used for multiple injections.
 To determine whether microneedle insertion leads to dermal delivery of the injectable, 
microinjections into ex vivo skin were performed and the injected site was visualized as 
shown in figure 6. After a microneedle was inserted into ex vivo human skin at a protrusion 
depth of 300 µm, a microinjection of 0.5 µL 0.4% trypan blue was performed. Four subsequent 
10 µm thick cryosections of the injected skin before (6A) and after (6B) H&E staining show 
that the microinjections are indeed inside the dermis. Furthermore, a microinjection into ex 
vivo rat skin of 3 µL at a protrusion depth of 300 µm also led to the delivery of the injectable 
into the dermis (6C). Figure 6C shows that trypan blue diffused deep inside the dermis when 
a volume as large as 3 µL was injected.
3.5 Immunization study
 In order to test the applicability of the hollow microneedles for dermal vaccination, rats 
were immunized with IPV serotype 1. The resulting antibody titers are shown in figure 7. This 
figure shows that the serum IgG responses after the (intradermal) microinjections with hollow 
microneedles at a protrusion depth of 300 µm are comparable with those after conventional 
intramuscular immunization and intradermal immunization, and were comparable to IgG 
responses found in the literature after a single intramuscular immunization with 5 DU IPV 
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Figure 8: Serum polio-virus 
neutralizing (VN) antibodies responses 
after immunization with PBS or 5 
DU inactivated poliovirus serotype 1 
intramuscularly (i.m.), intradermally 
(i.d.), or intradermally via hollow 
microneedles with a microinjection of 
9 µL containing either 5 or 15 DU IPV.
type 1 [17]. Furthermore, a higher dose IPV (15 DU) delivered by a microinjection of 9 µL 
appeared to slightly increase the IgG response as compared to a 5 DU microinjection, but 
the differenece was not statistically significant. Furthermore, no significant differences were 
observed between the IgG titers of the microneedle injection groups and the intramuscular 
and intradermal groups. 
 Besides the serum IgG responses, the rat sera were analyzed for VN antibodies, as 
shown in figure 8. Despite the slightly lower VN titers of rats intradermally immunized with a 
microinjection of 5 DU, compared to conventional intramuscular or intradermal immunization, 
this difference was not significant. The lower VN titer of the microinjection might be caused 
by reduced damage of the skin compared to intradermal injection, where the needle is much 
thicker, is injected at a greater depth, and a larger volume is injected. This intrinsic effect of 
less invasive injections might be overcome by adding an adjuvant to the IPV suspension [1, 
19]. Furthermore, the immune responses by intradermal injection might be higher than by 
intramuscular injection after booster immunizations, since intradermal immunization can lead 
to accelerated booster responses [11]. Therefore, in future experiments the insertion depth 
(50-1000 µm), the volume effect (3-50 µL), and the booster effect (up to 3 immunizations) 
should be evaluated. However, a higher dose of IPV by microinjections led to VN titers 
comparable to intradermal and intramuscular immunization. Therefore, these data show the 
applicability of microneedles to successfully induce VN antibodies against polio-virus.
4. Conclusion
 Microneedles were fabricated by using a novel cheap and scalable wet etching method 
that can be employed in a laboratory setting or modified for commercial fabrication. The 
microneedles were used with a custom-made microneedle applicator for successful depth-
controlled intradermal microinjections into human and rat skin. Intradermal microinjection 
of IPV in rats showed comparable IgG responses to conventional intramuscular injections 
or intradermal injections. Furthermore, immunization with IPV by microinjection led to the 
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induction of VN antibodies. Therefore, etched hollow microneedles can offer potentially 
pain free, minimally-invasive intradermal injections for vaccine delivery. Finally, this hollow 
microneedle technology enables fundamental research on factors, such as insertion depth, 
angle of insertion, and volume, on the immune responses after dermal immunization.
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 To assess the variation in the dimensions of the tip angle, a batch of 55 microneedles 
etched from 20 µm ID capillaries, etched for four hours, was measured as shown in figure S1. 
The batch of 55 needles had an average tip angle of 15.0° ± 2.8° (mean ± SD).
Figure S1: Distribution of the tip angle of 55 microneedles etched 
for four hours from 20 µm ID capillaries.
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 Microneedles are a promising tool for vaccination, because 
they enable minimally-invasive and potentially pain free delivery 
of vaccines into the skin (Chapter 2). Microneedles are needle like 
structures with a size of less than 1 mm that are used for dermal drug 
delivery via four different approaches. By the ‘poke and release’ 
approach a drug embedded in dissolving or porous microneedles 
is released upon application into the skin. In the ‘poke and patch’ 
approach, microneedles are used to pierce the stratum corneum to 
create conduits. Subsequently, a patch with a drug formulation is 
applied onto the conduits enabling the drug to diffuse into the skin. 
By the ‘coat and poke’ approach, microneedles are coated with a 
drug that is subsequently released into the skin upon application. 
By the ‘poke and flow’ approach hollow microneedles are pierced 
into the skin after which a drug formulation is passed through the 
bores of the microneedles. The latter three microneedle-based drug 
delivery approaches were used in this thesis to deliver vaccines into 
the skin in Chapter 3, 4 and 5, respectively.
 Chapter 2 provides a detailed overview of methods to 
produce microneedles from several materials and approaches for 
microneedle-based vaccine delivery, and contains a section that is 
dedicated to possible unwanted immunogenicity when delivering 
biomacromolecules (other than antigens) via microneedles. 
Furthermore, this chapter contains a detailed description of the 
four described microneedle-based dermal drug delivery approaches 
with their advantages and disadvantages. The ‘poke and patch’ 
approach is technically the simplest form of microneedle-based 
drug delivery, because it does not require a pump or encapsulation/
coating process. However, drug delivery via this approach is a two-
step administration process that requires reformulation of the 
drug. In contrast, hollow microneedles that are used in the ‘poke 
and flow’ approach lead to precise dosing without the requirement 
of reformulating the drug. However, this approach requires 
sophisticated systems to deliver the drug into the skin. The ‘coat 
and poke’ and ‘poke and release’ approach are both single-unit 






drug delivery systems that require encapsulation, absorption, or adsorption into/onto the 
microneedles. On the one hand this could lead to degradation of the drug. On the other 
hand, if degradation is prevented during manufacture, these solid dosage forms may be 
advantageous with respect to drug stability during storage. The main difference between 
the ‘coat and poke’ and ‘poke and release’ approach is that porous/polymeric microneedles 
may have a decreased strength, whereas coating of microneedles may lead to impaired 
microneedle sharpness. As discussed in this chapter, one common factor for all microneedle 
approaches is that the microneedles should pierce the stratum corneum in order to deliver a 
drug into the skin. 
 The research described in Chapter 3 focuses on microneedles-based drug delivery by 
the ‘poke and patch’ approach. The penetration ability of high-density microneedle arrays 
by microneedle users as well as the applicability of the high-density microneedles/applicator 
combination in mice in vivo was investigated in Chapter 3.1. The penetration ability of ex 
vivo human skin by manually applied high-density microneedles was mainly dependent on 
the force (up to 7.4 N) that was applied onto the microneedle arrays. Further increase of 
the force or prolonging the application time of the microneedles at a constant force only 
minimally affected the penetration efficiency. Microneedle application onto human skin by 
microneedle users using a manual application device led to low penetration efficiencies with 
low reproducibility. However, using an impact-insertion applicator improved the efficiency 
and reproducibility of microneedle insertion by microneedle users, enabling self-application 
of microneedle arrays into the skin. Moreover, the impact-insertion applicator was used for 
microneedle-mediated antigen delivery, which yielded robust antigen-specific IgG responses 
in mice. In Chapter 3.2 factors that influence microneedle-based vaccine delivery and immune 
responses were investigated, by using ovalbumin as a model antigen. The amount of 
ovalbumin delivered into ex vivo human skin via the ‘poke and patch’ approach depended on 
the geometry and size of the microneedle array, but this did not affect the ovalbumin-specific 
IgG response. However, antigen-specific IgG responses were found to be dependent on the 
usage of an impact-insertion applicator, the microneedle application area, and the location 
of microneedle application. The knowledge of the influence of these factors on the immune 
responses could be useful to improve microneedle-based immunization in general.
 In Chapter 4 a novel method is described to coat solid microneedle arrays for dermal 
vaccine delivery via the ‘coat and poke’ approach. The basic concept is to aid vaccine 
delivery by modifying the microneedle surface with pH-sensitive groups. In Chapter 4.1 
the development of a novel surface characterization tool is reported: the fluorescent 
nanoparticle adhesion assay (FNAA). This FNAA was successfully used to determine the 
surface pKa of amine- and carboxyl-modified silicon surfaces by using oppositely charged 
fluorescently labeled nanoparticles. This method provides a useful tool for determining pH-
dependent electrostatic protein and particle binding/release and to design solid microneedle 
surfaces with a pH-sensitive surface charge. In the research described in Chapter 4.2 pyridine-
modified silicon surfaces were synthesized of which the surface pKa was determined by using 
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the FNAA. This revealed that pyridine-modified surfaces had a pH-sensitive surface charge 
with a pKa of 6.9. Subsequently, the pyridine modification was successfully applied on the 
surface of silicon microneedles, thereby obtaining pH-sensitive microneedles. These pH-
sensitive microneedles were efficiently coated with ovalbumin (coating efficiency > 95%) at 
a pH below the surface pKa. Upon application of these microneedles onto ex vivo human 
skin 70% of the coated ovalbumin was released by a pH-shift (pH > surface pKa) into the 
skin. Next, in the studies reported in Chapter 4.3 it was shown that antigen delivery from 
the ovalbumin-coated pH-sensitive microneedles into ex vivo human skin is more efficient 
than via the ‘poke-and-patch’ approach. Moreover, in vivo vaccination studies showed 
the applicability of ovalbumin-coated pH-sensitive microneedles for the induction of both 
B cell and T cell responses in mice. Besides pH-sensitive pyridine-modified silicon surfaces, 
in Chapter 4.4 surfaces with a tunable isoelectric point (sIEP) were also developed. In this 
chapter a model was generated to predict and prepare surfaces with a target sIEP. This model 
was successfully applied to synthesize surfaces with an sIEP of 6 and 7, as confirmed by the 
FNAA, by simultaneously modifying these surfaces with pyridine and sulfate groups. These 
modified surfaces are positively charged at pH < sIEP and negatively charged at pH > sIEP. 
Besides, the applicability of surfaces with an sIEP was illustrated by using surfaces with an 
sIEP of 7 to bind positively and negatively charged (bio)macromolecules (trimethyl chitosan 
(TMC) and poly(I:C), respectively) and subsequently release them in a pH-dependent manner. 
Finally, in Chapter 4.5 high-density microneedle arrays, which have been shown to penetrate 
ex vivo human skin when using an impact-insertion applicator (Chapter 3.1), were coated with 
a polio vaccine. Besides, in Chapter 4.5 studies are described in which pH-sensitive (pyridine-
modified) microneedles were homogeneously coated via a layer-by-layer approach by coating 
ten layers of negatively charged inactivated poliovaccine (IPV) alternated with positively 
charged TMC. After the IPV-TMC coated pH-sensitive microneedles were inserted into ex vivo 
human skin, both IPV and TMC were delivered into the skin. Finally, the in vivo application of 
IPV-TMC coated pH-sensitive microneedles in rats led to the induction of antibody responses, 
showing the release and immunogenicity of the coating in vivo.
 The research described in Chapter 5 comprises a novel procedure to produce hollow 
microneedles by hydrofluoric acid etching of fused silica capillaries and presents a novel 
impact-insertion applicator to accurately insert these microneedles in a controllable manner 
into the skin at a predefined protrusion depth. Besides, using these hollow microneedles by 
the ‘poke and flow’ approach resulted in a depth controlled delivery of trypan blue into ex 
vivo rat skin and ex vivo human skin. During insertion of the microneedles no clogging or 
breakage of the microneedles was observed. Finally, an IPV immunization study in rats by 
using the hollow microneedle/applicator combination showed functional antibody responses 






Insertion of solid microneedles
 In order to enable vaccine delivery via microneedles into the skin, the microneedles 
should be inserted in a reproducible manner [1, 2]. However, there are several factors that 
influence the penetration ability of microneedles, e.g., insertion force, microneedle density, 
length, geometry and sharpness [1]. Therefore, the first aim of this thesis was to investigate 
the penetration ability of microneedles with and without using an impact-insertion applicator. 
The different microneedles that were used in this thesis are shown in figure 1. The ‘atom sharp’ 
U-Needle microneedle arrays (tip diameter < 50 nm) with a length of 300 µm efficiently and 
reproducibly penetrated ex vivo human skin by using a simple device for manual insertion, 
showing that the microneedle sharpness is of great importance for the penetration ability 
of microneedles. In contrast, microneedles with a tip diameter of more than 1 µm with a 
comparable length (Tyndall (300 µm), Leiden University (LU) (300 µm) [3], and Bosch (200 
µm) microneedles) required an impact-insertion applicator to reproducibly penetrate human 
skin. First results showed that the insertion of high-density microneedle arrays into ex vivo 
human skin can be efficiently and reproducibly performed by microneedle users, indicating 
that microneedles can be self-administered. However, to confirm the self-applicability of 
these microneedles a comparable penetration study should be performed in humans in vivo. 
Furthermore, the impact-insertion applicator that was used in this thesis would be too large, 
complex, and expensive for single use. Therefore, a small, cheap and disposable applicator 
should be developed that is designed for single-use for the insertion of microneedles into the 
skin.
Figure 1: The different microneedles that were used for the research described in this thesis: U-Needle (UN) (A 
and E), Tyndall National Institute (B, F), Leiden University (LU) (C and G), Bosch (D and H), and fused silica hollow 
microneedles (I and J).
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Antigen-coated microneedles
 Antigen-coated microneedles could be especially advantageous for developing countries, 
because dry formulations may be more stable than liquid formulations. For example, Chen et 
al. (2011) have shown that an influenza vaccine that was coated onto microneedles was stable 
for at least 6 months at 23°C, whereas the shelf life of the vaccine in liquid form at 25°C is only 
14-20 weeks [4]. Moreover, Andrianov et al. (2011) have shown that horseradish peroxidase 
(HRP) that was coated onto microneedles retained 50% of its activity after incubation at 70°C 
for 24 days in a thermal inactivation study, whereas the half life of HRP in an aqueous solution 
at 70°C was less than one hour [5]. Because of this increased stability, coated microneedle-
based vaccines could circumvent the cold chain and thereby significantly reduce costs and 
increase vaccination coverage. Furthermore, antigen-coated microneedles are a single-unit 
drug delivery system that could be self-administered or administered by minimally-trained 
personnel, which could contribute to cost reduction and increased vaccination coverage.
 Coated microneedles also have the advantage that they retain their strength after coating. 
However, increasing the coating thickness will lead to an increased tip diameter and thereby 
a reduced microneedle sharpness, which in turn could result in a decreased penetration 
ability. Besides, only limited amounts of drugs can be coated onto microneedles. Therefore, 
coating is only suitable for very potent drugs, such as vaccines. Besides, it is important to 
have a very efficient and reproducible release of the drug from the microneedles into the skin. 
Therefore, the second aim of this thesis was to develop nanolayered pH-sensitive surfaces to 
improve the coating and delivery efficiency of microneedles with vaccines without impairing 
microneedle sharpness and penetration ability.
 One important aspect for microneedle-based vaccination via coated microneedles is 
the possibility for upscaling the coating process. The modification of microneedles with 
pH-sensitive surface groups can easily be included in the manufacturing procedure of 
microneedles, i.e., a complete wafer with multiple microneedle arrays can be chemically 
modified. Subsequently, the microneedles should be mounted into an applicator/device that 
is suitable for high-throughput coating of microneedle arrays with antigens. In this thesis 
such a device is presented wherein pH-sensitive U-Needle microneedles were mounted. This 
enabled us to simultaneously coat 96 microneedle arrays in one 96-well plate. Moreover, 
this coating process could be adapted to coat alternately oppositely charged polyelectrolyte 
nanolayers onto the surface of microneedles to increase the amount of coated antigen onto 
pH-sensitive microneedles in a fully automated manner.
 Another important aspect of vaccine coated microneedles is that the antigenicity of the 
vaccine should be retained during coating, storage, and after release to keep its functionality 
[6]. There are several approaches to retain the antigenicity of vaccines during coating. For 
example, Kim et al. (2010) showed that carboxymethyl cellulose (CMC) was required in the 
coating formulation to coat a sufficient dose of influenza vaccine onto microneedles. However, 
the addition of CMC resulted in a reduced antigenicity of the vaccine, which was overcome 





less suitable for coatings that are based on electrostatic interactions, because trehalose is 
a non-ionogenic molecule. To retain the antigenicity of antigens in coatings that are based 
on electrostatic interactions other approaches could be pursued, e.g., by encapsulating the 
antigen into micro-/nanoparticles before they are coated onto the microneedle surface [8, 9].
Hollow microneedles
 Although several different hollow microneedles have been developed by other groups 
[10-15], they are often produced by expensive processes, e.g., micromachining and cleanroom 
processing. Also pulling techniques have been used to produce single hollow microneedles. 
However, such microneedles have an increased risk of clogging since they have a contracting 
inner diameter towards the tip of the microneedle. Therefore, the third aim of this thesis was 
to fabricate and characterize hollow microneedles for depth controlled microinjections into 
skin. Hollow microneedles have been produced from fused silica capillaries by a wet-etching 
method. This fabrication method is a scalable process that enables the production of large 
numbers of microneedles. Moreover, this fabrication process does not require expensive 
equipment and uses cheap materials to produce these microneedles.
 An applicator was developed for the application of hollow microneedles into mouse and 
rat skin in vivo and human skin ex vivo. This applicator allows the investigation of various 
parameters, such as the depth of vaccine delivery, injection volume, and injection speed, on 
the quality of the microinjection. Besides, this applicator allows the investigation of the above 
described parameters on the immune responses upon vaccination via hollow microneedles. 
In this thesis the hollow microneedles/applicator combination was only used at a protrusion 
depth of 300 µm with 9 µL vaccine formulation at a flow speed of 2 µL/min to immunize rats. 
To optimize vaccination via hollow microneedles, subsequent studies should be performed 
whereby the immune responses and the quality of the microinjection are investigated as 
a function of delivery parameters, such as protrusion depth, injection volume and antigen 
dose.
 Although this thesis shows the usability of the developed hollow microneedles/applicator 
combination for vaccination, there are still some major limitations that should be tackled 
before human application. The major limitation of the developed system is the relatively low 
flow speed of 2 µL/min. As most vaccines in the Netherlands are formulated in 0.5-1.5 mL [16], 
this implies that it would require four to twelve hours to vaccinate one person. Therefore, 
the hollow microneedle/applicator system should be adapted to increase the flow speed 
and reduce the injection time. Furthermore, as high volume injections (> 0.8 mL) into the 
skin are painful [17], and to decrease the injection time, the vaccine could be delivered in a 
small volume, requiring a relatively high concentration. Another approach to decrease the 
injection time is by increasing the number of microneedles that are simultaneously inserted 
into the skin. However, if one microneedle is not properly inserted into the skin, the whole 
formulation will leak through the non-inserted microneedle (path of the least resistance). 
Therefore, a system that contains multiple hollow microneedles preferably contains a 
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separate reservoir for each microneedle. Finally, to enable self-administration of vaccines 
via hollow microneedles, a simplified applicator should be developed with a fixed angle of 
insertion, penetration depth, insertion speed, injection volume and flow speed.
Microneedle-based vaccination
 All microneedles studied in this thesis were successfully used to deliver antigens into 
the skin. The final aim of this thesis was to evaluate the application of the ‘poke and patch’, 
the ‘coat and poke’, and the ‘poke and flow’ approach for vaccination in animal studies. The 
‘poke and patch’ approach is an excellent method to investigate immune responses upon 
microneedle-based vaccination because it is the most simple approach for microneedle-based 
drug delivery. Besides, this approach enables a fast investigation of the immune responses 
upon microneedle-based immunizations with different vaccine formulations. However, this 
approach would be the least appropriate general method for microneedle-based vaccination 
of humans, because the delivery is a two-step procedure (i.e., first the microneedles need to 
pierce the skin, and then the vaccine containing patch needs to be applied) and the delivery 
efficiencies via this approach are generally low (if worn for 2-4 hours) [18, 19]. However, the 
delivery efficiency could be increased by prolonging the wear time of the patch, but it would 
require several days to deliver the major dose of antigens from the patch into the skin [19], 
which is, especially for children, not appropriate.
 Numerous geometries of microneedles have been developed with differences in length, 
sharpness, density, etc. These differences can influence the immune responses. For example, 
ultra-high-density microneedles that are used in the group of Kendall result in high immune 
responses in animal models [20-22], which is also true for long microneedles (e.g., 800-1000 
µm) that have been used in other groups [23, 24]. However, microneedles with a length of 
more than 400 µm are more likely to induce pain [1]. In order to obtain optimal immune 
responses in mice by using short microneedles (< 400 µm), vaccination should be performed 
via the ear, either via high-density microneedles or applying microneedle arrays multiple times 
over a large skin area. Although several clinical studies have been successfully performed 
in humans [1], the effect of microneedle application site, microneedle density, microneedle 
length, and the area of microneedle application on the immune responses are unknown. In 
order to obtain optimal immune responses in humans, clinical studies should be performed 
whereby the above described factors are investigated. Finally, to direct the immune reaction 
towards a Th1 or Th2 response and to increase the immune responses upon microneedle-
based immunization, either mechanical (impact-insertion applicator) or chemical adjuvants 
(encapsulation of the antigen in micro-/nanoparticles and/or addition of CpG, LPS, poly(I:C) to 






 The different microneedles that were employed in this thesis were successfully used to 
pierce skin. However, microneedles with a tip in the nanometer range (UN) efficiently and 
reproducibly pierce skin, whereas microneedles with a tip diameter of more than 1 µm (Tyndall, 
LU, and Bosch) require an impact-insertion applicator for efficient and reproducible insertion. 
Besides, an impact-insertion applicator is required to insert fused silica hollow microneedles 
to a controlled depth into the skin. Therefore, to ensure efficient and reproducible skin 
penetration for self administration of microneedles (either solid or hollow), is by using an 
applicator that inserts the microneedles by a controlled force or by a controlled velocity, such 
as an impact-insertion applicator. A suitable approach to investigate the immune response 
upon microneedle-based vaccination is by using solid microneedles via the ‘poke and patch’ 
approach. However, because the delivery efficiency of this approach is low, it would be too 
expensive for general immunization. In order to achieve a sufficient amount of vaccine coated 
on the microneedles while retaining their sharpness, the coating and release process should 
be efficient, which can be achieved by applying ultrathin pH-sensitive coatings for microneedle-
based vaccination. Hollow microneedles that are produced from fused silica together with the 
applicator enable a precise dosing to a predetermined depth and do not or only minimally 
require reformulation of the vaccine. Because they are easily produced in large numbers 
with low production costs these hollow microneedles could be used for mass immunization. 
Finally, microneedle-based vaccination offers a minimally-invasive and potentially pain free 
vaccination strategy to successfully induce antigen-specific immune responses.
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 Vaccinatie is één van de grootste successen in de geneeskunde 
om ziekte en sterfte te voorkomen. Volgens schattingen van de 
Wereld Gezondheid Organisatie (Engels: World Health Organization, 
WHO) voorkomt vaccinatie jaarlijks zo’n 6 miljoen doden. Hierdoor 
zijn infectieziekten in westerse landen niet meer de primaire 
doodsoorzaak. Edward Jenner (1749-1823) en Louis Pasteur (1822-
1895) zijn belangrijke pioniers op het gebied van vaccinatie. Zij 
hebben veel bijgedragen aan het concept vaccinatie en de introductie 
daarvan om mensen te beschermen tegen infectieziekten. In 1796 
isoleerde Jenner de inhoud van puisten van een melkmeisje dat 
geïnfecteerd was met de koepokken. De geïsoleerde pus injecteerde 
hij in een 8-jarig jongetje, waarna hij het jongetje besmette met 
het gevaarlijke pokkenvirus. Jenner observeerde dat het jongetje 
geen symptomen van de ziekte kreeg. Vervolgens introduceerde 
Pasteur het gebruik van levende verzwakte ziekteverwekkers voor 
vaccinatie. Hij ontdekte dat ziekteverwekkende bacteriën die enkele 
maanden in laboratoriumbuisjes gekweekt waren niet meer in staat 
zijn om de ziekte te veroorzaken, maar wel hun immunogeniciteit 
behouden. Hierdoor kunnen deze levende verzwakte bacteriën 
gebruikt worden als vaccin om beschermende immuunreacties op 
te wekken. Sindsdien is vaccinatie sterk verbeterd en beschikbaar 
geworden tegen vele infectieziekten, zoals hepatitis B, difterie, 
kinkhoest en poliomyelitis. Bovendien zijn er therapeutische vaccins 
tegen onder andere kanker en hart- en vaatziekten in ontwikkeling.
 Ondanks de inspanningen en dusver behaalde successen van 
wereldwijde vaccinatieprogramma’s zijn infectieziekten nog steeds 
de belangrijkste doodsoorzaak in ontwikkelingslanden. Bovendien 
is vaccineren erg duur, wat onder andere door de productiekosten 
van vaccins komt. Daarnaast zijn er minder zichtbare factoren 
die eveneens bijdragen aan de hoge kosten voor vaccinatie, zoals 
opslag, transport, verpakking, koelketen (cold-chain) en het 
benodigde medisch personeel om de vaccins toe te dienen. Ook 
leidt vaccinatie niet altijd tot beschermende immuunreacties. Zo zijn 
er, ondanks alle inspanningen en onderzoeken die er de afgelopen 









infectieziekten zoals HIV, malaria, tuberculose en ebola, die momenteel veel slachtoffers eist. 
Ten slotte worden de meeste vaccins subcutaan of intramusculair toegediend door middel 
van klassieke injectienaalden. Hierdoor veroorzaakt vaccinatie pijn, angst en stress in kinderen 
en hun ouders, wat kan leiden tot een verminderde vaccinatiegraad. Om deze obstakels te 
overwinnen worden nieuwe niet- of minimaal-invasieve alternatieve vaccinatiestrategieën 
overwogen en onderzocht. Voorbeelden hiervan zijn onder andere inhalatiepreparaten en 
neussprays. Een andere alternatieve vaccinatiestrategie is gebruikmaking van de huid als 
toedieningsroute.
Dermale vaccinatie
 De huid wordt constant blootgesteld aan lichaamsvreemde stoffen zoals ziekteverwekkers 
die het lichaam proberen binnen te dringen. Daarom heeft de huid zich geëvolueerd tot een 
uitstekende barrière. De eerste barrière van de huid is het stratum corneum (de hoornlaag), 
dat een fysieke barrière is die vrijwel ondoordringbaar is voor de meeste stoffen. Bovendien 
bevat de huid gespecialiseerde cellen van het immuunsysteem (de zogenoemde antigeen-
presenterende cellen) die voorkomen dat binnendringende ziekteverwekkers systemische 
infecties veroorzaken. Aan de andere kant bemoeilijkt deze barrière (voornamelijk de 
hoornlaag) de toediening van medicijnen via de huid. Dit wordt geïllustreerd door het 
beperkte aantal medicijnen dat beschikbaar is voor toediening via de huid (ook wel dermale 
toediening genoemd): er zijn maar ongeveer 20 farmaceutisch actieve ingrediënten op de 
markt beschikbaar die via de huid met behulp van pleisters worden toegediend, waarvan 
alle deze ingrediënten bovendien kleine moleculen (grootte ongeveer 1 nanometer) zijn. 
Dit laat zien dat het nog moeilijker is om vaccins en andere (bio)macromoleculen, heel 
veel grotere moleculen of deeltjes (tientallen nanometers tot enkele micrometers), via de 
huid toe te dienen. Het heeft daarom ook tot midden jaren ‘90 geduurd voordat minimaal-
invasieve (trans)dermale vaccinatie voor het eerst preklinisch met succes werd toegepast. 
Hierbij werden hoge antigeen-specifieke antistoffen in muizen verkregen door model-
antigenen die verpakt waren in lipide deeltjes aan te brengen op de huid. Later werd de huid 
als toedieningsroute voor vaccinatie bevestigd in muizen (1998) en in mensen (2000) door 
vaccinformuleringen met cholera toxine op de huid aan te brengen. Echter, daaropvolgende 
klinische studies hebben uitgewezen dat deze methode niet effectief was. Een veel belovende 
methode voor minimaal-invasieve dermale vaccinatie is door middel van micronaalden, die 
voor het eerst beschreven werden in 1998.
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Micronaalden
 Micronaalden zijn structuren in de ordegrootte van micrometers met een lengte van 
minder dan 1 millimeter die gebruikt worden om medicijnen, inclusief vaccins, in of door de 
huid af te geven. Micronaalden moeten lang genoeg zijn om door de hoornlaag te prikken en 
tegelijkertijd kort genoeg zijn om de bloedvaten en zenuwbanen niet te raken. Op deze manier 
kunnen medicijnen en vaccins op een minimaal-invasieve en een pijnloze manier worden 
toegediend via de huid. Ook zouden micronaald-gemedieerde vaccinaties door patiënten 
zelf uitgevoerd kunnen worden. Het gebruik van micronaalden zou hierdoor kunnen leiden 
tot een verbeterde vaccinatiegraad. Daarnaast zou een droge vaccinformulering in of op 
micronaalden de cold-chain kunnen omzeilen, omdat droge formuleringen thermostabieler 
kunnen zijn. Ook heeft dermale vaccinatie potentie om de hoeveelheid antigeen te 
verminderen omdat de huid een immunologisch actief orgaan is. Hierdoor kan het gebruik 
van micronaalden bijdragen aan een signifi cante vermindering van de kosten voor vaccinatie. 
Over het algemeen kunnen micronaalden op vier verschillende manieren gebruikt worden 
om medicijnen, waaronder vaccins, via de huid toe te dienen, zie hieronder en fi guur 1:
1. ‘Poke and fl ow’. Holle micronaalden worden eerst in de huid geprikt, waarna een 
medicijn formulering via de holle kanalen van de micronaalden de huid in stroomt 
of wordt gepompt.
2. ‘Poke and patch’. De huid wordt voorbehandeld met massieve micronaalden 
waardoor microporiën in de huid gevormd worden. Vervolgens wordt een reservoir 
met daarin een medicijnformulering aangebracht op de microporiën, waardoor het 
medicijn via vooral de microporiën de huid in kan diff underen.
3. ‘Poke and release’. Een medicijn is ingesloten in oplosbare, bioafb reekbare of poreuze 
massieve micronaalden. Nadat de micronaalden in de huid gestoken worden, wordt 
het medicijn afgegeven in de huid.
4. ‘Coat and poke’. Het oppervlak van massieve micronaalden wordt eerst gecoat met 
een medicijn, dat wordt afgegeven nadat de micronaalden in de huid zijn gestoken.
Figuur 1: De verschillende manieren om 
medicijnen via de huid toe te dienen met 




 Hoewel micronaalden veel potentie hebben voor dermale vaccinatie, zijn micronaalden 
alleen vaak niet voldoende om de huid goed en/of reproduceerbaar te penetreren. Daarom 
zijn er vaak insertie-apparaten (micronaald-applicatoren) nodig die de krachten reduceren 
die de micronaalden nodig hebben om door de hoornlaag heen te prikken.
Deel II: Doelstellingen van het in dit proefschrift beschreven onderzoek
De hoofddoelen van het onderzoek in dit proefschrift zijn:
1. Het bestuderen van de huidpenetratie door middel van micronaalden, al dan niet in 
combinatie met een applicator;
2. Het bereiden en karakteriseren van ultradunne, pH-afhankelijke oppervlaklagen 
om de efficiëntie van de vaccincoating en -afgifte via micronaalden te verbeteren 
zonder de scherpte van de micronaalden aan te tasten;
3. Het fabriceren en karakteriseren van holle micronaalden voor micro-injecties in de 
huid op een gedefinieërde diepte;
4. Het in proefdierstudies evalueren van de ‘poke and patch’, de ‘coat and poke’, en de 
‘poke and flow’ methoden voor dermale vaccinatie.
Deel III: Samenvatting
 Micronaalden zijn een veelbelovend hulpmiddel voor vaccinatie, omdat ze het mogelijk 
maken om vaccins toe te dienen via de huid op een minimaal-invasieve en pijnloze manier 
(hoofdstuk 1). Zoals hierboven beschreven kunnen micronaalden over het algemeen op 
vier verschillende manieren gebruikt worden om medicijnen via de huid af te geven. In dit 
proefschrift zijn de ‘poke and patch’, de ‘coat and poke’ en de ‘poke and flow’ methoden 
gebruikt om vaccins via de huid toe te dienen in respectievelijk hoofdstuk 3, 4 en 5.
Micronaaldtechnologieën voor (trans)dermale toediening
 In hoofdstuk 2 wordt een gedetailleerd overzicht gegeven van de methoden om 
micronaalden te produceren van verschillende materialen. Daarnaast zijn de verschillende 
strategieën om vaccins af te geven in de huid met behulp van micronaalden beschreven. Ook 
is er een sectie gewijd aan mogelijke ongewenste immunogeniciteit als micronaalden gebruikt 
worden voor de toediening van biomacromoleculen (anders dan antigenen). Bovendien 
bevat dit hoofdstuk een gedetailleerde beschrijving van de vier hierboven beschreven 
methoden om medicijnen met behulp van micronaalden af te geven in de huid met hun 
voor- en nadelen. Holle micronaalden die gebruikt worden in de ‘poke and flow’ methode 
leiden tot een nauwkeurige dosering van het medicijn in de huid zonder dat het nodig is 
om het medicijn te herformuleren. Desalniettemin vereist deze methode geavanceerde 
systemen om een medicijn in de huid af te geven. De ‘poke and patch’ methode is technisch 
de meest eenvoudige vorm van medicijnafgifte met behulp van micronaalden, omdat geen 
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pomp of insluitings- of coatingsproces vereist is. Echter, medicijnafgifte op basis van deze 
methode is een tweestaps toedieningsproces die herformulering van het medicijn vereist. 
Daartegenover zijn de ‘coat and poke’ en de ‘poke and patch’ methode beide een single-
unit medicijnafgiftesysteem (éénstaps toedieningsproces), maar deze vereisen insluiting, 
absorptie of adsorptie van het medicijn in of aan het oppervlak van de micronaalden. Dit 
zou enerzijds kunnen leiden tot degradatie van het medicijn. Maar als degradatie voorkomen 
kan worden tijdens het productieproces, dan zouden deze massieve doseringsvormen 
anderzijds gunstig kunnen zijn met betrekking tot stabiliteit van het medicijn tijdens opslag en 
transport. Een belangrijk verschil tussen de ‘coat and poke’ en de ‘poke and release’ methode 
is dat poreuze/polymere micronaalden minder robuust kunnen zijn, terwijl het coaten kan 
leiden tot een verminderde scherpte van de tip van de micronaalden. Zoals besproken in 
dit hoofdstuk is er één gemeenschappelijke factor voor alle medicijnafgiftemethoden met 
behulp van micronaalden, namelijk dat micronaalden door de hoornlaag moeten prikken om 
een medicijn in de huid af te geven.
‘Poke and patch’ methode
 Het onderzoek dat beschreven is in hoofdstuk 3 is gefocusseerd op medicijnafgifte door 
middel van micronaalden die gebruikt worden met de ‘poke and patch’ methode.
 In hoofdstuk 3.1 wordt bestudeerd of hoge-dichtheid micronaalden arrays (HD-
micronaalden, 2304 micronaalden/cm2) in staat zijn om de hoornlaag te penetreren. Bovendien 
wordt onderzocht of deze micronaalden in combinatie met een impact-insertie-applicator tot 
een immuunresponse leidt in muizen. Uit deze studie blijkt dat de penetratie van de hoornlaag 
van ex vivo humane huid door handmatig aangebrachte HD-micronaalden voornamelijk 
afhankelijk is van de gebruikte kracht (tot 7.4 N). Bij een verdere toename van de kracht of 
het verlengen van de applicatietijd bij een constante kracht wordt de penetratie-efficiëntie 
nagenoeg niet beïnvloed. Vervolgens is de penetratie-efficiëntie onderzocht. Het handmatig 
aanbrengen van HD-micronaalden op ex vivo humane huid door micronaaldgebruikers 
leidt tot lage penetratie-efficiënties met een lage reproduceerbaarheid. Daarentegen is de 
penetratie-efficiëntie en reproduceerbaarheid van micronaaldinsertie sterk verbeterd als een 
impact-insertie-applicator gebruikt wordt door micronaaldgebruikers. Dit laat dus zien dat het 
mogelijk is om patiënten zelf micronaalden te laten aanbrengen indien ze een impact-insertie-
applicator gebruiken. Ten slotte, als HD-micronaalden worden aangebracht op muizenhuid 
in vivo met behulp van een impact-insertie-applicator voor micronaald-gemedieerde 
antigeenafgifte, resulteerd dit in robuuste antigeen-specifieke antistofresponsen.
 In hoofdstuk 3.2 is onderzocht welke factoren van invloed zijn op de vaccinafgifte en 
immuunresponsen na toepassing van de ‘poke and patch’ methode, waarbij ovalbumine als 
modelantigeen wordt gebruikt. Hoewel de hoeveelheid afgegeven ovalbumine in ex vivo 
humane huid afhankelijk is van de geometrie van de micronaalden alsmede van het aantal 
micronaalden per micronaald array, heeft de dosis geen invloed op de ovalbumine-specifieke 
Immunoglobuline G (IgG) responsen. Daarentegen zijn de antigeen-specifieke IgG responsen 
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afhankelijk van het gebruik van een impact-insertie-applicator, het huidoppervlakte waarop 
de micronaalden geappliceerd zijn en de plaats waar de micronaalden geappliceerd 
worden. De in deze studie opgedane kennis van de bovenstaande factoren kunnen gebruikt 
worden om niet alleen de ‘poke and patch’ maar ook de andere micronaald-gemedieerde 
vaccinatiemethoden te verbeteren.
‘Coat and poke’ methode
 In hoofdstuk 4 wordt een nieuwe methode gepresenteerd om massieve micronaalden 
te coaten voor dermale vaccinatie middels de ‘coat and poke’ methode. Het basisprincipe 
van deze methode is om vaccincoating en -afgifte te bevorderen door het oppervlak van 
micronaalden chemisch te modificeren met moleculen die een pH-afhankelijke lading 
hebben. De chemische oppervlakmodificaties die in dit hoofdstuk beschreven staan zijn 
enkele nanometers dik.
 In hoofdstuk 4.1 wordt de ontwikkeling beschreven van een nieuwe methode om 
oppervlakken te karakteriseren: de fluorescente nanodeeltjes adhesie assay (FNAA). 
Vervolgens wordt deze FNAA toegepast om de oppervlak pKa-waarde van amine- en carboxyl 
gemodificeerde siliciumoppervlakken te bepalen, waarbij fluorescent gelabelde nanodeeltjes 
met een tegenovergestelde lading gebruikt worden. Deze methode is een nuttig gereedschap 
om pH-afhankelijke elektrostatische bindingen en afgifte van eiwitten en deeltjes aan 
oppervlakken te bepalen. Bovendien kan deze methode gebruikt worden om micronaalden 
met een pH-gevoelig oppervlak te ontwerpen.
 De studies in hoofdstuk 4.2 beschrijven de synthese van pyridine-gemodificeerde 
oppervlakken waarvan de oppervlak pKa-waarde is bepaald door middel van de FNAA. 
Deze studies tonen aan dat pyridine-gemodificeerde oppervlakken een pH-afhankelijke 
oppervlaklading hebben met een pKa-waarde van 6,9. Vervolgens is het oppervlak van 
siliciummicronaalden met succes gemodificeerd met pyridinegroepen, resulterende in pH-
gevoelige micronaalden. De verkregen pH-gevoelige micronaalden worden efficiënt gecoat 
met ovalbumine (coatingefficiëntie > 95%) bij een pH-waarde die lager is dan de oppervlak 
pKa-waarde. Als ovalbumine-gecoate pH-gevoelige micronaalden in ex vivo humane huid 
geprikt worden, wordt 70% van de gecoate ovalbumine afgegeven in de huid door een pH-
verandering (pH > oppervlak pKa).
 Vervolgstudies (hoofdstuk 4.3) tonen aan dat de ovalbumine-afgifte in ex vivo humane 
huid door middel van ovalbumine-gecoate pH-gevoelige micronaalden veel efficiënter 
is dan via de ‘poke and patch’ methode. Bovendien laten vaccinatiestudies in muizen de 
toepasbaarheid van de antigeen-gecoate pH-gevoelige micronaalden voor het opwekken van 
antigeen-specifieke B en T-cellen in vivo zien.
 Naast de pH-gevoelige pyridine-gemodificeerde siliciumoppervlakken zijn er ook 
oppervlakken ontwikkeld met een af te stemmen iso-elektrisch punt (IEP), zoals beschreven 
in hoofdstuk 4.4. In dit hoofdstuk is een model gegenereerd om oppervlakken met een vooraf 
gekozen IEP te voorspellen en te genereren. Dit model wordt vervolgens toegepast om 
178
oppervlakken met een IEP van 6 en 7 te synthetiseren door oppervlakken tegelijkertijd met 
pyridine- (pH-afhankelijke positieve lading) en sulfaatgroepen (pH-onafhankelijke negatieve 
lading) te modificeren. Het succes van de synthese van de IEP oppervlakken kon worden 
aangetoond met behulp van de FNAA. De IEP oppervlakken hebben een positieve lading bij 
pH < IEP en een negatieve lading bij pH > IEP. Bovendien illustreert de binding van positief en 
negatief geladen (bio)macromoleculen (respectievelijk trimethyl chitosan (TMC) en poly(I:C)) 
aan oppervlakken met een IEP van 7 de toepasbaarheid van oppervlakken met een IEP. Deze 
(bio)macromoleculen laten vervolgens weer los van het oppervlak door een pH-verandering. 
Ten slotte worden HD-micronaalden in hoofdstuk 4.5 gecoat met een polio vaccin. In 
hoofdstuk 3.1 is beschreven dat deze micronaalden ex vivo humane huid kunnen penetreren 
als ze in combinatie met een impact-insertie-applicator gebruikt worden. In het onderzoek 
dat beschreven is in hoofdstuk 4.5 worden pH-gevoelige (gemodificeerd met pyridine) 
micronaalden homogeen gecoat door tien lagen negatief geladen geïnactiveerd polio virus 
(IPV) af te wissellen met positief geladen TMC. Zowel IPV als TMC worden in de huid afgegeven 
nadat de IPV-TMC gecoate pH-gevoelige micronaalden in ex vivo humane huid gestoken 
worden. Ten slotte zijn de IPV-TMC gecoate micronaalden gebruikt om ratten dermaal te 
vaccineren. Uit de polio-specifieke antistoffen blijkt dat de coating is afgegeven in de huid en 
nog immunogeen is.
‘Poke and flow’ methode
 Het onderzoek in hoofdstuk 5 beschrijft een nieuwe methode om holle micronaalden 
te produceren door samengesmolten siliciumdioxide (kwarts) capillairen te etsen met 
fluorzuur. Ook beschrijft dit hoofdstuk een nieuwe impact-insertie-applicator om holle 
micronaalden op een gecontroleerde manier de huid in te steken, waarbij de lengte die 
de micronaald uitsteekt accuraat kan worden ingesteld. Het gebruiken van deze holle 
micronaalden/applicatorcombinatie via de ‘poke and flow’ methode resulteert in een diepte-
gecontroleerde afgifte van trypaanblauw in ex vivo rattenhuid en ex vivo humane huid. Het 
appliceren van holle micronaalden in huid is uitgevoerd zonder dat er verstoppingen en 
breuken in de micronaalden optraden. Ten slotte zijn ratten geïmmuniseerd met IPV door 
gebruik te maken van de combinatie holle micronaalden en de speciaal hiervoor ontwikkelde 
applicator. Hieruit blijkt dat er na vaccinatie met micronaalden functionele antistof responsen 
opgewekt worden die vergelijkbaar zijn met de responsen na conventionele intramusculaire 
vaccinatie.
Deel IV: Conclusies van dit proefschrift
 De verschillende micronaalden die in dit proefschrift beschreven staan zijn met 
succes gebruikt om in de huid te prikken. De micronaalden met een tipdiameter in het 
nanometergebied blijken in staat om humane huid efficiënt en reproduceerbaar te prikken 
met een applicator voor handmatige insertie, terwijl micronaalden met een tipdiameter 
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van meer dan één micrometer een impact-insertie-applicator nodig hebben voor efficiënte 
en reproduceerbare insertie. Een impact-insertie-applicator is ook een vereiste om holle 
kwartsmicronaalden met een gecontroleerde diepte in de huid te steken. Om er zeker van te 
zijn dat de huidpenetratie door micronaalden (zowel massieve als holle) voor zelfmedicatie 
reproduceerbaar en efficiënt is, is het nodig om een applicator te gebruiken die micronaalden 
in de huid steekt met een gecontroleerde kracht of met een gecontroleerde snelheid, zoals 
een impact-insertie-applicator. Een geschikte methode om immuunresponsen via micronaald-
gemedieerde vaccinatie te onderzoeken is door massieve micronaalden te gebruiken met de 
‘poke and patch’ methode. Deze methode zou echter wellicht te duur zijn voor algemene 
vaccinatie, omdat de geneesmiddel afgifte-efficiëntie met deze methode laag is. Een andere 
methode om medicijnen af te geven met behulp van massieve micronaalden is via de ‘coat 
and poke’ methode. Om zowel een toereikende hoeveelheid vaccin op de micronaalden 
te coaten alsmede de scherpte van de micronaalden te behouden, moet het coatings- en 
afgifteproces efficiënt zijn. Voor micronaald-gemedieerde vaccinatie kan dit bereikt worden 
door ultradunne pH-gevoelige coatings op het oppervlak van micronaalden toe te passen. 
Holle micronaalden geproduceerd van kwartscapillair, die aangebracht worden met behulp 
van een applicator, maken het mogelijk om een precieze dosis af te geven op een vooraf 
bepaalde diepte in de huid. Bovendien is het niet nodig om het vaccin te herformuleren. 
Omdat deze holle micronaalden makkelijk in groten getale geproduceerd kunnen worden 
met lage productiekosten, zouden deze holle micronaalden gebruikt kunnen worden voor 
massa-immunisatie. Ten slotte biedt micronaald-gemedieerde vaccinatie een alternatieve 
strategie om minimaal-invasief en pijnloos te vaccineren en daarmee antigeen-specifieke 
immuunresponsen op te wekken.
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De termen zijn op alfabetische wijze vermeld en dienen in de context van de samenvatting van 
dit proefschrift gelezen te worden.
Absorptie Het proces waarbij een stof wordt opgenomen door een 
poreus materiaal (bijvoorbeeld de opname van water door 
een spons).
Adsorptie Het proces waarbij een stof hecht aan het oppervlak van 
een vaste stof (bijvoorbeeld het zuiveren van water met 
actieve kool).
Antigeen Lichaamsvreemde stof (meestal eiwit van een 
ziekteverwekker), waartegen een immuunreactie 
opgewekt kan worden.
Antigeen-presenterende cellen Cellen die antigenen opnemen om deze vervolgens te 
presenteren aan T-cellen van het immuunsysteem.
Antistof Ook wel antilichaam of immunoglobuline genoemd; een 
eiwit geproduceerd door B-cellen dat bindt aan antigenen, 
van bijvoorbeeld ziekteverwekkers, om deze onschadelijk 
te maken.
B-cel Cel van het immuunsysteem die antistoffen produceert.
(Bio)macromoleculen Grote moleculen zoals eiwitten of polymeren. Het 
voorvoegsel ‘bio’ wordt gebruikt wanneer de moleculen 
een biologische oorsprong hebben.
Capillair Een dun buisje.
Cold-chain Het proces waarbij vaccins bij een optimale temperatuur 
(meestal +2°C tot +8°C) gekoeld, vervoerd, bewaard en 
gehanteerd worden van bereiding door de producent tot 
toediening aan de patiënt.
Diffunderen Het proces waarbij stoffen zich verplaatsen van een gebied 
met een hogere concentratie naar een gebied met een 
lagere concentratie.
Ex vivo In of op vers geïsoleerd levend weefsel van een organisme.
Fluorescentie Een natuurkundig verschijnsel waarbij licht vrij komt uit 
aangeslagen moleculen. Eerst wordt een hoog-energetisch 
foton geabsorbeerd door een elcetron, waarna het in 
een aangeslagen toestand verkeert. Als het elektron 
terug valt in de grondtoestand wordt er een foton met 
lagere energie (dus met een andere kleur) uitgezonden. 
Fluorescentie wordt in de wetenschap onder andere 





Formulering De samenstelling van hulpstoffen van een 
medicijnpreparaat (bijvoorbeeld een tablet, drankje 
of injectievloeistof), waarin de werkzame stof stabiel 
is, een bepaald afgifteprofiel heeft (bijvoorbeeld 
directe afgifte of vertraagde afgifte) en geschikt is 
voor toediening.
Geometrie De vorm; d.w.z. afmeting, lengte en verhouding van 
hoeken en vlakken van ruimtelijke figuren.
Immunoglobuline G IgG; antistof die aan antigenen van ziekteverwekkers 
bindt om de afbraak daarvan te bevorderen.
In vivo  Op of in een levend organisme.
Infectieziekte Een ziekte die veroorzaakt wordt door een bacterie, 
schimmel, virus of een parasiet.
Immunogeniciteit  Het vermogen van een antigeen om een 
immuunreactie op te wekken, bijvoorbeeld de 
aanmaak van antistoffen te stimuleren.
Immuunreactie  De afweerreactie van het lichaam tegen 
lichaamsvreemde antigenen.
Impact-insertie-applicator  Een applicator die micronaalden in de huid schiet 
met een gecontroleerde snelheid.
Intramusculair In de spieren.
Iso-elektrisch punt  De pH-waarde waarbij een stof een netto lading van 
nul heeft.
Micrometer  Een tienduizendste (1/10.000) van een centimeter.
Micronaalden array  Een oppervlakte waarop zich meerdere 
micronaalden bevinden.
Millimeter  Een tiende van een centimeter.
Minimaal-invasive toediening Een methode om geneesmiddelen toe te dienen 
en daarbij zo min mogelijk weefselschade aan te 
richten. Een injectienaald gaat bijvoorbeeld door alle 
lagen van de huid heen, dus ook door de bloedbanen 
en pijnreceptoren (invasief), terwijl micronaalden 
alleen in de bovenste laag van de huid prikken 
(minimaal-invasief).
Nanometer Een tienmiljoenste (1/10.000.000) van een 
centimeter.
Ovalbumine  Een kippenei-eiwit dat in de wetenschap vaak 
als model antigeen gebruikt wordt om nieuwe 
vaccinatiestrategieën te testen.
pH   De zuurgraad.
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pKa   De zuurconstante; een kwantitatieve maat voor de 
sterkte van basen en zuren, waarmee de lading van het 
molecuul bij een bepaalde pH-waarde berekend kan 
worden.
Subcutaan Onder de huid.
Systemische infectie  Een infectie waarbij de ziekteverwekker zich door het 
hele lichaam verspreidt.
T-cel Cel van het immuunsysteem dat voor een cellulaire 
immuunreactie zorgt. 
Toedieningsroute  De plaats in het lichaam waar het medicijn gegeven/
toegediend wordt; hoe het medicijn het lichaam binnen 
komt.
(Trans)dermaal  Het afgeven van medicijnen in de huid (dermaal) of 
door de huid heen naar andere delen van het lichaam 
(transdermaal).
Herformuleren  Het veranderen van de samenstelling van de hulpstoffen 
van een medicijn formulering.
Vaccinatie  Algemene beschrijving voor het onvatbaar maken tegen 
(infectie)ziekten.
Vaccinatiegraad  Het percentage van een populatie dat gevaccineerd is 
tegen een bepaalde ziekte. Als meer dan 90% van de 
bevolking gevaccineerd is, dan wordt de verspreiding 
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kunnen doen in een gezellige omgeving. Tijdens een promotietraject 
sta je er gelukkig niet volledig alleen voor. Er zijn vele mensen geweest 
die mij geholpen hebben en/of waar ik goede discussies mee gevoerd 
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at my side during my defense.
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 Ook mag ik Raphaël niet vergeten voor alle keren dat ik met 
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 Also, I would like to mention the four Master students (Huixin, Jasmine, Emine, and 
Romain) who did their research internship under my supervision and contributed to five of 
my chapters.
Ook wil ik Bas en Heiko apart vermelden. Onze goede samenwerking heeft geleid tot een 
gezamenlijke publicatie. Ik denk met vreugde terug aan de avond dat we onze eerste holle 
micronaald gefabriceerd hadden (die we vervolgens op de grond terug moesten zoeken), 
wat we daarna gingen vieren met een maaltijd en wat biertjes.
 Pim, ik ken je al heel lang (vanaf de eerste dag van het introductiekamp van de studie 
Farmacie). We kwamen daar allebei als een van de laatste aan voor het eten, omdat we er 
niet van houden om in een rij te staan wachten. We werden goede vrienden en hebben de 
afgelopen tien jaar veel samen meegemaakt, geleerd en gediscussieerd. Ik ben dan ook zeer 
verheugd dat jij aan mijn zijde staat als Paranimf tijdens de verdediging van mijn proefschrift.
 Connie, jij zorgt er altijd voor dat afspraken goed geregeld zijn en als er een probleem is 
(zoals de helpdesk bijvoorbeeld) dat er actie ondernomen wordt. Ook zorg jij dat de kleine 
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goedkeuring van bestellingen/declaraties die te lang op zich laten wachten, geregeld worden 
en had je altijd een luisterend oor (en een goede kop koffie).
 Verder wil ik iedereen van DDT bedanken voor de kritische vragen en opmerkingen 
tijdens presentaties en koffie- en lunchpauzes en de goede tijd die ik de afgelopen vier jaar 
tijdens mijn promotieonderzoek heb gehad.
 Daarnaast wil ik Tim bedanken voor alle tijd en moeite die hij genomen heeft om dit 
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4-FBDA  4-formyl-1,3-benzenedisulfonic acid disodium salt
4-PCA  4-pyridinecaboxaldehyde
AFM  atomic force microscopy
APTES  (3-aminopropyl)triethoxysilane
AR   analytical grade reagent
BSA  bovine serum albumin
CD   circular dichroism
CLSM  confocal laser scanning microscopy
CMC  carboxymethylcellulose
CPTA  (3-carboxypropyl)trimethylammonium chloride
DCC  N,N’-dicyclohexylcarbodiimide
DLS  dynamic light scattering
EDTA  ethylenediaminetetraacetic acid
ELISA  enzyme-linked immunosorbent assay
FNAA  fluorescent nanoparticle adhesion assay
H&E  hematoxylin and eosin
HEPES  (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HPLC  high-performance liquid chromatography
HRP  horseradish peroxidase
i.d.   intradermal 
i.m.   intramuscular
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IPV   inactivated polio vaccine
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PLGA  poly(lactic-co-glycolic acid)
POM  polyoxymethylene
PTH  parathyroid hormone
rhGH  recombinant human growth hormone
rpHPLC  reversed-phase HPLC
s.c.   subcutaneous
SA   succinic anhydride
SAM  self-assembling monolayer
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SC   stratum corneum
SEM  scanning electron microscopy
THF  tetrahydrofuran
TMB  3,3’,5,5’-tetramethylbenzidine
TMC  N-trimethyl chitosan chloride
UN   U-Needle
VN   virus neutralizing
